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Abstract
The Th1/Th2 cell balance is crucial for the outcome of many infections and 
autoimmune diseases. The identification of novel Th1 and Th2 cell specific 
markers can expand our knowledge about Th1 and Th2 cell function, and these 
markers can be used to manipulate Th1/Th2 cell responses. Recently, ST2L (an 
orphan receptor of the IL-1R family) was identified to be selectively expressed on 
Th2, but not on Th1 cells. Factors that determine this differential expression 
pattern are still unknown. Antibodies against ST2L as well as a ST2-Fc fusion 
protein, mimicking the soluble form (ST2), were able to decrease Th2 effector 
functions. ST2 is thought to compete with ST2L for the ligand and therefore 
prevent ST2L signalling. These studies demonstrated that ST2L functions are 
closely linked to Th2 responses in vitro and in vivo. However, with the ligand of 
ST2L still unidentified, the function of ST2L and especially of ST2 are 
controversial.
The aim of my thesis was to expand the knowledge about the role and regulation 
of ST2 and ST2L in murine T helper cells. In my initial experiments (Chapter 3) I 
established a method to express and purify ST2 from baculovirus-infected insect 
cells and from stably transfected mammalian OHO cells. The protein was tested 
for its biological activity on LPS-stimulated macrophages, where it was able to 
decrease the production of inflammatory cytokines (IL-6 and IL-12).
Next, I examined the effects of ST2 on CD4(+) T cell activation (Chapter 4). ST2 
could bind to naïve CD4(+) T cells and suppressed Th1 and Th2 type cytokine 
production. It worked directly on Th cells without the need for APC. CD4(+) T cells,
whose TCR had been engaged before, did not bind ST2 and therefore did not 
show any decrease in cytokine expression.
I then assessed the regulatory effect of Th1 and Th2 cytokines on the gene 
expression of ST2 and ST2L at protein, mRNA and promoter level to clarify 
whether these cytokines are responsible for the differential expression of ST2 and 
ST2L (Chapter 5). IL-4, a major cytokine for Th2 development and proliferation, 
increased ST2L protein expression, while IFN-y, the main Th1 cytokine, decreased 
ST2L protein expression. Similar results were obtained at the mRNA level, where 
IL-4 upregulated and IFN-y down regulated the ST2L mRNA expression. 
Interestingly, IL-4 induced an early increase in ST2 mRNA expression and a 
delayed increase in ST2L mRNA, suggesting differential regulation of the two 
splice variants. The upstream promoter showed increased activity when treated 
with IL-4, but decreased activity when IFN-y was added. Hence, IL-4 was able to 
upregulate ST2L and drive Th2 cell development simultaneously. IFN-y had 
opposite effects to IL-4.
In order to stably transfect Th cells with a ST2L antisense construct, toxicity 
studies for G418, the selection marker, were carried out on Th1 and Th2 cells 
(Chapter 6). G418 and its structural analogue gentamicin were found to modulate 
the Th1/Th2 balance in vitro by selectively suppressing Th2 cells to a greater 
extent than Th1 cells. To investigate the ability of gentamicin to regulate the 
Th1/Th2 cell balance in vivo, I treated Leishmania mayor-infected BALB/c mice 
with high doses of gentamicin for 12 days. Complete suppression of the disease 
was achieved, providing gentamicin treatment was started early after infection.
Analysis of antigen-specific proliferation, cytokine release and antibody production 
revealed a complete suppression of antigen-responding Th lymphocyte activity. 
However, a shorter period of gentamicin treatment (7 days), started immediately 
after infection, selectively suppressed Th2 but not Th1 cytokine expression, 
confirming the ability of gentamicin to modulate Th1/Th2 type responses. 
Gentamicin also caused a partial suppression of macrophage viability. The 
appearance and activity of parasites changed upon short term gentamicin 
treatment, but this did not affect their infectivity in vivo. In vitro experiments 
suggested an increased uptake of the aminoglycoside by macrophages in the 
presence of parasites, promoting increased clearance of the organism.
In this thesis I undertook a series of defined studies which together further 
advance our knowledge on the regulation of Th1 and Th2 cells. This is based on 
the function of ST2L/ST2 and gentamicin, both of which have significant effects on 
the balance between Th1 and Th2 cells. These results can contribute to our ability 
to modulate some of the most important infectious and inflammatory diseases.
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Chapter 1 General Introduction
26
The human body is constantly under siege. It must defend itself from a whole host 
of bacterial parasitic and viral invaders. The immune system is the primary line of 
defense avoiding “self” antigens, while vigorously attacking foreign ones. T 
lymphocytes, the strategists in this game, both direct the responses of the rest of 
the immune system and play an active role themselves. T cells orchestrate the 
Immune response via the production of cytokines - secreted proteins that instruct 
other cells to behave in specific ways. T cells may be broadly classified as either 
helper T cells (Th cells), distinguished by surface expression of the molecule CD4, 
or cytotoxic cells (Tc cells, expressing CD8). Th cells consisted of two major 
subsets - Th1 and Th2 cells. The balance between Th1 and Th2 cells determines 
the outcome of a wide range of infections with extra- and intracellular pathogens, 
and an inappropriate Th1- and Th2-dominated response can lead to autoimmune 
diseases. In recent years, several molecules have been identified which are 
differentially expressed on Th1 and Th2 cells. These findings gave more insight 
into the molecular basis of the different functions of Th1 and Th2 cells. 
Additionally, some of these molecules can be used to modulate the Th1/Th2 cell 
balance in vitro and in vivo. The purpose of the work described in this thesis was 
to explore the ability of two molecules, ST2 and gentamicin, to modulate the 
balance of Th1 and Th2 type immune responses.
27
1. T helper cells in the Immune response
1.1 Subsets of CD4(+) T cells
CD4(+) T cells leave the thymus as naïve ThO cells, destined to recognise major 
histocompatibility complex II (MHCII)- peptide complexes on antigen presenting 
cells (ARC). At this stage the Th cell will produce IL-2 and clonally expand. 
Following activation, naïve ThO cells are capable of “polarising” or differentiating 
into several Th cell subsets (Table 1.1, Fig. 1.1).
Previously, two major subsets of effector T cells have been defined on the basis of 
the cytokines that they secrete and the immunomodulatory effects provided by 
these cytokines (reviewed in Mosmann and Coffman, 1986 and 1989; Paul and 
Seder, 1994). The two most discernible populations were termed Thi and Th2, 
with effector Thi cells producing IL-2 and proinflammatory cytokines such as 
interferon (IFN)-y and lymphotoxin-a, and Th2 cells producing IL-4, IL-5, IL-6, IL-9, 
IL-10and IL-13.
The two helper cell classes also differ in the type of immune response they 
produce. Thi cells tend to generate responses against intracellular pathogens 
such as bacteria, parasites, yeast and viruses, mainly by expression of the Thi 
cytokines which can activate microbicidal activity, as well as cytokine production 
by macrophages. A Thi response is often accompanied by the production of 
complement-fixing antibodies of the lgG2a isotype, as well as the activation of 
natural killer (NK) cells and cytotoxic CD8(+) T cells expressing IFN-y and perforin 
(reviewed in O’Garra and Arai, 2000). Th2 cells produce immune responses
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Fig. 1.1 Responses of innate and adaptive immunity
Overview of different T helper cell subsets involved in innate and adaptive 
immune responses (from O’Garra and Arai, 2000).
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Subtype Defining
cytokines
EfFect(s)
Naïve ThO IL-2 Proliferate and differentiate to 
effector cells
Th1 IL-2, IFN-y, 
lymphotoxin-a
Cell-mediated immunity, opsonizing 
antibody
Mature ThO IFN-y, IL-4, others Unclear
Th2 IL-4, IL-5. IL-9, IL- 
10, IL-13
Humoral immunity, inhibits 
inflammation
Th3 TGF-p Regulates mucosal immunity and 
stimulates B cell secretion of IgA
T-regulatory 1 High levels of IL-10, 
some TGF-p
Suppression of immune response
Table 1.1 Subtypes of CD4{+) T-helper (Th) cells and their characteristic 
cytokines and effects (from Spell berg and Edwards, 2001)
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against helminth and other extracellular parasites (reviewed in Perkel, 2001) by 
activating mast cells and eosinophils. However, these cells also mediate allergic 
and atopic manifestations, which is in keeping with findings that Th2-derived 
cytokines can induce hyperresponsiveness to an allergen (Tournoy et al., 2001) 
as well as the production of IgE (reviewed in O’Garra and Arai, 2000).
Mature ThO cells are characterised by the secretion of both IL-4 and IFN-y as well 
as IL-2 (Miner and Croft, 1998). It is yet to be clarified whether the ThO phenotype 
represents a transitory state of priming cells during their development into a 
Th1/Th2 phenotype, or whether the ThO phenotype indeed represents a fully 
differentiated subpopulation of cells (Firestein et al., 1989, Murphy et al., 1996, 
Bucy et al., 1995). ThO cells can be generated in vitro by antigenic stimulation of 
CD4(+) T cells in the presence of IL-2 (Rogers et al., 1998) or by priming antigen- 
specific naïve CD4(+) T cells with a moderate dose of exogenous IL-4 in 
combination with endogenous IFN-y (Miner and Croft, 1998). In the presence of 
IL-12, differentiated Th2 cells have been shown to revert into a population 
predominantly containing ThO and Th1 cells (Bornasse et al., 1996). In vivo ThO 
cells have been found to be involved for example in the killing of melanoma cells 
(Imro et al., 1995), in resistance to Listeria monocytogenes infections (Hiromatsu 
et al., 1996) or in autoimmune diseases such as Sjogren’s syndrome (Matsumoto 
et al., 1999). It has also been suggested that ThO cells are involved in eliminating 
many pathogens, where a balance of both regulated cell-mediated immunity and 
an appropriate humoral response will eradicate an invading pathogen with 
minimum immunopathology (reviewed in O’Garra, 1998).
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Its now well established that immune responses driven by Th1 and Th2 cells are 
sometimes also influenced by a third T cell type whose main function is counter­
regulation or suppression of immune responses mediated by Th1 and Th2 cells 
(Chen et al., 1994; Fukaura et al., 1996). It has been shown, for instance, that the 
induction of oral tolerance by the feeding of relatively low amounts of myelin basic 
protein leads to the induction of immunoregulatory T cells, which prevent the 
development of experimental autoimmune encephalitis (Chen et al., 1994; 
Fukaura et al., 1996). Such T cells have a unique cytokine production profile in 
that they produce high levels of TGF-p without necessarily producing either Th1 or 
Th2 cytokines; therefore, they have been dubbed Th3 T cells (Fukaura et a!., 
1996). Th3 cells producing TGF-p have also been shown to occur in experimental 
models of colitis or diabetes or in hlgCl2-induced autoimmune diseases, and in 
these instances it is thought that such T cells play an important role in disease 
prevention or cure (Neurath et al., 1996; Powrie et al., 1996; Han et al., 1996; 
Bridoux et al., 1997). The cytokine TGF-p is implicated in oral tolerance (Neurath 
et al., 1996), in the prevention of colitis in mice (Powrie et al., 1996), in the control 
of adjuvant-induced encephalitogenic T cells in mice (Chen et al., 1994), in the 
prevention of the autoimmunity induced by Th2 cells (Bridoux et al., 1997) and in 
airway hypersensitivity (Haneda et a!., 1997).
Recently, another type of regulatory T cell has been identified (in mice and 
humans) that may be related to the aforementioned Th3 T cells. This cell, termed 
T regulatory cell 1 (Tri), is induced in vitro by stimulation of T cells in the presence 
of IL-10 and is a T cell that produces high levels of IL-10 and also low levels of
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TGF-p (Groux et al., 1997; Buer et al., 1998). Functionally, these T cells have 
inhibitory effects on Ag-specific activation of naïve autologous T cells, which is 
partially mediated by IL-10 and TGF-p (Groux et al., 1997). In addition, in a murine 
model of inflammatory bowel disease in SCID mice, cotransfer of Tri cell clones 
together with pathogenic CD4(+) CD45RB'^‘®^ T cells prevented the induction of 
disease (Groux et al., 1997). Donor-derived T cells specific for host alloantigens 
that possess a Tri profile of cyrokine production were also isolated from tolerant 
SCID patients who had been reconstituted with HLA-mismatched stem cells 
(Bacchetta et al., 1994; Bacchetta et al., 1993; Bacchetta et al., 1990). Together, 
these data indicate that Tr1 cells can function as regulatory cells in vivo. 
Additionally, naturally anergic and suppressive CD4(+) CD25(+) T cells have been 
identified, that prevent autoimmune diseases in vivo and are naturally 
unresponsive (anergic) to TCR stimulation in vitro. Upon TCR stimulation, which 
upregulates their CD25 expression levels strongly, they are able to suppress the 
activation/proliferation of other T cells. The function of these cells may be 
dependent on secretion of IL-10 (Read et al., 2000; Hara et al., 2001; Annacker et 
al., 2001). There are strong similarities between effector functions and the 
cytokine profiles of CD25(+) suppressive T cells and T ri, Th3, which suggest that 
these subsets may overlap.
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1.2 Cytokines
1.2.1 Thi type cytokines
IFN-y (reviewed in Farrar and Schreiber, 1993; De Maeyer and De Maeyer- 
Guignard, 1992), first identified by its anti-viral activity (Wheelock, 1965), is 
produced by activated CD4(+) and CD8(+) T cells and NK cells, although the 
CD4(+) Th1 cells are considered the major producer in response to antigen 
(Mosmann and Coffman, 1989). IFN-y has potent immunoregulatory effects on a 
variety of cells including activation of macrophages, induction of FcyRI on 
macrophages and FcyRI I on granulocytes, enhanced production of lgG2a by B 
lymphocytes and enhanced expression of class I MHC gene products and class II 
MHC gene products on most cells in vitro, thus rendering them able to participate 
in class ll-mediated immune reactions. IFN-y enhances the differentiation of lgG2a 
secreting B cells and counteracts the effects of IL-4 on B cells (Mosmann and 
Coffman, 1989; Hasbold et ai., 1999). The proliferation and effector functions of 
Th2 cells is suppressed by IFN-y (Gajewski et ai., 1988; Fitch et al., 1993). IFN-y is 
also responsible for inducing non-specific cell mediated mechanisms of host 
defence through its macrophage activation ability and is required for the resolution 
of microbial infections such as Leishmania.
IL-2 (reviewed in William et al., 1991; Smith et al., 1988) is produced mainly by 
CD4(+) T cells following activation by mitogen or antigen. Effector Thi and ThO 
cells produce large amounts of this cytokine upon stimulation. It can cause 
proliferation of T cells, inducing cell cycle progression in resting cells and thus
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allows clonal expansion of activated T lymphocytes. This growth-promoting 
property is the best characterized and perhaps most important function of this 
cytokine. IL-2 appears to be a T cell differentiation factor, as it is able to induce 
production of other cytokines such as IFN-y and IL-4 (Farrar et al., 1982). IL-2 also 
promotes the proliferation of activated B-cells, although this also requires the 
presence of additional factors such as IL-4. NK cells as well as monocytes and 
macrophage precursors proliferate and increase their cytolytic activities in 
response to IL-2 (Trinchieri et al., 1984; Baccarini et al., 1989, Malkovsky et al., 
1987, Ralph et al., 1988).
Lymphotoxin-a (TNF-p) is expressed by naïve CD4(+) T cells, differentiated Thi, 
but not Th2 cells, due to an IL-4 induced down regulation of LT-a expression 
(Gramaglia et al., 1999). Apart from activated CD4(+) T cells, CD8(+) T cells, B 
cells and NK cells express this cytokine (Murphy et al., 1998). LT-a and p 
(membrane bound form) and their close relative TNF are involved in lymphoid 
organogenesis. LT-a-deficient mice lack all peripheral lymph nodes and Payer’s 
patches, have disorganized splenic architecture with no mature follicular DCs and 
are not able to form germinal centres (Banks et al., 1995; De Togni et al., 1994, 
Matsumoto et al., 1996). Other activities ascribed to either the membrane or 
secreted forms of LT include a direct cytotoxic effect (Makay et al., 1997; 
Browning et al., 1996), promoting inflammatory reactions and homing of 
lymphocytes (Kratz et al., 1996; Sacca et al., 1998), and controlling effector 
functions by stimulating responses of B cells, T cells and macrophages (Estrov et 
al., 1993).
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1.2.2 Th2 type cytokines
IL-4 (reviewed in Boulay and Paul, 1992; Paul, 1987) is mainly produced by Th2 
cells, which are the biologically most active helper cells for B-cells. Non-T/Non-B 
cells of the mast cell lineage also produce IL-4. This cytokine promotes the 
proliferation and differentiation of activated B cells, T cells and mast cells. It 
induces the expression of class II MHC antigens and of low-affinity IgE receptors 
in resting B-cells. In activated B-cells, IL-4 stimulates the synthesis of IgGI and 
IgE and inhibits the synthesis of other antibody Isotypes. Another property of IL-4 
is the ability to drive precursor T cells to Th2 cells (Le Gros et a/., 1990), which is 
supported by IL-13 (see below). Pretreatment of macrophages with the cytokine 
prevents the production of inflammatory mediators, such as IL-1 and TNF-a, in 
response to activation by LPS or IFN-y and it therefore counteracts the Th1- 
mediated effects on macrophages.
IL-5 production is restricted to a few cell types, which include T cells (Robinson et 
al., 1992), mast cells (Plaut et al., 1989) and eosinophils (Broide et al., 1992), the 
predominant source being Th2 cells (Robinson et al., 1992). IL-5 gene expression 
in Th2 cells has been shown to be stimulated by antigen and cytokines (Bohjanen 
et al., 1990; Lee et al., 1993). IL-5 plays a centrai role in orchestrating the 
inflammatory response in asthma, for example by influencing the development of 
eosinophilia (Sanderson, 1992; Walker et al., 1991). It promotes the proliferation, 
activation, differentiation and recruitment of eosinophilic granulocytes. It primes 
basophils and is also involved in the response to allergens for increased histamine 
production (Bischoff et al., 1990). IL-5 is a late-acting factor in the differentiation of
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primary B cells (O’Garra et al., 1986) and has been suggested to be involved in 
the production of IgA (Sonoda et al., 1992).
IL-6 is produced by many different cell types including macrophages, fibroblasts, T 
and B lymphocytes, synovial cells, endothelial cells, glial cells and kératinocytes 
(reviewed in Ray etal., 1989 and Hirano, 1992). LPS enhances IL-6 production by 
monocytes and fibroblasts. IL-6 is a pleiotropic, proinflammatory cytokine with 
several roles in the immune response (reviewed by Hirano, 1992). For example, it 
plays a role in the terminal differentiation of B cells (Hirano et a/.,1985) through 
induction of IL-2 receptor expression on B cells (La Flamme et al., 1999). It 
induces immunoglobulin synthesis by activated B cells (Yoshizaki et ai, 1982; 
Hilbert et al., 1989; Splawski et al., 1990), promotes proliferation of endothelial 
cells (Giraudo et al., 1996) and cloned T cells by inducing expression of lL-2 
receptor (Akira et al., 1993; Lee et al., 1988). IL-6 can mediate Th2 cell 
differentiation via enhanced IL-4 production and Thi cell inhibition via the 
suppressor of cytokine signalling 1 (S0CS1) (Diehl et al., 2000). It is a 
differentiation factor for cytotoxic T cells (Takai et al., 1988). During a septic 
reaction, IL-6 stimulates the production of acute phase proteins by hepatocytes 
(Steel etal., 1994).
The lL-9 gene is expressed in freshly isolated T cells upon stimulation by lectins or 
anti-CD3 antibodies and is enhanced by PMA. Its expression has been detected in 
Th2 but not on Thi cells (Schmitt et al., 1990). IL-9 promotes growth of mast cells 
(Renauld et al., 1995), previously activated T cells but not freshly isolated T cells 
(Houssiau et al., 1993). lL-9 has been suggested as a candidate gene for asthma
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(Doull et al., 1996; Noguchi et al., 1997), which was supported by the findings in 
IL-9 transgenic mice challenged with allergen in vivo (McLane et al., 1998; 
Temann et al., 1998). Transgenic mice with lung-specific expression of IL-9 
develop airway inflammation, eosinophilia, mast cell hyperplasia and increased 
airway hyper-responsiveness (Temann et al., 1998).
IL-10 (reviewed in de Waal-Malefyt et al., 1992; Howard and O'Gara, 1992) is 
produced mainly by murine Th2 cells following stimulation. It is also expressed 
late in the activation process of B cells, monocytes/macrophages, mast cells and 
kératinocytes (Moore et al., 1993; Rennick et al., 1992; de Waal Malefyt et al., 
1992). IL-10 inhibits the synthesis of a number of Th1 cytokines such as IFN-y, IL- 
2 and TNF-a. The inhibitory effect on IFN-y production is indirect and appears to 
be the result of suppression of IL-12 synthesis by accessory cells (Florentine et 
al., 1991). In LPS or IFN-y stimulated macrophages, IL-10 inhibits the synthesis of 
IL-1, IL-6 and TNF-a by promoting for example the degradation of cytokine mRNA. 
It inhibits IFN-y-induced production of reactive oxygen intermediates and nitric 
oxide by macrophages. Therefore, IL-10 has anti-inflammatory activities (Moore et 
al., 1993; Bogdan et al., 1991). In contrast, IL-10 can exhibit pro-inflammatory 
activities, for example it synergizes with LPS and IFN-y to increase the expression 
of the leukocyte chemoattractant calcium binding protein S100A8 (A8, Xu et al., 
2001). It also leads to an inhibition of antigen presentation by down regulating the 
expression of class II MHC molecules on the surface of monocytes and 
macrophages (de Waal Malefyte et al., 1991). IL-10 acts as a costimulator of the 
proliferation of mast cells and peripheral lymphocytes (mature and immature
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thymocytes). In B cells activated via their antigen receptors or via CD40, IL-10 
induces the secretion of IgG, IgA and IgM (reviewed in de Waal-Malefyt et al.,
1992).
Murine IL-13 is produced by activated Th2 cells, but not by Th1 cells (Zurawski et 
al., 1994). It has also been detected in mast cells (Burd et al., 1995). IL-13 down- 
modulates macrophage activity, reducing the production of pro-inflammatory 
cytokines (e.g. IL-1, IL-6, IL-12, TNF-a) in response to IFN-y or LPS (de Waal- 
Malefyt et al., 1993). IL-13 can decrease the production of nitric oxide by activated 
macrophages, leading to a decrease in parasiticidal activity (Doherty et al., 1993). 
It induces human monocyte differentiation and human B cell differentiation, 
proliferation and isotype switching to IgE (Briere et al., 1993; Zurawski et al., 
1994). Mice deficient for IL-4 have been shown to develop residual Th2 responses 
(Kopf et al., 1993; Pearce et al., 1996; Kopf et al., 1995), suggesting that there is 
a functional equivalent of IL-4. IL-13 is a cytokine that shares some, but not all 
biological activities with IL-4, for example isotype switching to IgE (Minty et al., 
1993; Zurawski etal., 1994). There is now compelling evidence that IL-4 and IL-13 
share receptor components, including IL-4R and IL-13R1 (Callard et al., 1996; 
Flilton et al., 1996). NIppostrongylus braslllensls-\nfecXe6 IL-4Ra-deficient mice 
show an increased impairment of Th2 differentiation when compared to infected 
IL-4 deficient mice, suggesting a regulatory role for IL-13 on Th2 cell development 
(Barner et a!., 1998). Supporting observations were made in IL-13- or IL-4/IL-13- 
deficient mice (McKenzie et al., 1998; McKenzie et al., 1999), where Th2 
responses were completely abolished. In aggreement with these results, IL-13
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contributes to the susceptible phenotype in Leishmania major infections (section 
1.9.3.1), but prevents Schistosoma egg-induced pathology and allergic asthma 
(reviewed in Brombacher, 2000).
1.3 Generation of Th1 and Th2 cells
Although a number of factors (Fig. 1.2) have been proposed to influence the 
induction of Th1 versus Th2 cells, cytokines present in the local milieu appear to 
play an overriding role. It is generally recognized that IL-12 produced by ARC 
(macrophages and DC), together with TCR activation, drives the differentiation of 
precursor T cells to Thi cells. Among CD4(+) lymphocytes, functional receptors 
for IL-12 appear to be restricted to recently activated, uncommitted cells and to 
Thi cells, and are lost on differentiated Th2 cells (Szabo et a/.; 1995). In the 
mouse, IL-12 induces Thi differentiation, while IFN-a has no effect; in contrast, 
Thi differentiation of human T cells can be induced by either IL-12 or IFN-a 
(reviewed by Murphy ef a/., 2000; 0 ‘Garra etal., 1997). The cytokine IL-18 (IFN-y- 
inducing factor), related to IL-1, synergizes powerfully with IL-12 to promote Thi 
differentiation, in part by increasing the efficiency of Thi differentiation and in part 
by acting on differentiated Thi cells to enhance cytokine expression (reviewed by 
Akira, 2000; Kohno et al., 1997). Mice deficient in both IL-12 and IL-18 have a 
more severe defect in IFN-y production than mice lacking IL-12 or IL-18 alone 
(Akira, 2000). IL-23, assembled from a novel protein (p19) related to IL-12 p35 
and IL-12 p40, also stimulates IFN-y production and proliferation in PHA blast T
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Fig.1.2. Generation of Thi and Th2 effector ceiis
The local cytokine environment determines if a naïve CD4(+) T cell polarises 
towards the Thi or the Th2 phenotype. IL-12 drives the differentiation of 
precursor T cells to Thi cells. The cytokine IL-18 synergises with IL-12 to 
promote Thi differentiation. Binding of IL-12 to its receptor activates the STAT4 
signalling pathway and the Thi-specific transcription factors ERM and T-bet, 
which controls the expression of IFN-y. IL-4 induces the differentiation of Th2 
cells through activation of the STAT6 signalling pathway and transcription factors 
c-Maf and GATA-3. The introduction of GATA-3 into Thi cells leads to an 
increase in IL-4 and IL-5 production, while IFNy is downregulated. T-bet 
transfected into Th2 cells causes the development of a Th2 phenotype (reviewed 
in O’Garra and Arai, 2000).
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cells, as well as in memory T cells (Oppmann et al., 2000). Hence, IL-23 might 
also promote Th1 cell differentiation.
IL-4 is generally thought to induce the differentiation of Th2 cells (O’Garra, 1998a; 
Constant and Bottomly, 1997). Sources of the early burst of IL-4 could be the Th 
cell themselves (Schmitz et a!., 1994; Chen et a!., 1999) and/or CD4(+) NK1.1(+) 
T cells which may recognise antigens presented in association with the non- 
poiymorphic beta2-microglobulin-associated molecule CD1 (Yoshimoto and Paul, 
1994). However, mice lacking NK1.1(+) T cells develop normal Th2 responses 
(Daseref a/., 1998; Wang etal., 1998; Chen etal., 1997).
Several factors apart from the cytokine microenvironment influence differentiation 
along the Thi or Th2 pathways. These include the concentration of antigen, 
costimulation of the T cells, the type of APC, the route of antigen entry and the 
presence of immunologically active hormones (reviewed in Abbas et al., 1996; 
Romagnani, 1997). Low antigen concentrations and low dose infections tend 
preferentially to induce Thi responses, whereas high doses induce Th2 
development (Bretscher et al., 1992; Hosken et al., 1995). Very high antigen dose 
ranges and therefore the highest microbial burdens in infected patients suppress 
cell-mediated immunity (Livingston et al., 1999). This might seem contradictory to 
recent findings that Thi responses are associated with T cells expressing higher 
affinity TCR (Tao et al., 1997; Rees et al., 1999). However, it is probable that the 
higher affinity TCR clones are preferentially selected when the Ag dose is low and 
reciprocally, lower affinity TCR clones, necessarily augmented by costimulatory 
molecules interactions, are more likely to be activated when the concentration of
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Ag is high (Jankovic et al., 2001). Costimulatory signals are widely reported to 
modulate Th1/Th2 type immunity. CD28 ligation can dramatically favour the 
development of Th2 cells (Burr et al., 2001; Howland et al., 2000), perhaps by 
enhancing IL-4 production (Ruiifson et al., 1997) or by direct activation of STAT-6 
(Oki et al., 2000). Mouse inducible costimulatory molecule (ICOS) is expressed by 
activated T cells and has homology to CD28 and CD 152. Its expression is 
enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells to 
Th2 cells (McAdam et al., 2000). It is thought that CD28 primes T cells and ICOS 
regulates effector responses (Gonzalo et al., 2001). CD40-CD40L interaction 
selectively induces Thi cells as a result of the production of IL-12 by APC 
(Howland et al., 2000). 0X40-0X40L interaction favours Th2 responses (Akiba et 
al., 2000; Ohshima et al., 1998) as does CD30-CD30L (Del Prete et al., 1995) and 
CD4 signals (Rogers and Croft, 2000). In contrast, LFA-1 signals appear to 
potently switch cells towards the Thi phenotype (Salomon et al., 1998).
The type of APC stimulating the T cell may also play a role in the polarisation of a 
lymphocyte to a Thi or a Th2 phenotype (Aloisi et al., 1999). Some studies have 
reported that B cells are particularly prone to inducing type 2 outcomes (Liano and 
Abbas, 1987), which is consistent with their need to drive a type 2 response to 
stimulate their own production of antibody. Conversely, macrophages may be 
more likely to stimulate type 1 outcomes (Schmitz et al., 1993). Dendritic cells, the 
most potent antigen-presenting cells (Croft et al., 1992; Cassell et al., 1994; 
Masten et al., 1999), are capable of driving both type 1 and type 2 outcomes, 
depending on the local cytokine environment (Hilkens et a i, 1997). DC
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phenotypes that elicit Th1 or Th2 development have been described as DC1 and 
DC2, respectively. In mice, these distinct subsets selectively induce Th1 or Th2 
responses as a result of their differential secretion of IL-12 (Maldonado-Lopez et 
al., 1999).
Further, the route of antigen entry also influences the type of immune response. 
For example, intramuscular injections of DNA vaccine induced Th1 type 
responses , whilst intravenous injections gave a mixed Th1/Th2 type response as 
assessed by antigen-specific antibody classes (McCluskie et al., 1999).
Finally, hormones such as glucocorticoids, are powerful stimulators of type 2 
responses and powerful inhibitors of type 1 responses, directly inducing IL-4 and 
IL-10 production from lymphocytes and APC (Daynes et al., 1990; van der Poll et 
al., 1996; Ramirez, 1998). Like glucocorticoids, estrogens, progestins and 
catecholamines inhibit type 1 cytokine production and stimulate the secretion of 
type 2 cytokines (Guilbert, 1996; Szekeres-Bartho and Wegmann, 1996; Kanda 
and Tamaki, 1999; Sanders et al., 1997; Coqueret etal., 1994).
1.4 Transcription factors for Thi or Th2 development and commitment
IL-12 binds to a receptor that consists of two chains, IL-12Rp1 and IL-12Rp2, 
causing binding and activation of the transcription factor Janus kinase (JAK)1 and 
tyrosine kinase (TYK)2 which in turn will then activate the signal transducers and 
activator of transcription (STAT)1, STATS and STAT4. STAT4 signalling is 
especially crucial for Thi responses (reviewed by O’Garra and Arai, 2000, Fig. 
1.2). The ectopic expression of IL-12R(32 in developing Th2 cells results in the
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ability of IL-12 to activate STAT4 and proliferation in these cells, however, it does 
not lead to significant production of IFN-y. These results confirms that IL-12Rp2 
and IL-12-dependent STAT4 activation is required for Thi responses, but 
activation of this pathway is not sufficient to restore a Thi phenotype in 
developing or committed Th2 (Nishikomori et al., 2000; Heath et al., 2000).
Szabo et al. (2000) have recently isolated T-bet, a protein selectively expressed in 
Thi but not in Th2 cells. T-bet belongs to the T box family of transcription factors 
that play crucial roles in diverse developmental processes (Szabo et al., 2000). IL- 
12 seems to induce expression of T-bet, which is enhanced by IL-18 (Heath et al., 
2000). It controls the expression of the hallmark Thi cytokine, IFN-y. In contrast, 
T-bet expression represses the activation of the IL-2 promoter, explaining findings 
that differentiating Thi cells down regulate IL-2 expression. Retroviral gene 
transduction of T-bet into polarised Th2 and Tc2 primary T cells redirected them 
into Thi and Tel cells, respectively. Remarkably, introduction of T-bet into a 
stably committed Th2 population also dramatically increased the number of IFN-y- 
producing cells and reduced the number of IL-4- and IL-5-producing cells (Szabo 
et al., 2000). Thus, T-bet can convert Th2 into Thi cells.
A number of transcription factors have been implicated in Th2 differentiation: 
STAT6, NF-IL-6, NFATc/2, AP-1/Jun-B, c-Maf, SKAT2 and GATA-3 (O’Garra, 
1998; Murphy et al., 1999; Rincon and Flavell, 1997; Szabo et al., 1997a; Zheng 
and Flavell, 1997; Zhang etal., 1997; Ho etal., 1996; Blanchard etal., 2000). 
Ligation of IL-4 with its receptor activates signalling through several pathways. 
JAK1 and JAK3 activate STAT1, STAT3 and the Th2 specific STAT6 (Hou et al.,
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1994). STAT6-deficient mice showed defects in Th2 responses (Kaplan et al., 
1996; Shimoda et al., 1996; Takeda et al., 1996), similar to the phenotype of IL-4- 
deficient mice (Kuhn et al., 1991; Kopf et al., 1993), indicating a crucial role for 
STAT6 in inducing Th2 differentiation. When STAT6 was transduced retrovirally 
into naïve T cells driven under Thi conditions, activation of STAT6 induced the 
production of IL-4, IL-5 and IL-10 and repressed Thi development and production 
of IFN-y at least in part through inhibition of IL-12 Rp2 (Kurata et al., 1999). 
Additionally, GATA-3 and c-maf expression was induced, suggesting that these 
factors are downstream from STAT6 in the IL-4R signalling cascade (Kurata et al.,
1999).
Although NFAT and AP-1 proteins are important for inducing IL-4 and IL-5 
transcription, they are present in both Thi and Th2 subsets and do not appear to 
account for the Th2-restricted expression of IL-4 (Rooney et a/.,1995). Recent 
findings show that NFATp and NFAT4/X can excert a negative regulatory role on 
IL-4 expression in vivo, whereas NFATc apparently positively transactivates the 
IL-4 promoter (reviewed in Szabo et al., 1997a).
c-Maf is another transcription factor selectively expressed in naïve T cell at low 
level and in Th2, but not Thi cells (Ho et al., 1996). It directly augments IL-4 
promoter activity through cooperative interaction with Nip-45, NF-AT (Ho et al., 
1996, 1998) and JunB (Rincon and Flavell, 1997). c-Maf-deficient mice have been 
shown to be defective in IL-4 production (Kim et al., 1999), but retroviral infection 
of developing Thi cells with c-Maf did not induce the expression of IL-4 (H.J. Lee 
et al., unpublished).
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SKAT2 has also been identified in Th2 but not in Th1 cells (Blanchard et a!., 
2000). Transfection studies suggest that it upregulates the activity of the gene 
promoter for IL-4 but not IL-5 (Blanchard et al., 2000). Thus, SKAT2 and GATA-3 
(see below) might contribute to the selective regulation of Th2 cytokine genes.
The importance of GATA-3 in Th2 cytokine gene expression and/or Th2 
differentiation has been demonstrated by several investigators. GATA proteins (1- 
6) are members of a zinc-finger superfamily of DNA-binding proteins and 
recognize a common consensus motif through a conserved zinc-finger DNA- 
binding domain (Orkin, 1992). Zheng et al. (1997) reported that the transcription 
factor GATA-3 is expressed in naive T cells and Th2 but not Thi cells and is 
critical for IL-5 gene expression by activating the IL-5 promoter. A GATA-3 binding 
site was identified in the IL-5 promoter (Zheng and Flavell, 1997; Lee et al., 1998). 
In a different study, GATA-3 was shown to be important and sufficient for the 
expression of other Th2 cytokines including IL-4, IL-6 and IL-10; GATA-3- 
dependent enhancer activity has been found within several regions surrounding 
the IL-4 gene (Zheng and Flavell, 1997; Ranganath et al., 1998). This suggests 
that GATA-3 controls also IL-4 expression through distal enhancer elements 
outside the IL-4 promoter. cAMP enhanced the GATA-3 effects to induce IL-4 and 
IL-5, although it had no effect on inducing these cytokines in Thi cells in isolation 
(Lee et al., 2000). Further, STAT6 and CD28-mediated signalling can also 
upregulate the expression of GATA-3 (Kurata et al., 1999; Rodriguez-Palmero et 
al., 1999). Retroviral infection of naïve T cells with GATA-3 when cultured under 
Thi conditions induced the production of Th2-specific cytokines and
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downregulated IFN-y production at least in part through repression of IL-12 
signalling (Ferber et al., 1999; Ouyang et al., 1998). In addition to modulating 
cytokine production, ectopic expression of GATA-3 induced the expression of 
endogenous GATA-3 in developing Thi but not in committed Thi cells, 
suggesting autoregulation of GATA-3 in Th2 cells (Ouyang et al., 2000; Lee et al.,
2000). It is thought to be a major factor in the control of the production of all Th2- 
specific cytokines, thus maintaining the Th2 phenotype (reviewed in O’Garra and 
Arai, 2000).
1.5 Thi and Th2 cytokine gene regulation at the chromatin ievel
Thi and Th2 differentiation are accompanied by changes in Dnase I 
hypersensitivity and the méthylation state of the IFN-y ar\6 linked the IL-4/IL-13/IL- 
5 genes (Takemoto et al., 1998; Agarwal et al., 1998). These changes are 
associated with selective accessibility of gene regulatory regions to DNA-binding 
proteins. While the cytokine IL-2 is produced by antigen-stimulated naïve T cells 
even prior to S phase, the production of IFN-y becomes apparent after one cell 
cycle, the production of IL-4 after 3-4 cycles (Bird et al., 1998; Gett et al., 1998). In 
naïve T cells the IFN-y and the linked IL-4/IL-13/IL-5 genes reside in a chromatin 
environment that is not accessible to transcription factors (reviewed in Bird et al., 
1998; Agarwal et al., 1998). The first exposure of naïve T cells to antigen and 
cytokine results in specific changes in the chromatin structure and DNA 
méthylation of the relevant cytokine genes. The differentiation to Th2 cells is 
associated with changes in the chromatin structure of the IL-4 and the IL-13 gene
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(Agarwal et al., 1998; Agarwal et al., 1998a; Takemoto et al., 1998). 
Complimentary changes in chromatin occur at the /FA/-/locus in the course of Th1 
commitment (Agarwal etal., 1998; Agarwal etal., 1998a).
Transcription factors such as GATA-3 and T-bet, the main inducers of Th2 and 
Thi differentiation, might control the production of subset specific cytokines also 
by inducing epigenetic changes in the chromatin structure. T-bet has been shown 
to specify Th1 effector fate by targeting chromatin remodeling to individual IFN-y 
alleles (Mullen et al., 2001). After polarisation, the majority of silenced cytokine 
alleles were repositioned to heterochromatin. Naïve T cells transit through 
sequential stages of cytokine activation, commitment, silencing and physical 
stabilization during polarisation into differentiated effector subsets (Grogan et al., 
2001).
1.6 Cross-regulation between Thi and Th2 cells
Thi and Th2 cells can antagonize each other by blocking both differentiation and 
effector functions. IL-4, STAT6, GATA-3 and Maf act to maintain the Th2 
phenotype of differentiated T cells and down regulate Thi cytokine expression. 
The presence of high concentrations of IL-4 and IL-10 inhibits the secretion of IL- 
12 and IFN-y, blocking the ability to generate Thi cells from naïve T cells (Hsieh et 
al., 1993; Rincon and Flavell, 1997; D'Andrea et al., 1993; Ohmori et al., 
1997,Gajewski et al., 1988; Demeure et al., 1994). The downregulation of IFN-y 
production by IL-4 appears to be mediated through the STAT6 target gene 
products GATA-3 and Maf. Ectopic expression of GATA-3 or Maf, even in IL-4-
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deficient naïve T cells results in marked inhibition of IFN-y production by Th1 cells 
(reviewed in Rao and Avni, 2000). In the mouse, differentiating Th2 cells lose 
expression of the p2 subunit of the IL-12 receptor, thus dampening their ability to 
respond to IL-12 stimulation and focusing their cytokine production towards IL-4. 
Ectopic expression of GATA-3 in murine Thi cells also results in downregulation 
of IL-12RP2 chain expression, indicating that this downregulation is also mediated 
by GATA-3. IL-10 which is produced in large amounts by Th2 cells inhibits 
macrophage functions such as secretion of IL-12, that induces Thi cell 
development. IL-10 also antagonizes the upregulation of MHC molecules caused 
by IFN-y (reviewed in Moore et al., 1993; Mosmann and Moore, 1991).
Conversely, ectopic expression of the Thi transcription factor T-bet in 
differentiating T cells leads to down-regulation of IL-2 and several Th2-specific 
cytokines, suggesting that the role of this transcription factor in the Th2 lineage is 
analogous to that of GATA-3 in the Th2 lineage (reviewed in Rao and Avni, 2000). 
IFN-y secreted by Thi cells directly suppresses IL-4 secretion and therefore 
inhibits differentiation into Th2 cells (Gajewski et al., 1988; Demeure et al., 1994) 
and blocks the proliferation of Th2 effector cells (Fitch et al., 1993). Thi cells are 
unaffected because they do not express the p chain of the IFN-y receptor (Pernis 
et al., 1995).
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1.7 Definition of Thi and Th2 cells by differentially expressed cell 
surface proteins
The identification of novel cell surface markers specific for the Thi or Th2 cell 
subset could provide a tool to assess and modulate the Th1/Th2 cell balance in 
diseases. CD4(+) effector T cells generated in vitro express a broad range of 
chemokine receptors, some of which are preferentially expressed on Thi cells, 
such as CXCR3, CCR5 (reviewed in D’Ambrosio et al., 2000). CXCR3 binds to the 
chemokines IP10 (interferon-inducible protein 10), l-TAC (interferon-inducible T 
cell alpha-chemoattractant) and Mig (monokine induced by gamma-interferon), 
while CCR5 binds to MIP1( (macrophage-inflammatory protein) (Sallusto et a!., 
1998; Laurence et al., 2001). The chemokine receptors CCR3, CCR4, CCR8, 
which bind to eotaxin, TARC (thymus and activation-regulated chemokine) and 
MDC-1 (macrophage-derived chemokine) respectively (Sallusto et al., 1998; 
Sallusto et al., 1998a), are preferentially expressed on Th2 cells (Sallusto et al., 
1997; Bonecchi et al., 1998; Sallusto et al., 1998; O’Garra and McEvoy et al., 
1998). Chemokines which act as agonists for CXCR3, are antagonists for CCR3 
(Loetscher et al., 2001). These results suggests that chemokines that attract Thi 
cells via CXCR3 can concomitantly block the migration of Th2 cells in response to 
CCR3 ligands, thus enhancing the polarisation of T cell recruitment. Recently, a 
novel leukocyte chemoattractant receptor, expressed only on Th2 cells, has been 
reported, which was designated CRTH2, (chemoattractant receptor-homologous 
molecule expressed on Th2 cells). Allergen-induced proliferation of peripheral 
blood mononuclear cells is significantly reduced by antibody-mediated depletion of
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CRTH2(+) cells (Nagata et a/., 1999). These findings suggest, that distinct 
chemotactic signals may contribute to the preferential localization of Thi and Th2 
cells in sites of inflammation.
Other Thi cell-specific cell surface molecules include the IL-12R[32 chain, whose 
expression ensures Thi type polarisation and IFN-y production and which is lost 
from polarising Th2 cells (Szabo et al., 1997). IL-18R is a member of the IL-1R 
family and its signalling in combination with IL-12R signalling induces a strong 
IFN-y production and drives Thi development (Robinson et al., 1997). IL-18R was 
found to be selectively expressed on Thi cells (Xu et al., 1998a). LAG-3, another 
Thi cell-specific surface marker, is a MHC class II ligand that has been used in 
vivo to stimulate MHC class ll(+) ARC to increase tumor-specific immune 
responses (El Mir et a!., 2000). Its expression is strongly increased by IFN-y 
(Annunziato et al., 1997; Scala et a i, 1998). IFN-y receptor (3 chain expression is 
downregulated in polarising Thi cells and stays unaffected in polarising Th2 cells, 
maintaining their susceptibility to IFN-y induced suppression of proliferation 
(Pernis et al., 1995). Lymph node homing receptor CD62L (L-selectin) expressing 
CD4(+) T cells were found to produce IL-4 and IL-5, whereas CD62L negative 
CD4(+) T cells expressed IFN-y (Kanegane et al., 1996). Finally, the molecule of 
interest for this thesis - the orphan receptor ST2L, which has been linked to Th2 
cell effector functions, is differentially expressed on Th2 but not on Thi cells (Xu 
et al., 1998).
Expression patterns of “stable” cell surface makers for Thi and Th2 cells should 
be unique for the respective subset. Chemokine receptors are generally not used
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to distinguish Th1 from Th2 cells due to their transient expression and partly 
overlapping expression patterns. For example, major fractions of circulating 
CCR4(+) memory CD4 lymphocytes co-express the Th1-associated receptors 
CXCR 3 and CCR5, suggesting a potential problem in using these markers for 
Th1 versus Th2 lymphocyte cells (Andrew et a/., 2001). In the murine and the 
human system, ST2L and IL-18R are widely applied to distinguish Thi and Th2 
cells (Liew et a/., 1999; Chan et a/., 2001). IL-12 receptor |32 and IFN-y receptor p 
are also useful markers for Thi and Th2 cells, respectively (Hamalainen et al., 
2000; Rogge et al., 1999; G roux et al., 1997a). Thi and Th2 responses can be 
modulated by using anti-ST2L antibodies, anti-IL18R antibodies or anti-IL-12 
antibodies in vitro and in vivo (Xu et ai., 1998; Xu et al., 1998a; Heinzel and 
Rerko, 1999).
1.8 ST2 and ST2L: members of the IL-1 receptor superfamily
1.8.1 IL-1 receptor/Toll-llke superfamlly
The interleukin-1 (IL-1) receptor/Toll-like receptor (TLR) superfamily is an 
expanding group of receptors that participates in host responses to injury and 
infection. The superfamily is defined by the Toll/IL-1 receptor (TIR) domain, which 
occurs in the cytosolic region of family members and is further subdivided into two 
groups based on homology to either the Type I IL-1 receptor or the Drosophila Toll 
receptor extracellular domain (Fig.1.3). The former group includes the IL-18 
receptor and ST2L, which may have a role in Th2 cell function. The latter group
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Fig. 1.3 IL-1 Rl Toll family
The family is defined by the presence of the Toll/IL-1 receptor (TIR) domain, 
which is involved in signalling, and is subdivided into two groups based on 
homology to either IL-1R-like extracellular immunoglobulin loops (shaded 
elipses) or Toll-like leucine-rich repeats (stippled elipses).The family includes 
members from mammals, insects and plants (reviewed in Fitzgerald and 
O'Neill, 2000).
54
includes at least ten mammalian TLRs (Kaisho and Akira, 2001), including TLR2, 
binding to gram-positive bacteria and mycobacteria, and TLR4, part of the 
lipopolysaccharide (LPS) receptor and essential for the recognition of both gram- 
negative bacteria and respiratory syncytical virus (reviewed in Bowie and O’Neill, 
2000; Takeuchi et al., 1999; Brightbill et al., 1999; Poltorak et al., 1998; Kurt- 
Jones et al., 2000).
1.8.2 IL-1R family members
IL-1 (reviewed in Nicola, 1994) is secreted mainly by monocytes, macrophages 
and kératinocytes. There are three members of the IL-1 gene family: IL-1 a , IL-ip 
and IL-1 Ra (IL-1 receptor antagonist). IL-1 a and IL-lp are agonists and IL-IRa 
acts as a specific receptor antagonist. In most studies the effects of IL-1 a and IL- 
lp  in terms of biological activity are indistinguishable. IL-1 is produced in response 
to microbes and microbial products such as LPS as well as in response to viruses, 
IFN-y and TNF-a. It has a central role in inflammatory responses and autoimmune 
diseases such as rheumatoid arthritis. IL-1 affects a wide range of cells involved in 
immune and inflammatory responses including fibroblasts, where it causes 
proliferation and prostaglandin release. It causes for example keratinocyte 
proliferation and IL-6 release, B cell differentiation and Ig secretion and Th2 cell 
proliferation.
IL-1RI, IL-1RII and the IL-1 receptor accessory protein (IL-1RAcP) belong to the 
IL-1R superfamily (reviewed in Dinarello, 1998). The extracellular domains of the 
IL-1RI, IL-1RII and the IL-1R-AcP are members of the immunoglobulin superfamily
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and are heavily glycosylated. Blocking the glycosylation sites reduces the binding 
of their ligand IL-1 (Mancilla et al., 1992). IL-1R family members have a single 
transmembrane segment and a cytoplasmic domain of varying length. IL-1RI is 
the primary signal transducing receptor (Stylianou et al., 1992, Sims et al., 1993), 
while the type II receptor lacks a signal transducing cytosolic domain and is 
therefore nonfunctional. IL-1 binds first to the IL-1RI with a low affinity, which may 
cause a structural change in IL-1, which allows the IL-1R-AcP to join the IL-1RI-IL- 
1 complex, producing a high-affinity binding complex. (Greenfeder et al., 1995) 
(Fig. 1.4). After binding of IL-1 to the IL-1RI/IL-1R-AcP complex, the adapter 
protein MyD88 is recruited and binds to IRAK-1 and 2 (IL-1R-associated kinase-1 
and 2) and the signalling complex of the two receptor chains. Thereby it mediates 
the association of IRAK-1 and 2 with the receptor. IRAK-1 and 2 become heavily 
phosphorylated and concomitantly activated. Then IRAK-1 and 2 regulate the 
redistribution of TAB2 (TAK-1 binding protein 2), facilitating the formation of a 
TRAF6 (TNF receptor-associated factor 6)-TAB2-TAK1 (TGF-p activating kinase 
1) complex, which is an essential step to activate TAK1. TAK1 then activates NIK 
(NF-KB-inducing kinase) leading to the activation of NF-kB via the signalsome (a 
large multiprotein signalling complex that contains IKKs [I-kB kinases]). MyD88 
and IRAK-1 also participate in the activation of p38 and JNK (Jun N-terminal 
kinase) pathways (reviewed in O'Neill and Dinarello, 2000; Wesche et al., 1997; 
Knop and Martin, 1999; Takaesu et al., 2001; Takaesu et al., 2000; Ninomiya- 
Tsuji et al., 1999). In T lymphocytes the addition of IL-1 increases nuclear binding 
of c-jun and c-fos, the two components of AP-1 (Muegge et al., 1989). The
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Fig. 1.4 IL-1 receptor (IL-1 R) signalling pathways
IL-1 binds first to the IL-1RI with low affinity. This allows the IL-1R accessory 
protein (AcP) to join and form a high-affinity binding complex. After binding of 
IL-1 to the IL-1 RI/!L-1R-AcP complex, the adaptor protein MyD88 is recruited 
and binds to the IL-1R-associated kinase-1 and 2 (IRAK-1 and 2) and the 
signalling complex of the two receptor chains. This then mediates the 
association of IRAK-1 and 2 with the receptor. IRAK-1 and 2 become 
phosphorylated and concomitantly activated. Then IRAK-1 and 2 regulate the 
redistribution of TAK-1 binding protein 2 (TAB2) and facilitates the formation of 
a TNF receptor-associated factor 6 (TRAF6) -TAB2-TAK1 complex, which is an 
essential step to activate TAK1 (TGF-p activating kinase 1). TAK1 then 
activates the NF-KB-inducing kinase (NIK) leading to the activation of NF-kB via 
the signalsome [a large multiprotein signalling complex that contains IKKs (I-kB 
kinases)]. MyD88 and IRAK-1 also participate in the activation of p38 and JNK 
pathways. The translocation of the transcription factors NF-kB, p38, JNK and 
AP-1 to the nucleus leads to the expression of a large number of genes 
characteristic of inflammation (reviewed in Dinarello, 1998).
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translocation of the transcription factors NF-kB, p38, JNK and AP-1 to the nucleus 
leads to the expression of a large number of genes characteristic of inflammation, 
such as IL-6, IL-8, ICAM-1 and IL-1 itself (reviewed in Nicola, 1994).
The IL-18R was originally identified using degenerate oligonucleotides based on 
conserved regions in the TIR domain. The amino acid sequence of IL-18R is 
identical with that of IL-1R-related protein (IL-IRrp, Yoshimoto et a i, 1998), which 
was initially cloned as an orphan receptor bearing similarity to the type I IL-1R (IL- 
1RI, Parnet et a i, 1996). It was shown to signal given the fact that a chimeric 
receptor incorporating the extracellular domain of IL-1RI fused to the intracellular 
domain of IL-18 could bind IL-1 and lead to NF-kB activation (Parnet et a i, 1996). 
Similar to IL-1, IL-18 requires an accessory protein (IL-18R-AcP) to associate with 
the receptor-ligand for signalling. IL-18 binds to IL-18R and induces the activation 
of IL-1R-associated kinase, TRAF-6, NF-kB, and c-Jun N-terminal kinase (JNK) in 
Thi cells (Okamura et al., 1998; Torigoe et a i, 1997; Kojima et a i, 1998; Adachi 
et a i, 1998). Further, MyD88 is a critical component in the IL-1 and IL-18 receptor 
signalling cascade (Adachi et a i, 1998). Therefore, IL-1R and IL-18R share 
common signalling pathways, such as the MyD88/IRAK/TRAF6 signalling pathway 
leading to the activation of NF-kB and JNK (Kojima et a i, 1998).
The member of the IL-1R family this thesis is concerned with is ST2L, an orphan 
receptor and its shorter soluble variant ST2 (Yanagisawa et a i, 1993; Tominaga 
et a i, 1989). ST2L is able signal to NF-kB by using a chimeric receptor 
incorporating the extracellular domain of IL-1RI fused to the intracellular TIR- 
containing ST2L domain (Mitcham et a i, 1996).
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1.8.3 ST2 and ST2L
Murine ST2 mRNA (2.7 kb) was first identified to be expressed in growth- 
stimulated murine fibroblasts and found to be related to the immunoglobulin 
superfamily (Tominaga et a!., 1989). A 5 kb long mRNA transcript called ST2L, 
exhibiting 28% sequence similarity to IL-1RI (Yanagisawa et al., 1993), was 
identified through screening of a fibroblast library with a ST2 cDNA fragment 
(Yanagisawa et al., 1993). The longer transcript (ST2L) translates to a membrane 
bound form consisting of three parts: an extracellular region with three 
immunoglobulin domains and N-glycosylation sites, a putative transmembrane 
domain and a cytoplasmic domain. The shorter transcript (ST2) translates to the 
soluble form, which shares the common extracellular domain, but lacks the 
transmembrane and the intracellular domain (Gaechter et al., 1996; Gaechter et 
al., 1998) (Fig. 1.5).
The expression pattern of the murine soluble and membrane bound receptor form 
differ drastically. The ST2L mRNA transcript is restricted to cells of major 
haemopoietic organs like fetal liver, spleen, bone marrow (Roessler et al., 1995) 
and to cells of the lung, a non-haemopoietic organ, throughout ontogenesis 
(Bergers et al., 1994). It was also found in macrophage cell lines, erythroid 
progenitors and bone marrow-derived mast cells (Roessler et al, 1995; Bergers et 
al., 1994). Further, Xu et al. (1998) reported that ST2L is expressed on Th2, but 
not Th1 cells. The short mRNA transcript is predominantly expressed in non 
haemopoietic tissues such as embryonic bone, skin and retina. It was also
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Fig. 1.5 Structure of IL-1 Rl, ST2L and ST2
ST2L is an a orphan receptor related to IL-1RI, consisting of 3 parts, an 
extracellular region with three immunoglobulin-like domains and N-glycosylation 
sites, a putative transmembrane domain and a cytoplasmic domain. ST2, the 
shorter splice variant, shares the common extracellular domain but lacks the 
transmembrane and the intracellular domain (taken from Yanagisawa et al.,
1993).
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identified in developing mammary gland, fibroblast cell lines and some T cell lines 
(Roessler etal., 1995).
These differential expression patterns suggests that ST2L and ST2 may have 
different functions on different cell types and that their expression should be 
controlled at promoter level and/or post-transcriptional level. In rat fibroblasts, 
alternative promoter usage leads to the generation of ST2 and ST2L from the 
proximal and distal promoter, respectively. The sequence difference at their 3’ end 
results from alternative 3’ processing (Berger et a!., 1994). In contrast, in the 
mouse and human, the mRNA for both ST2 and ST2L is transcribed from one 
promoter. The murine upstream (distal) promoter directs transcription of ST2 and 
ST2L in haemopoietic cells such as mast cells, whilst the murine downstream 
(proximal) promoter directs expression in fibroblasts (Thomassen et a/., 1995; 
Gaechter ef a/., 1996; Iwahana et a!., 1999). Gaechter et al. (1996) suggested that 
transcription initiation is tightly coupled to 3’ processing, such that if transcription 
starts at the distal promoter, the long mRNA is produced, whereas initiation at the 
proximal promoter instructs the transcription machinery to give rise to the short 
transcript. Which one of these two promoters is active in murine T cells is yet to be 
identified.
ST2L expression is upregulated by serum stimulation of Th2 cells (Xu et al.,
1998), by overexpression of the GATA-1 transcription factor in mast cells, the 
expression of Fos-ER in fibroblasts and by addition of LPS to monocytes 
(Gaechter et al., 1998; Berger ef a/., 1994; Saccani et al., 1998), Recently, Meisel 
et al. (2001) reported that ST2L is not expressed on naïve Th cells, but Th2
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polarising conditions dramatically increase the number of ST2L expressing cells. 
Several ARC or T cell-derived cytokines, such as IL-6, IL-5, IL-1, TNF-a, which are 
growth and/or survival factors for Th2 cells (Joseph et a/., 1998; La Flamme et a/.,
1999), are able to enhance the expression of ST2L on Th2 cells (Meisel et al., 
2001).
ST2 expression is induced by inflammatory stimuli such as LPS (Saccani et al., 
1998). Further, IFN-y, TNF-a, IL-ip, UVB, calcium ionophores as well as 
oncogenes (Fos and Ha-ras) and the growth factors PDGF, FGF and bFGF 
induce ST2 expression in fibroblasts and mast cells (Kumar et al., 1997; Laursen 
et al., 1998; Gaechter et a/., 1998; Werenskiold et al., 1989). However, the role of 
Thi and Th2 type cytokines in the differential regulation of ST2 and ST2L gene 
expression in T helper lymphocytes is unclear.
The function of ST2L is still controversial. Anti-ST2L antibodies have been 
successfully used to alter the Th1/Th2 type balance in in vivo disease models, 
such as Leishmania major infection in BALB/c mice, where an increased 
resistance to the infection was reported in antibody treated mice (Xu et al., 1998). 
This treatment also exacerbated collagen-induced arthritis in DBA/1 mice, 
attenuated eosinophilic inflammation and reduced the lung inflammation caused 
by respiratory syncytial virus (Xu et al., 1998; Loehning et al., 1998; Walzl et ai., 
2001). These results showed that inhibition of ST2L and/or complement mediated 
killing of ST2L-expressing Th cells resulted in decreased Th2 responses. Cross- 
linking of ST2L with monoclonal anti-ST2L antibody (anti-ST2L mAb) provided a 
costimulatory signal for Th2 but not for Thi cells and directly induced proliferation
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and type 2 cytokine production (Meisel et a i, 2001). This demonstrates that ST2L 
plays an important role in the activation of Th2 cells. Several groups used a ST2- 
Fc fusion protein, containing the extracellular part of ST2L, to mimic the effects of 
ST2. Treatment with ST2-Fc reduced the number of eosinophils in the airway and 
the secretion of Th2 cytokines during eosinophilic inflammation (Loehning et a!., 
1998; Coyle et al., 1999) as well as lung inflammation and airway 
hyperresponsiveness in a murine model of allergic asthma (Coyle et al., 1999). 
Inhibition of ST2L signalling with either anti-ST2L mAb or ST2-Fc fusion protein 
selectively inhibited cytokine secretion from Th2 cells (IL-4, IL-5, IL-6) without 
modifying IFN-y secretion by Thi cells (Coyle et al., 1999). Presuming that ST2 
and ST2L compete for the same ligand and therefore ST2 can block ST2L 
signalling, the results suggest that ST2L signalling is required for optimal 
production of Th2, but not Thi cytokines. In contrast, ST2-Fc fusion protein 
impaired inflammatory cytokine responses in LPS-stimulated macrophages, which 
do not express ST2L (Sweet et al., 2001). ST2-Fc was shown to mediate this 
function by binding to an unidentified cell surface molecule (Sweet et a i, 2001). 
ST2L is an orphan receptor, so the identification of its ligand is essential to extend 
the knowledge about its function. Binding studies using ST2L revealed affinity to 
membrane-bound molecules of B cell lines (myeloma-derived RPMI8226 cells) 
(Yanagisawa et a i, 1997) and activated B cells (Lambrecht et a i, 2000), dendritic 
cells and activated macrophages (unpublished data from Coyle, 1999; Sweet et 
a i, 2001). Gayle et a i (1996) reported the cloning of a putative ligand, a cell 
surface protein from a neuroblastoma cell line, which was unable to initiate signal
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transduction by ST2L receptor. ST2L also bound to a putative ligand secreted 
from BALB/c 3T3 fibroblasts and human umbilical vein endothelial cells (Kumar et 
al., 1995).
One out of three created ST2L knockout mice demonstated the importance of 
ST2L signalling for Th2 development and effector function. Townsend et a i (2000) 
found, that in a primary pulmonary granuloma model induced by Schistosoma 
mansoni eggs eosinophil infiltration was abrogated in ST2L-/- mice and the level 
of Th2 cytokine was impaired. Even in a secondary pulmonary granuloma model, 
draining lymph nodes cells from the ST2L-/- animals produced significantly 
reduced levels of IL-4 and IL-5, despite developing granulomas of a magnitude 
similar to those of wild type mice and comparable antigen-specific Ig isotype 
production. ST2L expression does not play a role in the in vitro generation of Th2 
cells and Th2 cytokines in cells derived from naïve animals, but its presence can 
affect the onset of Th2 cytokine responses to antigenic stimulation in vivo. 
However, Hoshino et al. (1999) and Senn et al. (2000) reported no effects of ST2L 
deficiency on Th2 cell development and effector functions induced by infection 
with the helminthic parasite Nippostrongylus brasiliensis and in the mouse model 
of allergen-induced airway inflammation. In summary, ST2L signalling is essential 
for Th2 cell effector functions but not for Th2 cell development, which was 
confirmed by studies with anti-ST2L antibodies, ST2-Fc fusion protein and ST2L 
knockout mice. Binding of ST2L to cell surface molecules and soluble molecules 
has been found, but no functional ligand has yet been cloned.
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In ST2L expressing cells, ST2 might compete for the ligand and therefore prevent 
ST2L signalling. In cells which do not express ST2L, ST2 might mediate its 
function by binding to a membrane bound ST2 binding protein (Fig. 4.1), which 
then can signal and cause changes in effector functions as seen in macrophages 
(Sweet et al., 2001 ). Part of this current work was designated to establish an effect 
of ST2 on ST2L(-) naïve T helper cells and to address the question whether this 
effect is mediated by binding of ST2 to a Th cell surface molecule.
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1.9 Function of Thi and Th2 cells in disease
The cytokine profiles determine the effector functions of the Th cell subset during 
immune response.
Table 1.2 Th1/Th2 cell protective/pathogenic effects in diseases
Thi effector cells Th2 effector cells
Protective
against
• intracellular bacterial infections, 
e.g. mycobacteria
• fungal infections
• intracellular parasites, 
e.g. L. major
• most extracellular bacteria
• metazoan parasites, e.g. helminth 
infections
Pathogenic
in
• organspecific autoimmune diseases, 
e.g. experimental allergic 
encephalomyelitis (EAE), 
insulin-dependent diabetes, 
rheumatoid arthritis
• L. major infections
• chronic graft-versus host disease
• progressive systemic sclerosis
• systemic lupus erythematosus
• allergies, e.g. asthma
(reviewed in Spellberg and Edwards, 2001 : Lafaille, 1998; Romagnani, 1997)
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1.9.1 Type 2 protective and pathogenic responses
Th2 cell mediated responses make BALB/c mice inherently resistant to infections 
by helminths (Else et al., 1991). Type 2 responses correlate with diminished worm 
burden, whereas type 1 responses allow chronic infection and scarring to develop 
(Else et al., 1993). Abrogation of IFN-y production or administration of exogenous 
IL-4 in mice susceptible to helminths reversed their normal type 1 immunity and 
the resultant type 2 responses mediated expulsion of the parasite from the gut 
(Else et al., 1994). Th2 cell responses are pathogenic during allergic responses 
such as asthma, which is a chronic disorder of the airways characterised by 
airway narrowing, mucus hypersecretion, and Infiltration of the airway wall with 
eosinophils. It is now believed that asthma is controlled by Th2 lymphocytes 
producing cytokines such as IL-4, IL-5, IL-9, and IL-13 (reviewed in van Rijt et al., 
2001). The infiltration of the tissues with increased numbers of eosinophils is the 
result of the co-ordinated action of cytokines, particularly IL-5 as well as CCR3 
binding chemokines and the adhesion molecules P-selectin and VCAM-1, acting 
in concert to cause selective trafficking of eosinophils into allergic tissue. This 
process is orchestrated by allergen-specific Th2 lymphocytes (Ward I aw et al.,
2000).
1.9.2 Type 1 protective and pathogenic responses
Pathogenic intracellular bacteria such as Salmonella typhimurium directly induce 
IFN-y production in infected mice. Strains of mice producing higher levels of IFN-y 
clear the microbes up to 10-fold more efficiently than lower IFN-y producing strains
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(Pashine et al., 1999). Therefore, type 1 repenses are used here by the immune 
system for protection against acute bacterial infection. Further, type 1 immunity 
has been shown to be protective against mycobacteria, such as Mycobacterium 
leprae. Mice inherently resistant to M. leprae produce IL-12 early on at the site of 
infection (Kobayashi et al., 1998; Sugawara et al., 1999), but mice susceptible to 
M. leprae infection fail to produce early IL-12 (Kobayashi et al., 1998).
Thi responses are pathogenic in autoimmune diseases such as diabetes mellitus. 
Type I (insulin-dependent) diabetes mellitus (IDDM) is an autoimmune disease 
that results from the destruction of insulin-secreting pancreatic islet beta-cells by 
autoreactive cells and their mediators. It is well established that IDDM is 
associated with dysregulated humoral and cellular immunity, exemplified by 
altered production of and response to macrophage and T cell-derived cytokines 
and a shift in T helper (Th) cell differentiation in favour of a pathogenic Th1 
pathway. Thi cytokines, including IL-2 and IFN-y, induce islet beta-cell destruction 
directly by accelerating activation-induced cell death (apoptosis) and by up- 
regulating the expression of selected adhesion molecules, Thi cytokines facilitate 
the pancreatic homing of autoreactive leukocytes, hence enhancing beta-cell 
destruction (reviewed in Almawi et al., 1999).
1.10 Antagonistic Thi and Th2 celi influence on L. ma/or infections
The classic model of type 1/type 2 immunity is Lelsmania major infection of 
BALB/c mice (reviewed in Spellberg and Edwards, 2001; Sher, 1992).
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1.10.1 Common forms of leishmaniasis
Leishmaniasis is a widespread and destructive protozoal disease of humans and 
animals. There is a range of clinical forms such as visceral, cutaneous and 
mucocutaneous leishmaniasis (Table 1.3). The Leishmania parasite is a protozoa 
subtype mastigophora/flagellate, which alters its host between a vertebrate 
(human) and the sandfly of the genera Phlebotomus and Lutzomyia, which is the 
vectors for the disease.
Table 1.3 Classification of Leishmaniasis
Disease Species
Visceral L. donovani
L. chagasi
Cutaneous L. major
L. tropicana
L. mexicana
L. amazonensis
Mucocutaneous L. brasiliensis
Cutaneous leishmaniasis (CL) caused by L. major (Oriental sore) is found mainly 
in the Middle East and Africa. Cutaneous lesions begin as small erythrematous 
papules on exposed areas of the body where infected sandfly vectors have fed. 
The incubation period may be as short as 1-2 weeks up to as long as 1-2 months. 
The early lesions may be pruritic, but the ulcer is not painful. The ulcer can remain 
relatively dry, or may exude seropurulent material. Cutaneous leishmanial lesions
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will eventually heal spontaneously, but they can persist for up to a year or more 
without treatment. Another form of cutaneous leishmaniasis, diffuse cutaneous 
leishmaniasis (PCD, is a striking but uncommon complication of cutaneous 
disease associated with immunological unresponsiveness to leishmanial antigens. 
This causes widespread thickening of the skin lesions that ultimatively resemble 
those of lepromatous leprosy and fail to heal spontaneously.
Visceral leishmaniasis (VL, Kala azar or Chaga’s disease) caused by L. donovani 
or L. chagasi is found in Africa, South Europe, Asia and South America. The 
parasite replicates in mononuclear phagocytic cells of the spleen, liver, lymph 
glands and bone marrow and produces a chronic disease. The incubation period 
of VL is usually long, 1-3 months. Common symptoms include fever, weight loss, 
anaemia, skin darkening and hepatosplenomegaly. In untreated cases deaths are 
common due to secondary bacterial infections such as pneumonia or tuberculosis. 
Mucocutaneous leishmaniasis, found in Middle and South America, is almost 
never self-healing. It occurs as a result of the parasite spreading from an initial 
lesion at the sandfly bite to the mucosal membranes. The lesions that develop can 
restrict airways and be grossly disfiguring, often requiring plastic surgery to repair.
1.10.2 Morphology and life cycle of the parasites
The leishmanial parasites exhibit only two forms in their life cycles (reviewed in 
detail by Chang et a!., 1990). In the alimentary tract of their insect vectors, the 
parasite exists extracellularly as the flagellate, motile promastigote. In the 
phagolysosomal vesicles of host mononuclear phagocytes, the parasite occurs
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intracellularly in the nonmotiie amastigote form. The amastigote, when ingested by 
the sandfly during a blood meal taken from an infected vertebrate host, migrates 
to the midgut of the sandfly, where it transforms into the promastigote in a process 
that takes about 3 days. As a result of replication by means of binary fission and 
subsequent migration to the foregut of the insect, the promastigote partially 
obstruct the digestive tract of the insect. When the infected sandfly takes a 
second blood meal, it regurgitates promastigotes from its pharynx into the 
bloodstream of the vertebrate. Once inside the bloodstream of the vertebrate, 
such as humans, canines or rodents, the promastigotes are phagocytosed by the 
mononuclear phagocytic cells of the host, whereupon they transform into 
amastigotes and begin replication within modified phagolysosomes designated 
parasitophorous vacuoles. Eventually, the host cells lyse, releasing free parasites. 
The newly released amastigotes then infect other cells or are taken up by 
sandflies, thereby completing the life cycle of the parasite (Fig. 1.6).
It seems that the amastigote has adapted to survive and multiply in an acid 
environment (pH4.5-5.5), because the environment of the phagosome becomes 
acidified after parasites or bacteria are ingested by macrophages. L. major 
amastigotes express a surface proton-translocating ATPase that can regulate the 
intracellular pH of the parasite (Zilberstein et al., 1985). In contrast, promastigotes 
survive maximally when the pH of the incubation medium is near 7.0 (Mukkada et 
al., 1985). The three clinical forms of leishmaniasis result from different affinities 
of the various species of Leishmania for macrophages located in different part of 
the body. Temperature may be one of the major factors involved in this tropism.
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Fig. 1.6 LeisAiman/a lifecycle
Typical lifecycle of Leishmania parasites. Extracellular flagellated promastigotes 
reproduce in the midgut of Phlebotomus and Lutzomyia sandflies. In a process 
called metacycligenesis they cease dividing, detach from epithelial cells and 
migrate to the insect mouthparts. When the sandfly feeds, metacyclic 
promastigotes are injected into the skin of the mammalian host (e.g. human) 
and enter the bloodstream. Parasites invade macrophages and differentiate into 
non-flagellated amastigotes in the phagolysosome. In this hostile environment, 
amastigotes are able to proliferate and are released by lysis of the host cell to 
infect other macrophages. Infected macrophages are ingested by feeding 
sandflies and parasites transform to the promastigote stage again to continue 
the cycle (reviewed in Chang et a/., 1990).
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The Leishmania species that produce cutaneous and mucocutaneous diseases 
grow better at the slightly cooler temperature (35°C) of the skin. In contrast, L. 
donovani, the cause of visceral leishmaniasis, prefers the slightly higher 
temperature of 39°C for growth (Berman and Neva, 1981).
1.10.3 Immunology of leishmaniasis
It is essential to investigate the immunology of leishmaniasis to be able to develop 
treatments against this destructive disease.
1.10.3.1 Animal models of leishmaniasis
The disease pattern produced in animals infected experimentally wih Leishmania 
differs widely according to both the animal and the Leishmania species involved. 
Experimental infections of hamsters and mice with L. donovani have been used as 
experimental models for human visceral leishmaniasis. In particular, studies of the 
murine model of infection with L. donovani have provided important information 
regarding the genetic aspects of resistance and susceptibility to infection by this 
parasite (Bradley, 1977).
Upon infection of mice with L. major, almost the entire spectrum of the disease 
pattern seen in human leishmaniasis can be observed (Behin et ai., 1979). The 
severity of disease depends on the genetic backround of the mouse (Howard et 
a/., 1980). For example, BALB/c mice exhibit severe lesions at the site of 
inoculation, followed by disseminated disease and death. Mice of other strains 
(e.g. CBA, C57BL) are resistant to infection, developing only small lesions at the
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site of inoculation which heal after a few weeks, followed by solid immunity to 
reinfection.
1.10.3.2 Protective mechanisms in leishmaniasis 
i) Role of macrophages
In humans infected with the promastigote form of L  major, the parasite is an 
obligate intracellular parasite of macrophages, in which it transforms into its 
amastigote form. Amastigotes are found in phagolysosomes in the macrophage, 
where they not only survive, but replicate, until parasite-specific T cell-mediated 
immunity intervenes and activates the macrophages sufficiently so that they can 
destroy the parasite (Titus et a!., 1992; Alexander et al., 1992).
There are different macrophage defence strategies to kill the intracellular parasite. 
An oxygen burst, producing reactive oxygen intermediate, is induced in 
nonactivated macrophages after phagocytosis of L  major, but the parasite can 
produce catalase and glutathione peroxidase in response (Murray, 1982; Murray, 
1981; Murray, 1981a). A second mechanism for killing the parasite is nitric oxide 
(NO) produced by inducible NO synthase (iNOS) (Green ef al., 1991; Liew et al., 
1991; Liew and Cox, 1991). Mice resistant to L. major infection produce 
significantly more NO and iNOS than susceptible mice (Liew ef al., 1991a). 
Inducible NOS-deficient mice showed susceptibility to Leishmania infection, 
confirming that reactive nitrogen intermediates are necessary and sufficient for 
control of visceral leishmaniasis infection (Murray ef al., 1999; Wei ef al., 1995).
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Additionally, TNF-a production in macrophages can destroy L  major parasites by 
increasing the NO production (Liew et a/., 1990). These macrophage resistance 
mechanisms are also induced by IFN-y released by Th1 cells (see below) (Titus et 
al., 1984; Nacy et al., 1985).
il) Role of humoral immunity
Healing of an established infection in mice is independent of the specific anti- 
leishmanial antibody response (reviewed in Liew, 1986) and, indeed, mice with 
progressive disease have significantly higher levels of specific antibodies than 
mice that have recovered from the infection (Coile et al., 1983). Furthermore, mice 
are not protected by the passive transfer of large amounts of specific antibody 
from mice effectively immunised with killed promastigotes (Howard et al., 1984). 
However, if present at the start of infection, specific antibodies may hamper the 
initiation of infection by preventing the attachment of promastigotes to 
macrophages. Monoclonal antibodies specific for lipid containing glycoconjugates 
of L. major have been shown to prevent parasitization of macrophages in vitro by 
inhibiting their binding to the macrophage membrane (Handman and Coding, 
1985). Parasites that fail to be internalized are destroyed within a few minutes 
(Handman and Mitchell, 1985).
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Hi) Role of T cells
It is now generally accepted that L. mayor-specific T cells play a central role in 
determining whether the host will develop a healing or progressing disease with 
the parasite.
a) CD4(+) T cells
As mentioned above, some strains, such as BALB/c, are highly susceptible to L. 
major infection and fail to develop a T cell-mediated response to the parasite. In 
contrast, other strains of mice, such as C3H, C57BL/6 and CBA, develop self- 
healing lesions associated with strong cell-mediated immunity (Reiner ef a/., 1995; 
Locksley et al., 1991). Howard et al. (1981) found that the extreme susceptibility of 
BALB/c mice to L. major could be abrogated if the animals were sublethally 
irradiated and this resistant state could be overcome by transfer of CD4(+) T cells 
from normal BALB/c mice. Conversely transfer of GD4(+) T cells from animals that 
had healed L. major infection enhanced resistance. Since then, GD4(+) parasite- 
specific T cells have been shown to have both beneficial (Scott et al., 1988; Scott 
et al., 1990; Muller et al., 1989; Holaday et al., 1991) or detrimental (Holaday et 
al., 1991; Titus et al., 1984; Titus et al., 1991) effects in L. major infected mice, 
with Th2 cells mediating susceptibility and Thi cells mediating resistance (Scott et 
al., 1988). Furthermore, susceptibility to infection in mice is associated with 
preferential production of IL-4, while cells from animals that are resistant to L. 
mayor produce high levels of IFN-y and little IL-4 (Heinzel et al., 1989; Scott 1991; 
Ghatelain et al., 1992). As noted above, IFN-y is thought to act by its ability to
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activate macrophages to destroy parasites through oxygen burst activity (Murray 
1982; Murray 1981; Liew et al., 1990a; Green et al., 1990). On the other hand, IL- 
4 can block the ability of IFN-y to activate macrophages to destroy Leishmania 
(Lehn et a i, 1989; Liew et al., 1989).
Early events
Consistent with what is known of the factors that regulate Th1/Th2 cell 
polarisation, depletion of either IL-12 or IFN-y prior to infection of normally 
resistant mice abrogates Thi development, leading to Th2 cell dominance and 
susceptibility to L. mayor (Scott 1991; Scharton-Kersten et al., 1995). Conversely, 
neutralization of IL-4 in susceptible BALB/c mice blocks Th2 development, 
allowing mice to develop a Thi response and self-heal (Heinzel et al., 1989). To 
mediate their influence on Th cell development, these cytokines must be present 
early after infection. During the first days of infection, lymph node cells from C3H 
mice produce IFN-y, but not IL-4, while cells from BALB/c mice produce less IFN-y 
and substational amounts of IL-4 as early as 16 h after infection (Scott 1991; 
Louis et al., 1998). NK cells are the source of IFN-y produced at this early stage of 
infection in C3H mice (Scharton and Scott 1993). L. mayor infection in C3H mice is 
also associated with increased level of IL-12 production that is required both for 
NK cell activation and Thi cell response (Scharton-Kersten et al., 1995). 
Consistent with these results are findings demonstrating that treatment of L. 
mayor-infected BALB/c mice with IL-12, given at the time of infection, enhances 
Thi cell development and healing (Sypek et al., 1993; Heinzel et al., 1995). The
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most stringent test for the importance of IL-12 comes from studies with IL-12 p40 
knockout mice, which have been shown to be susceptible to L  major (Mattner et 
al., 1996). The likely source of IL-12 are macrophages stimulated by the parasite, 
but there are strong indications that dentritic cells may also be responsible for the 
IL-12 production as shown following infection with L  donovani (Gorak et al., 
1998).
The early burst of IL-4 production influences the outcome of the disease in 
infected BALB/c mice. Louis et al. (1998) showed that a burst of IL-4 mRNA, 
peaking in the draining lymph nodes of BALB/c mice 16h after infection, occurs 
within CD4(+) T cells that express V beta 4-V alpha 8 T cell receptors. V beta 4- 
deficient BALB/c mice are resistant to infection, demonstrating the role of these 
cells in Th2 development. The early IL-4 response is absent in these mice, and 
Thi responses occurs following infection. The LACK {Leishmania homologue of 
receptors for activated 0 kinase) antigen of L. major induces comparable IL-4 
production in V beta 4-V alpha 8 CD4(+) T cells. Thus, the IL-4 required for Th2 
development and susceptibility to L. major is produced by a restricted population 
of V beta 4-V alpha 8 CD4(+) T cells after cognate interaction with a single antigen 
from this complex parasite. IL-4 produced rapidly by these CD4(+) T cells induces 
within 48 hours a state of unresponsiveness to IL-12 among parasite-specific 
CD4(+) T cell precursors by downregulating the IL-12 receptor p2 chain 
expression.
There is some evidence that immunity to Leishmania is much more complex than 
can be explained by a simple Th1/Th2, IFN-y/IL-4-dichotomy. L. mayor-specific T
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cell lines and clones have been described that produce large amounts of IFN-y 
and mediate parasite-specific delayed-type hypersensitivity, but can exacerbate 
the course of cutanous leishmaniasis in either susceptible BALB/c or normally 
resistant CBA mice (Titus et al., 1984; Titus et al., 1991). In addition, it has been 
reported that a CD45RB '^®^ subset of CD4(+) cells from infected BALB/c mice 
contains a population of Thi-type cells, which produce IFN-y in vitro and transfer 
resistance to L. major infection in SCID mice (Powrie et al., 1994). Moll and 
Rollinghoff (1990) showed that while protective CD4(+)T cells in L  mayor infection 
were Thi cells, defined by their IFN-y production, excacerbative T cells were not 
Th2 cells, but rather showed overlapping Thi and Th2 type cytokine pattern. 
Boom et al. (1990) showed that when BALB/c mice were vaccinated against L. 
major, CD4(+) L. mayor-specific T cells isolated from the animals no longer 
produced IL-4, but, suprisingly, did not produce IFN-y. Instead, the cells produced 
large amounts of TNF-a, which is known to increase NO and iNOS (inducible NO 
synthase) production in macrophages (Liew etal., 1990).
Regulation of established Immune responses to L  major
Most current treatments of leishmaniasis in BALB/c mice, such as IL-12 
administration, must be given prior to, or at the time of infection, suggesting that 
they act by influencing events in initial T cell differentiation, rather than by 
reversing established T-cell responses. The failure of various cytokine or anti­
cytokine therapies to alter the course of the disease when treatment is delayed 
until the 2"^ or 3^  ^ week after infection suggests that once established, polarised
79
Th2 type responses may not be amenable to immune manipulation. However, 
there is considerable evidence from in vitro studies that a variety of factors have 
the potential to regulate the effector function of differentiated T helper cell 
subsets. For example, treatment of IFN-y producing CD45RB '^®' ,^ normally 
protective T cells with antibodies to IFN-y before transfer into SCID mice render 
these cells ineffective (Powrie et a!., 1994). Conversely, normally susceptible 
CD45RB'°^ cells, when treated with anti-IL-4 antibodies, conferred resistance to L. 
mayor infections when transferred to SCID mice (Powrie et a/., 1994). In summary, 
agents, able to decrease L  mayor-specific Th2 type cytokine expression during an 
established immune response, might still be able to cure the infection.
b) CD8(+) T cells
CD8(+) T cells are involved in the resolution of lesions induced in mice by L  
major, although it appears that their role might be less than that of CD4(+) T cells. 
MHCM-deficient mice of C57BL/6 backround, lacking CD4(+) T cells, become 
susceptible to infection with L. major (Erb et a/., 1996). Further, CD8-deficient 
mice exhibit an effective and long-lasting immunity against the L. major infection 
(Huber et a/., 1998), confirming that CD8(+) T cells are not required to control the 
infection. However, in comparison to susceptible mice, resistant mice produce 
three times more parasite-specific CD8(+) T cells and these can transfer specific 
DTH reactions to naïve recipients (Titus et a!., 1987). Depletion of CD8(+) T cells 
by treatment of infected mice with anti-CD8 mAb also exacerbates skin lesions 
and abrogates the induction of resistance which is normally seen following
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immunization with killed promastigotes (Farrell and Louis, 1989). As CD8(+) T 
cells produce IFN-y as well as TNF-a (Fong and Mosmann, 1990), the production 
of these cytokines by CD8(+) T cells may help macrophages to kill Leishmania. 
Therefore, CD8(+) T cells might contribute to the CD4(+) T cells mediated 
resistance to the infection by killing LeishmaniaAniected macrophages, both by 
production of lymphokines and by direct lysis (da Conceicao-Silva et ai., 1994).
1.10.4 Treatment of L. mayor infections in mice and humans
Extensive research has been carried out using murine leishmaniasis models such 
as BALB/c mice, that are highly susceptible to the disease, which led to the 
identification of a number of treatments that are now being investigated in 
humans. Treatments used in the murine model are generally based on inhibiting 
the L. major parasite directly (Iniesta et ai., 2001; Selzer et ai, 1999) or on 
increasing Thi cell responses, e.g. through anti-IL-4 antibodies or IL-12 
administration (Heinzel et ai., 1989; Sypek et ai., 1993). The standard clinical 
treatments for cutaneous leishmaniasis (reviewed in Berman, 1997) is pentavalent 
antimony (sodium stibogluconate), but this can cause significant pancreatic, 
cardiac, musculoskeletal and hematologic morbidity. Paromomycin, an 
aminoglycoside, in combination with methylbenzethonium chloride (MBCL) have 
also been used topically (Herwaldt and Berman, 1992; El-On et ai., 1985, 1986, 
1992). The latter shows toxic effects when administed to mice (Neal et ai., 1994) 
and can produce local inflammation (El-On et ai., 1986). Due to the side effects of 
MBCL, Grogl et ai. (1999) tested other paromomycin-based formulations and
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found that topical treatment with WR 279.396 (15% paromomycin + 0.5% 
gentamicin) healed L. major infections successfully without toxic side effects. 
Among the aminoglycosides, paromomycin is the only one with clear antiprotozoal 
and antileishmanial activity (El-On and Greenblatt, 1983), but early work by El-On 
et al. (1984) demonstrated that 12% gentamicin had a modest activity in L. major 
infections when used topically. Nevertheless, the mechanism of gentamicin in L. 
major infections remains unclear. In this thesis, the in vitro ability of gentamicin to 
modulate the Th1/Th2 type balance was discovered. Whether this feature of 
gentamicin is causing its beneficial effect in L. mayor infections will be addressed.
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Specific Aims of Study
In infections like Leishmania major the balance between Th1 and Th2 cells 
determines the disease outcome. Detection and modulation of this balance may 
become possible by exploiting newly discovered cell surface markers specific for 
Th1 cells (e.g. 1L-18R) and Th2 cells (e.g. ST2L). This thesis focuses on the 
modulation of the Th1/Th2 cell balance through ST2L, which have been closely 
linked to Th2 cell effector functions, and its splice variant soluble ST2 (ST2). In 
addition, the ability of gentamicin, an aminoglycoside that suppresses Th2, but not 
Th1 type responses, to modify L. ma/or infections in susceptible BALB/c mice was 
also examined.
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Chapter 2 Materials and Methods
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2.1 Animals
Female, 6 weeks old, BALB/c mice were purchased from Harlan Olac (Bichester, 
UK). DO. 11.10 TCR transgenic mice homozygous for the chicken OVA (cOVA) 
peptide323-33g/FA^ on the BALB/c background were bred in the University of 
Glasgow’s facilities.
2.2 Aminoglycosides
G418 (geneticin sulphate, Gibco BRL, Life Technologies, Paisley, UK) was prepared 
as a 20 mg/ml stock solution in 100 mM HEPES buffer, pH 7.3. Gentamicin sulphate 
(Sigma-Aldrich Company Ltd., Poole, England) was prepared as a 50 mg/ml stock 
solution in PBS. Both reagents were sterile filtered and kept at -20°C until use.
2.3 Estimation of gentamicin contents in serum
Serum of mice injected with 50 mg/kg gentamicin was collected at different time 
points and pooled. The serum concentration of gentamicin was assessed in 
collaboration with the Dep. of Pathology (Western Infirmary, Glasgow) using the TDx 
system (Abbott Laboratories, Abbot Park, Illinois), which applied fluorescence 
polarisation immunoassay technology (Nielsen et a/., 2000). This technology is 
based on antigen/antibody reactions (Gentamicin/antibody against Gentamicin). The 
added surplus of antibody is labelled with a fragment of a fluorescence dye molecule 
and is able to freely rotate as long as it is unbound in solution. Antigen/antibody 
complexes stabilise the plain of polarisation, which is emitted. This plain of 
polarisation can then be measured and gives information about the amount of 
antigen in solution. The sensitivity of this assay is 10 ng/ml.
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2.4 Preparation of spleen and Ivmph node cells
To obtain spleen and lymph node cells, mice were sacrificed by dislocation of the 
neck, a schedule 1 method. Spleen and lymph nodes were dissected under semi- 
sterile conditions. A single cell suspension was obtained by gently pressing spleen 
and lymph nodes through a sterile tea strainer and then filtered through sterile nylon 
mesh (Cadisch Precision Meshes, London, UK) and washed twice with RPMI 1640 
medium (Gibco BRL). The cell number was counted in a 1:10 dilution in 0.1% Trypan 
Blue (Sigma) in 1x PBS buffer, using a counting chamber (Improved Neubauer, 
Weber Scientific International Ltd., Teddington, UK).
2.5 Cell culture -  general conditions
All cells types described below were grown In complete RPMI (RPMI 1640 medium, 
10% (v/v) PBS, 2 mM L-glutamine, 50 U/ml Penicillin and 50 pg/ml Streptomycin, 50 
pM 2-Mercaptoethanol) at 37°C supplemented with 5% CO2 unless otherwise stated. 
Cells were centrifuged at 400 x g for 5 min at 4°C unless otherwise stated.
2.6 Preparation of antigen presenting cells (APC)
For use as APC, BALB/c spleen cells were either irradiated with X-ray (llOkV, 2500 
rads) at the Beatson Radiation Unit, Western Infirmary, Glasgow or 1 x 10  ^ BALB/c 
spleen cells were treated with 50 pg of mitomycin C (Sigma) for 45-60 min at 37°C 
followed by 4 washes.
2.7 Cell culture of Th cell clones
Th cell clones were grown in complete RPMI medium. Dorris (specific for egg 
lysozyme, Sigma) and DIO (specific for conalbumin, Sigma), both on CBA
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backround, were obtained from American Type Culture Collection (ATCC, Atlanta, 
Georgia). X4, X9 and X12, all on BALB/c backround, were specific against group A 
streptococcal M protein (cells and antigen were a gift from Dr JH Robinson, 
University of Newcastle upon Tyne, UK). The cell lines were maintained by monthly 
stimulation with irradiated APC In a ratio of 1:10 and an appropriate amount of their 
specific antigen (Table 2.1). After 3 days, 10 ng/ml lL-2 (gift from Genosys) was 
added to stimulate the proliferation. The cells were split 1:5 every 7-10 days and 
further stimulated with IL-2.
Table 2.1 Cell culture of T helper cell clones
Th cell clones Antigen Concentration used
D10(Th2) Cab (conalbumin) 100 pg/ml
Dorris (Thi) HEL (hen 
egg lysozyme)
500 pg/ml
X4 (Thi) Peptide 15-33 12.5 pg/ml
X9 (Thi) Peptide 300-319 25 jag/ml
X I2 (Th2) Peptide 300-319 25 jag/ml
2.8 Negative selection of CD4(+) T cells
The negative selection of CD4(+) T cell was performed by magnetic cell sorting 
(MACS) with magnetic beads bound antibodies and CS columns as described by the 
manufacturer (Miltenyi Biotec Inc., Bergisch Gladbach, Germany). Single cell 
suspension was prepared from spleen cells or lymph nodes from DO11.10 TCR 
transgenic mice as described in 2.2. To lyse the red blood cells, 1ml of Red Blood 
Cell Lysis Buffer Hybri-Max® (Sigma) was added to a pellet of 10® cells and 
incubated for 1 min at room temperature. Two washes removed Lysis buffer and cell
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debris. The adherent cells were removed by incubating the cells in complete RPMI 
1640 medium for 45-60 min in a 75 cm^ flask at 37°C followed by collection of non­
adherent cells with the supernatant. The cells (2x10®) were washed with sterile 
MACS buffer (1 x PBS, 2% (v/v) FBS) and resuspended in a final volume of 1 ml 
MACS buffer containing rat antibodies against CDS (12.5 pg/ml), C D IIb  (100 pg/ml), 
CD19 (90 pg/ml) and CD 16/32 (30 pg/ml). After a 20 minute incubation on ice, the 
unbound antibodies were washed off with 2 washes of 15 ml MACS buffer at 200 x g 
for 10 minutes at 4°C. The cells were then resuspended in 1 ml MACS buffer and 
200 pi anti-rat IgG conjugated beads (Miltenyi Biotech Inc.) was added for a further 
20 minute on ice. After 2 washes with MACS buffer the cells were resuspended in 
800 pi MACS buffer and applied through a nylon mesh filter to a MACS CS 
separation column which had been washed previously with 65 ml MACS buffer. To 
remove the unbound CD4(+) cells, the column was washed with 35 ml MACS buffer 
and the cells were collected and washed twice in RPMI 1640. Flow cytometry 
analysis indicated that these cells were 85-90% CD4(+), 65-90% KJ1.26(+) with < 
5% of CD8(+) T cells and CD19(+) B cells (Fig. 2.1).
2.9 Derivation of polarised CD4(+) T cells in vitro
As described by Xu et ai. (1998), CD4(+) T cells from OVA-specific TCR transgenic 
mice were cultured with 300 nM OVA peptide (OVA 323-339) and Irradiated BALB/c 
spleen cells (1:10 - APC : Th cells). To drive CD4(+) T cells under neutral conditions 
(Coyle et ai., 1999), the cells were grown in the presence of 10 ng/ml lL-2 from day 2 
after antigenic stimulation. Thi cells were established by the addition of 10 ng/ml IL- 
12 (Gentech, USA) and 1 pg/ml monoclonal anti-IL-4 antibody (R&D), given at the 
time of antigenic stimulation. Th2 cells were grown in the presence of 10 ng/ml lL-4
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KJ 65
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Fig. 2.1 Test of successful negative selection of CD4(+) I  cells by 
flow cytometry
T cells were purified from spleen of DO11.10 mice as described in section 2.4. 
The success of the negative selection of CD4(+) T cells (section 2.8) was 
checked by staining for cell surface markers CD4, KJ, CDS and CD19 (section 
2.34). The table above shows the percentage of living cells which stained 
positive for each of the markers.
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(Gentech, USA) and 3 jul/ml polyclonal rabbit anti-IL-12 serum given at the time of 
antigenic stimulation. Both Th1 and Th2 cells were expanded with 10 ng/ml IL-2, 
which was added on day 3. Antigenic stimulation under polarising conditions was 
repeated every 7-10 days after the previous stimulation to enhance the number of 
polarised Thi or Th2 cells. The success of polarisation was assessed by ELISA and 
Real time PGR (Fig. 2.2). IL-4, IL-5 and the Th2 cell marker ST2L, but no IFN-y were 
expressed in polarised Th2 cells, whilst Thi cells expressed only IFN-y and very low 
amounts of ST2L.
2.10 Culture of macrophage cell line RAW264
The murine macrophage cell line, RAW264, was obtained from ATCC (Atlanta, 
USA). The cells were grown on 10 cm bacteriological plastic plates (Bibby Sterilin, 
Staffordshire, UK) and, once confluent, were detached by injecting in and out of a 
syringe before being split at 1:5 or 1:10 ratio.
2.11 Culture of bone marrow macrophages
Bone marrow macrophages were obtained from the femurs of BALB/c mice by gently 
flushing out the marrow with a syringe containing RPMI 1640 medium. After 2 
washes with RPMI 1640 the single cell suspension was cultured with complete RPMI 
1640 medium containing 10 ng/ml (10^ U/ng) recombinant human CSF-1 (a gift from 
Professor David Hume, Brisbane, Australia). Cultures were fed with CSF-1 on days 
0, 3 and 6 . At day 7 the adherent macrophages were harvested by scraping.
For in vitro experiments the cells were stimulated with 100 ng/ml LPS from 
Salmoneila minnesota (Sigma, Poole, UK).
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Fig.2.2 Real-time PCR of polarised Th1 and Th2 cells
CD4(+) T cells were purified by negative selection and polarised towards Thi 
and Th2 cells as described in section 2.4 and 2.8. The gene expression of 
IFN-y, IL-4 and ST2L were assessed by Real time PCR (section 2.31 and 
2.32). The error bars represent the standard deviation between triplicate cDNA 
samples.
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2.12 Culture of peritoneal macrophages
BALB/c mice (6 - 8  week old) were injected intraperitoneally with 2 ml thioglycollate 
broth (40.5 g/L, DIFCO, East Molesey, UK) and after 3 days the peritoneal 
macrophages were removed by washing the peritoneum out with 2 x 5 ml PBS. 
Macrophages were stimulated with 100 ng/ml LPS.
2.13 Culture of L  ma/or parasites
Leishmania major parasites were obtained from frozen culture or from the footpad of 
infected BALB/c mice. The footpad was cut into small pieces, filtered through nylon 
mesh and the remaining suspension was washed twice with saline at 1 2 0 0  x g for 1 0  
min at 20°C. The parasites were then cultured in 5 ml Schneider’s medium (Gibco 
BRL) supplemented with 20% (v/v) FBS, 2 mM L-glutamine, 50 U/ml Penicillin and 
50 jLig/ml Streptomycin at 27°C for 3 days in air. 100 jal of this culture were then 
passaged into 40 ml of Schneider’s medium and cultured for a further 6 - 8  days to 
obtained parasites in the stationary phase.
2.14 L  ma/or infection of BALB/c mice
BALB/c mice, used for in vivo trials, were 6  weeks of age, female and around 20 g in 
body weight. The footpad was injected with 1x10^-5x10^ L. major promastigotes, 
growing in late stationary phase culture, diluted in 50 pi sterile 1x PBS. The footpad 
swelling was measured weekly with a caliper (Kroeplin, Germany) and the difference 
between uninfected and infected foot was calculated. When the footpad swelling 
increased above 4 mm the animals were sacrificed by dislocation of the neck 
(schedule 1 method).
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2.15 Serial limiting dilution assay for L. major parasites
L  major parasites, which were extracted from infected footpads, were diluted in 
serial dilutions (1:10^-1:10^^) in complete Schneider’s medium and incubated for 2-3 
days at 27 °C in air. The relative parasite numbers were then analysed for the end 
dilution, which does not contain parasites.
2.16 Preparation of L  ma/or antigen
Lag phase parasites were spun down at 1200 x g for 10 min at 20°C and washed 
twice with sterile saline. Parasites were counted in 1% formaldehyde in PBS. The 
parasite number was adjusted to 1 x 10® parasites/ml in complete RPMI medium. 
The parasite culture was put through three ”freeze/thaw” cycles (-70°C for 20 min, 
37°C for 5 min) to obtain non-infectious L  mayor antigen, which was stored at -20°C 
until use.
2.17 Infection of bone marrow macrophages with L  ma/or parasites
Mature bone marrow macrophages maintained in complete RPMI medium were 
infected at a ratio of 1:10 (macrophages : parasites) with late lag phase L  major 
parasites. After 3 days incubation, the remaining parasites were washed off with pre­
warmed medium and the macrophages lysed as described by Huang et al. (1998). 
SDS (0.01% (w/v)) in 100 pi of pre-warmed medium were added to infected cells and 
incubated for up to 30 min at 37°C, assisted with repeated pipetting of the cells. The 
released amastigotes were resuspended in 600 pi Schneider’s medium containing 
30% (v/v) FBS and a serial limiting dilution assay was performed by adding 200 pi 
aliquots in triplicate to 96 well flat bottom plates and analysing them after 3 days.
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2.18 MTT assay
Lymphocytes were cultured in complete RPMI 1640 in round bottom 96-well plates. 
The supernatant was removed by centrigugation at 400 x g for 5 min at 4°C. Cell 
viability was assessed by adding 1 mg/ml MTT reagents (3-(4,5-Dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide Thiazolyl blue; Sigma) in complete RPMI 1640. 
After 2 h at 37°G the medium was removed by centrifugation of the plate and the 
precipitate dissolved in isopropanol. The solution was transfered into a flat bottom 96 
well plate and the absorbance was determined at 570 nm with the MRX plate reader 
(Dynex).
2.19 Cell Proliferation Assay
Spleen and lymph node cells, obtained from single cell suspensions (section 2.4) 
and Th cell clones were grown in flat bottomed 96-well plates at 4x10® - 1x10® cells 
per 200 pi complete RPMI 1640. The cells were stimulated with the appropriate 
antigen or 4 pg/ml anti-CD3 or 2 pg/ml ConA or 1 pg/ml LPS. They were pulsed with 
1 pCi ®H-Thymidine/well (West of Scotland Radionucleotide Dispensary, Western 
Infirmary, Glasgow) and incubated for 4 h or overnight at 37°C in 5% C02. The cells 
were harvested onto glass filter mats using a Betaplate™96-well Harvester (LKB 
Wallac, Turku, Finland). The incorporated ®H-Thymidine was determined by 
scintillation counting, using EcoScint, in a Liquid scintillation counter (LKB Wallac).
2.20. Griess reaction
To assess the production of NO by macrophages the nitrite concentration in culture 
supernatants was determined by Griess reaction (Ding et al., 1998). Griess solution 
A (0.1% (v/v) a-naphtyl-amine in distilled H2O) and Griess solution B (1% (v/v) 
sulfanilamide in 5% (v/v) phosphoric acid) were mixed in a 1:1 (v/v) ratio. The mixture
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was prepared immediately before every use and 1 0 0  pi were added to 1 0 0  pi sample 
in a flat bottomed 96-well plate and then incubated for 10 min at room temperature. 
The colour change was assessed at 570 nm and the sample concentrations were 
calculated from the standard curve using serial dilutions of sodium nitrite. The 
detectable concentration ranged from 80 ng/ml to 10 pg/ml (145 pM to 1 pM).
2.21 Measurement of cvtokines by ELISA
Culture supernatant was analysed for cytokine levels by sandwich ELISAs. 
lmmunolon4 plates (Dynex Technologies, Ashford, UK) were coated overnight with 
the appropriate concentration of rat-anti-cytokine antibody (see Appendix, table 
A.2.1) diluted in 0.1 M NaHCOa buffer. The plates were washed twice with 1x 
PBS/0.05% (v/v) Tween 20 (wash buffer) and blocked for 1 h at 37°C with 200 pi of 
10% (v/v) FBS (Gibco-BRL) in PBS (ELISA buffer). After 2 washes with wash buffer, 
50-100 pi sample were added in triplicate to the plate. Serial dilutions of recombinant 
cytokine in duplicate were also added as standards (see Appendix, table A.2.2). The 
plates were then incubated for 2 h at 37°C or overnight at 4°C to allow binding 
between cytokine and antibody. Biotinylated-detection antibody (50 pi of the 
appropriate concentration, see Appendix, table A.2.3) in ELISA buffer were added 
after 4 washes and incubated for 1 h at 37°C. The plates were washed 6  times, 
before 100 pi of a 1:1000 dilution of Extravidin Peroxidase (Sigma) in ELISA buffer 
were added to each well. After incubation for 30-60 min at 37°C, the plates were 
washed 6  times and then lOOpI of the chromophore TMB and H2O2 (Dynatech 
Laboratories Ltd., Billinghurst, UK) were added and incubated until the colour 
reaction was visible. The plates were read at 630 nm on an MRX microplate reader
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(Dynex). The level of cytokine present in test wells was calculated from the standard 
curve.
2.22 Activation of TGF-B1
TGF-pi in supernatants is produced in an inactive precursor form, acid treatment 
allowed the precursor form to be cleaved, allowing the antibody to detect the 
cytokine. Supernatants for determination of TGF-p1 levels were treated with 1/25 
volume 1 N HCI for 15 minutes at room temperature or for 1 h at 4°C. The 
supernatant was neutralised with 1/25 volume IN  NaOH and used immediately in 
ELISA or stored at -80°C.
2.23 ST2 ELISA
100 pi of ST2-containing supernatant, in triplicate, were allowed to coat an 
lmmunolon4 plate overnight at 4°C. After two washes with PBS/Tween20 the plates 
were blocked for 1 h at 37°C with ELISA buffer. Monoclonal biotinylated anti-ST2L 
antibody was diluted to 2pg/ml in ELISA buffer and 100 pi added to each well. After 
incubation for 2 h at 37°C the plates were washed 6  times, before 100 pi of a 1:1000 
dilution of Strepavidin Peroxidase (Diagnostic Scotland, Carluke, Scotland) in ELISA 
buffer were added to each well. After 1 h at 37°C, the plates were washed 8  times 
and the colour reaction revealed using 100 pi TMB. The plates were read at 630 nm.
A similar method was applied to assess the amount of serum IgGI and lgG2a. 
The amount of anti-IgG antibody is stated in section A.3.3.
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2.24 Protein quantification
Two methods were applied to estimate the amount of ST2 protein, purified from 
insect or CHO cells. Firstly, the OD at 280nm of the solution was measured by 
spectrophotometer (Pharmacia-Biotech, Bucks, UK ) and the quantity of protein was 
calculated using the following formula: 1.4 (OD280nm) s 1.0 mg/ml.
Secondly, the Coomassie® Protein Assay (Pierce, Rockford, USA) was used 
according to manufacture’s instructions. Briefly, 960 pi of Coomassie Protein 
Reagent was added to 40 pi of sample and the colour change was read at 600 nm in 
the spectrophotometer. The OD values were then compared to bovine serum 
albumine (BSA) standards, ranging from 12.5-200 pg/ml.
2.25 SDS-PAGE
Separation of proteins was achieved under reducing conditions by SDS-PAGE 
(Laemmli, 1970). All gels had a ratio of 29:1 of acrylamide to bis-acrylamide (Biorad). 
Resolving gels were made at 10% in 1.5 M Tris-HCI buffer, pH 8 .8 ; 1% (w/v) SDS; 
1% (w/v) ammonium persulphate (BDH) and 0.1% (v/v) N,N,N’,N’-
tetramethylenediamine (TEMED) (Sigma). Stacking gels (5%) were similarly 
prepared using 0.5% 1.5 M Tris-HCI buffer, pH 6 .8 . All gels were run using a 
standard electrophoresis buffer containing 25 mM Tris, 0.25 M glycine (BDH) and
0.1% (w/v) SDS. Samples to be electrophoresed, were mixed with 50% (v/v) of 2x 
concentrated sample buffer (1 M Tris-HCI, pH 6 .8 , 0.2 M DTT, 4% (w/v) SDS, 0.4% 
(w/v) bromophenol blue and 20% (v/v) glycerol (BDH), heated to 100°C for 5 min and 
cooled on ice prior loading on gels. The protein standards (See Blue™ Plus 2 Pre­
stained Standard, 3-188 kDa, No vex ™; ‘Rainbow’ molecular weight marker, 10-250 
kDa, Amersham) were treated similarly and run on all gels. Electrophoresis was
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carried out at a constant current of 5 mA/cm gel length until the bromophenol blue 
marker reached the bottom of the gel. The gel was then used for Western Blotting or 
stained with Coomassie blue.
2.26 Coomassie blue staining of SDS-PAGE gels
At the end of electrophoresis, the gels were stained for 1 h with 0.5% (w/v) 
Coomassie brilliant blue R250 (Sigma) in 40% (v/v) methanol (BDH) and destained 
over 4-5 h in several changes of 40% (v/v) methanol, 10% (v/v) glacial acetic acid 
until the background was colourless. Stained gels were transferred to 3 MM filter 
paper (Whatman) and dried under vacuum at 80°C.
2.27 Western Blotting
Protein, run on a SDS gel, was transferred to nitrocellulose using a transblot system 
(Hoeffer Scientific SE600, San Francisco, USA). Four pieces of 3 MM filter papers 
were cut to a size slightly bigger than the gel selected for Western blot analysis and 
were then soaked in transfer buffer (20 mM Tris, 40 mM glycine, 20% (v/v) methanol, 
BDH). Two of the filter papers were placed on the cathode of the electroblotter. The 
gel, soaked in transfer buffer, was placed on the filter papers. A sheet of 
nitrocellulose (Biorad), cut to the same size as the gel and pre-wetted with transfer 
buffer, was placed on top of the gel. The remaining two sheets of filter paper were 
placed on top of the nitrocellulose. Proteins were transferred to the nitrocellulose by 
applying a constant current of 0.8mA/cm^ of gel area overnight. Nitrocellulose filters 
were then incubated with wash buffer 1 (0.01 M Tris-HCI buffer, pH 7.5; 0.1 M NaCI 
and 0.1% (v/v) Tween-20) containing 2% (w/v) BSA (SIGMA, Poole, UK) for at least 
1 h to block non-specific protein binding. Primary antibodies were diluted in wash 
buffer 1 containing 1% (w/v) BSA, and applied to the filter for 1 h at room
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temperature or overnight at 4°C. Blots were washed twice in wash buffer 1, followed 
by two washes in wash buffer 2 (0.01 M Tris-HCI, pH 7.5; 0.5 M NaCI and 0.1 % (v/v) 
Tween-20) and finally twice with wash buffer 1 again. Each wash lasted 10 min. The 
blots were then incubated with the appropriate HRP-conjugated secondary antibody 
(diluted up to 1:5000 in wash buffer 1 containing 1 % (w/v) BSA) for 1 h at room 
temperature. After washing again, as described above, immuno-reactive bands were 
visualised by the Enhanced Chemiluminescence (ECL) system (Amersham, Little 
Chalfont, UK) and exposed to X-OMAT film (Kodak, New York, USA).
2.28 Dot Blotting
Protein containing supernatants were applied to nitrocellulose membrane and dried 
for 1 h at room temperature. The membrane then was blocked with 2  % (w/v) BSA- 
containing wash buffer 1 and further treated as described in section 2.27 (Western 
Blotting).
2.29 RNA extraction
Total cellular RNA was extracted by using the RNAZOL™B method, adapted from 
Chomczynski and Sacchi (1987). All steps were performed at 4°C with RNAse-free 
equipment. Approximately 2x10® cells were harvested from cell cultures and 
transferred into 1.5 ml microcentrifuge tube. After centrifugation at 400 x g for 5 min, 
the supernatants were removed and the pellets kept on ice. 400 pi RNAzol™ B 
(Biogenesis) was then added to lyse the cells. The RNA was solubilized by passing 
the lysate a few times through the pipette. Then 40 pi chloroform were added and 
the tube shaken for 15 s and rested on ice for 5 min. The suspension was 
centrifuged at 12000 x g for 15 min and the upper aqueous phase transferred to a 
fresh tube. 1 volume isopropanol was added to precipitate RNA in 15 min on ice,
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which was spun down for 20 min at 12.000 x g (4°C). The pellet was washed with 2 
volumes pre-cold 75% ethanol and centrifuged at 10.000 x g for 8 min. The pellet 
was semi-dried at room temperature and resuspended in 30 pi water. To determine 
the total RNA content, the OD at 260nm and 280nm were measured and the 
concentration (pg/ml) was calculated by following formula: [(OD260nm x 62) -  (ODzsonm 
X 36) X dilution]
RNA samples were stored at -70°C until used.
2.30 Agarose gel electrophoresis
Appropriate amounts of agarose powder (1 g in 100 ml buffer for a 1% gel) were 
dissolved in 0.5 x TBE electrophoresis buffer (0.045 M Tris-borate, 1 mM EDTA) in a 
glass bottle and heated in a microwave oven until the agarose dissolved. The 
solution was cooled to 60°C and mixed with ethidium bromide (SIGMA) to a final 
concentration of 0.5 pg/ml. The warm agarose was poured into a mould with a comb. 
After the gel had completely set, the comb was carefully removed and the gel was 
mounted in an electrophoresis tank (Pharmacia LKB. GNA 100) filled with 0.5 x TBE. 
The DMA samples and a DMA Ikb marker (BRL, Scotland) were mixed with loading 
buffer (0.25% (w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol FF, 15 % (v/v) 
Ficoll in water) and loaded into the slots of the gel. The gel was run at 1-5 V/cm for 
an appropriate time before being the examined by ultraviolet light and photographed 
(Polaroid DS-34 Direct Screen Instant Camera) if necessary.
2.31 First strand svnthesis with DNAse treatment
To avoid amplification of genomic DNA, RNA (1-5 pg) was incubated for 15 min at 
37°C with 1 pi 10 X PGR buffer, 1 pi MgCl2 (50 mM) and 1 U DNAse free RNAse 
(Gibco-BRL) in a total volume of 10 pi. The enzyme was heat inactivated at 65°G for
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10 min, 1 pi random primers (100 ng/pl) was then added and the mix heated to 70°C 
for 10 min and then cooled to 4°C. The synthesis of the cDNA was initiated by 
adding 2 pi 10 x PCR buffer, 1 pi dNTP (lOmM), 2 pi DTT (0.1 M) and 100 U 
Superscript II RT-Polymerase (GIBCO-BRL) in a total volume of 20 pi. The synthesis 
was performed using the following conditions: 15 min at 25°C to allow the random 
primers and polymerase to bind, 50 min 42°C to extend the parallel cDNA strand and 
10 min 70°C to inactivate the enzyme and degrade remaining RNA.
2.32 TaqMan real-time PCR
TaqMan real-time PCR (Gibson et al. 1996) was performed according to the 
manufacturer’s instructions (PE Biosysystem, Foster City, USA) and as described by 
Overbergh et al. (1999). The principle of this method is outlined in Figure 2.3.
Primers and fluorogenic probes (see table 2.2) were designed using the 
PrimerExpress™v1.0 program purchased from PE Biosystem. The fluorogenic 
probes contained a reporter dye (FAM) covalently attached at the 5' end and a 
quencher dye (TAMRA) covalently attached at the 3’ end, and were HPLC purified. 
Extension from the 3’ end was blocked by attachment of a 3’ phosphate group.
PCR reactions were performed in the ABI-prism 7700 Sequence Detector, which 
contains a Gene-Amp PCR system 9600 (PE Biosystems). PCR amplifications were 
performed in a total volume of 25 pi, containing 0.5 pi cDNA sample, 50 mM KCI, 19 
mM Tris-HCI (pH 8.3), 10 pm EDTA, 200 pM dATP, dCTP, dGTP and 400 pM dUTP, 
5 mM MgCb, 300 nM each primer, 0.625 U AmpliTaqGold™ and 0.25 U AmpErase 
Uracil N-Glycosylase (PE Biosystems). Each reaction also contained 200 nM 
fluorogenic probe. Each PCR amplification was performed in triplicate wells, using 
the following conditions: 2 min at 50°C and 10 min at 94°C, followed by a total of 40 
two-temperature cycles (15 s at 94°C and 1 min at 60°C).
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The TaqMan probe consists of an oligonucleotide with a 5‘ reporter dye (R) and 
a 3‘ quencher (Q). When the probe is intact the proximity of the quencher to the 
reporter results in suppression of reporter fluorescence. As PGR proceeds the 
polymerase enzyme cleaves the probe with it's 5-3' nuclease activity. The 
reporter and quencher become separated, resulting in increased reporter 
fluorescence. The 3‘ end of the probe is blocked to prevent extension of the 
probe during PCR.
Table 2.2 Real time PCR probes and primers
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Gene Species Forward primer Probe Reverse primer
ST2 murine 5'd(TGGTCTTTCCAGAATGT
TTCTGTCT)3'
5 'FAM
{CCGCTCTCTGTGTGCCC 
TGGTGGTT)TAMRA 3'
5'd(GGAGGATGGGG
GGAGAA)3'
ST2L murine 5'd(CCAGAATAGCAGAAGA
CAGGTGTTT)3'
5 'FAM
d(TTCTGGGGGGTGAGATG 
STGGAGA)TAMRA 3'
5'd(GCTGGTGGTAGG
GAAATTGCT)3'
HPRT murine 5'd(GGAGTACAGCCCCAAA
ATGG)3’
5 'FAM
d(TAAGGTTGGAAGGTTGG 
TGGTGAAAAGGA)TAMRA 3'
5'd(AAGAAAGTGTGGG
GTGTATGGAA)3'
Data analysis was performed using the Sequence Detection software (PE 
Biosystems) which calculates the threshold cycle, Ct (see Figure 2.4). This 
represents the PCR cycle at which an increase in fluorescence above a threshold 
can be first detected. Samples were normalised by their reference reporter (HPRT) 
by subtracting the Ct value of HPRT from the Ct value of the gene of interest: this 
value is ACt. To obtain a value for fold increase relative to HPRT the formula 2 
was used. Multiplication of this value by 100 gives expression of the gene of interest 
as a percentage of HPRT. The positive error is the standard deviation of the 
difference , s=V(si^+S2 )^, where si and S2 are the standard deviations of the Cts of 
HPRT and the gene of interest.
2.33 Biotinvlation of monoclonal anti-mouse ST2L antibodv
1 mg/ml of antibody was dialysed against 1L of 50 mM Na2C0 3  (pH 8.5) overnight at 
4 °C before 37 pi of a 1 mg/ml solution of Sulfo-NHS-Biotin (Pierce) was added for 2 
h on ice. The mixture was then dialysed against 1x PBS, 0.1% (w/v) NaNa overnight
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Fig. 2.4 Typical TaqMan amplification plot
The amplification plot shows the fluorescence emission (normalised Reporter, 
RN) varies with the PCR cycle number. Initially, the fluorescent signal is below 
the detection limit of the Sequence Detector. In the second stage, the signal can 
be detected as it continues to increase in direct proportion to the amount of 
specific amplified product. As PCR continues, the ratio of polymerase enzyme 
to PCR product decreases and hence the amount of PCR product ceases to 
increase exponentially, until eventually the RN reaches a plateau. The Ct 
(threshold cycle) is determined during the exponential phase (threshold 
indicated by black line). Two triplicate samples are shown (A-C8 , E-F5).
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and aliquots of 100 [û were stored at 4°C until use. The antibody was tested by 
showing that Th2 cells expressed ST2L on their surface whereas Thi cells did not 
(Fig. 5.1, 5.2).
2.34 Staining of cell surface markers
Aliquots of 5x10^ - 1x10® cells were washed with FACS buffer (1x PBS, pH 7.5; 5% 
(w/v) FBS and 0.1% (w/v) sodium azide) and non-specific binding was blocked by 
incubating with 2.5 ^ig/ml Fc block (see Appendix, table A. 1) for 10 min on ice. Then 
the first anti-mouse antibody (conjugated with Biotin, FITC, PE or unconjugated) at 
the appropriate concentration was added to the cells and incubated for 30 min on 
ice. The samples were washed twice with 2 ml FACS buffer at 400 x g for 5 min and 
if necessary a secondary antibody was added to the cells and incubated for 30 min 
on ice (concentrations in Appendix, table A.1). The cells were then washed three 
times and analysed immediately using the Flow cytometer FACSALIBUR ® (Becton 
Dickinson FACS Brand Analyzer, San Jose, USA) and CELLQuest Software or fixed 
in Fixation buffer (1% (v/v) formaldehyde in FACS flow (Becton Dickinson, San Jose, 
USA)) and kept for up to 24 h at 4°C in the dark before being analysed. The emitted 
wavelength for FL1 (FITC-labelled antibodies) was 530 nm and for FL2 (PE-labelled 
antibodies) 585 nm.
To enumerate the positively stained white cells in a spleen cell population, red blood 
cells and cell debris were removed using FACS Lysing solution (Becton Dickinson, 
San Jose, USA). 2 ml of 1x FACS Lysing solution were added to the cell pellet 
containing 1 0 ® cells, gently mixed and stored for 1 0  min at room temperature in the 
dark. A centrifugation at 300 x g for 5 min followed by a resuspension of the cells in 1 
ml FACS buffer and a second centrifugation at 200 x g for 5 min ensured the 
removal of all debris. The leukocytes were then analysed by flow cytometry.
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2.35 Binding studies with ST2-Fc on Th cells
After blocking nonspecific binding with 2.5 jug/ml Fc block for 10 min on ice, 100 
pg/ml ST2-FC or hIgG (Sigma) as a control were added to the cell aliquots and 
incubated for 30 min on ice. The unbound protein was removed by two washes with 
2 ml of ice-cold FACS buffer (400 x g, 5 min, 4°C). Monoclonal FITC-labelled anti­
human hlgGI antibody (2.6 pg/ml. Sigma) or the FITC-isotype control (FITC-mouse 
lgG2a) and 2.5 pg/ml Fc block were added and incubated for 30 min on ice. The 
cells were then washed twice and analysed for positive staining by flow cytometry.
2.36 Propidium iodide/ annexin V staining
Propidium iodide (PI) will intercalate into DNA of cells, whose plasma membrane has 
been ruptured due to necrosis or in the state of late apoptosis (Lecoeur et al., 2001). 
Annexin V marks cells that show early signs of apoptosis by binding to 
phosphatidylserine, which externalises in apoptotic cells (BD Pharmingen, 1999). 
Cells (1x10®) were resuspended in 100 pi 1x Binding buffer (10 mM HEPES/NaOH, 
pH 7.4; 140 mM NaCI; 2.5 mM CaCl2) containing 5 pi FITC-annexin V (Pharmingen) 
plus 10 pi of a 50 pl/ml stock solution PI (Pharmingen) and incubated at room 
temperature for 30 min. After one wash with 1x Binding buffer the cells were 
analysed by flow cytometry for positive staining within 1 h.
Table of flow cytometry antibodies (Appendix, table A.1)
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2.37 Expression and purification of ST2
2.37.1 Cell culture of insect cell lines Sf9 and High5
Insect cell lines Sf9 and HighS were purchased from Invitrogen Corp. (Leek, The 
Netherlands). Sf9 cells were cultured in IPL41 medium (GIBCO-BRL, Eggstein, FRG) 
containing 10% (v/v) FCS, while HighS cells were grown in serumfree SF900 medium 
(GIBCO-BRL). The cell lines were grown as monolayers at 27°C in the dark under air 
and split 1:5 when confluent.
2.37.2 Amplification of baculoviruses In Sf9 cells
A stock of 1x10® plaque-forming units (pfu) of recombinant baculovirus was received 
from Dr. Werenskiold, Munich. To infect Sf9 cells, the cells were split to obtain a 
semi-confluent layer and 0 .1  plaque-forming units (pfu) per cell of baculovirus were 
added for 1 h and then washed off. After 4-5 days cultures were confluent with 10-20 
% dead cells and had released baculovirus. The supernatants were harvested and 
examined for the presence of recombinant baculoviruses by PCR.
Infected Sf9 cell supernatants were boiled at 100°C for 5 min and 5 pi supernatant 
were then incubated with 5 pi 10x PCR buffer (0.5 M KCI, 0.1M Tris-HCI, pH 8.3), 1.5 
pi MgCE (50 mM), 1 pi dNTP mix (10 mM), 0.5 pi of each primer (10 pM stock 
concentration) and 1.25 U of Taq-Polymerase (Gibco-BRL). Water was added to give 
a total volume of 50 pi. The amplification was performed under following conditions: 
1 min at 94°C, followed by 40 cycles at 94°C for 40 s, 50°C for 30 s and 72°C for 40 
s, followed by 10 min at 72°C. Specific for the extracellular domain of the ST2 gene 
the following PCR primers, designed by Dr. Xu (Westerm Infirmary, Glasgow), were 
used to detect ST2 in Sf9 cell supernatants.
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(1a) Forward primer: 5’ d(TTACAAATCCTCCATACAAC) 3’
(3’) Reverse primer: 5’ d(TCAAGCAATGTGTGAGGGACACTCCTT) 3'
In a semi-quantitative PCR, three dilutions (1:1, 1:5 and 1:10) of each supernatant 
were tested in the PCR and compared with supernatant containing 1x10® pfu/ml 
virus. If the titre of baculovirus in the tested supernatants was found lower than 10® 
pfu/ml, then fresh Sf9 cells were infected with the analysed supernatant to increase 
the virus titre.
2.37.3 Infection of Highô cells with baculovirus and release of ST2 into the 
supernatant
High5 cells were grown to a confluent layer in tissue culture flasks before being 
infected with 10 pfu /cell of baculovirus. Supernatant was harvested after 3-4 days 
and analysed by Western Blot for the expression of ST2 using 1 pg/ml polyclonal 
rabbit anti-mouse ST2L antibody (Xu et a/., 1998).
2.37.4 Purification o f baculovirus-derived ST2
Supernatant from baculovirus-transfected High5 cells was concentrated 5-10 fold in 
a Stirred Ultrafiltration Cell 8010 (Millipore Corp Ltd., Watford, UK). The YM30 
membrane (Millipore) in the Stirred Ultrafiltration Cell excluded all molecules smaller 
than 30 kD. The concentrated supernatant was dialysed against 1 L PBS, pH 7.5 
overnight at 4°C and then added to a column containing anti-FLAG M2 affinity gel 
(Sigma), which had been pre-equilibrated with PBS, pH 7.5. Non-specifically bound 
protein was removed by washing the column with 50 ml PBS, pH 7.5 and ST2 was 
then eluted by competition with 10 ml of 100 pg/ml FLAG peptide (Sigma) in PBS to 
avoid protein inactivation. Any remaining protein was eluted using 10-20 ml of 0.1 M
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glycine-HCI, pH 3.5. The success of the purification was confirmed through Western 
Blots with anti-FLAG antibodies (Sigma) used at a 1:1000 dilution of the stock 
solution.
2.38 Expression and purification of ST2-Fc from stably transfected CHO cells
2.38.1 Cell culture of CHO cells
Stably transfected CHO cells, overexpressing a fusion protein of the extracellular part 
of ST2L with human lgG1 (ST2-Fc), were obtained from Dr. Daiwu Kang (Astra 
Zeneca, Lund, Sweden). Cells were cultured in DMEM w GlutamaxI (Gibco-BRL) 
supplemented with 1% MEM (1x), 14 pg/ml G418 and 10% FBS (Gibco-BRL). When 
the CHO cells became confluent, the medium was washed off and replaced by 
DMEM w GlutamaxI with 10 % FBS with low IgG (GIBCO-BRL). Thus, the CHO cells 
released ST2-Fc into medium with a low IgG content. The cells were cultured in this 
way for 5-6 days, before the supernatant was collected.
2.38.2 Purification of ST2~Fc
5 ml Protein A Sepharose (Amersham-Pharmacia-Biotech, Bucks, UK) were packed 
on a column and washed with at least 10 column volumes of binding buffer A (20 
mM sodium-phosphate pH 7.0). 1-2 L supernatant of ST2-Fc-transfected CHO cells 
were loaded onto the Sepharose A column and the column was washed extensively 
with buffer A (20 mM sodium-phosphate pH 7.0). The amount of protein in the eluate 
was monitored by OD 280nm and buffer A was added until the OD 280nm indicated that 
no protein remained in the eluate. Protein A-bound material was then eluted with 0.1 
M glycine-HCl, pH 2.5 into 1/10 volume neutralisation buffer (1 M Tris-HCI pH 9.0, 
0.2% (v/v) Tween 20). The flow rate was 5 ml/min and 3.5 ml eluate per tube were
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collected. The OD 280nm of all fractions was monitored during the elution and protein 
contents was confirmed by running the supernatants on a denaturing SDS gel and 
staining with Commasie blue. The fractions with the highest protein contents were 
pooled and dialysed overnight with two changes of 1 L PBS, 0.02% (v/v) Tween 20, 
pH 7.4 at 4°C. The protein was concentrated to a total volume of 2-3 ml in the Stirred 
Ultrafiltration Cell 8010 (Millipore), containing the YM30 membrane. The total protein 
content was determined by using the Coomassie Plus assay (Pierce). To determine 
the protein purity, the purified ST2-Fc was run on a Coomassie blue-stained 10% 
SDS gel.
2.39 Cell contact experiments between fixed Th cells and macrophages
To investigate whether Th2 cell expressed ST2L could mimic the suppressive effect 
of ST2-FC on activated macrophages, 5x10® cells of Th2 clone X I2 and Th1 clone 
X9 were resuspended in 1 ml sterile Fixing buffer ((1% (w/v) paraformaldehyde in 1x 
PBS, pH 7.0) and incubated for 30 min on ice. The cells were washed 4 times and 
resuspended in complete RPMI 1640. CSF-1 matured macrophages were added to 
the fixed Th cells in a ratio of 10:1 (macrophages : Th cells), stimulated after 1 h with 
100 ng/ml LPS and incubated for a further 18 h. Cytokine expression (lL-6, IL-12) in 
macrophage supernatant and in fixed Th cell clones (IFN-y, IL-5) was assessed by 
ELISA.
2.40 Photoqraphv of cells
2.40.1 Th cell clones treated with G418
Th clone cells were cultured with 10 ng/ml IL-2 and 0, 400 and 800 pig/ml G418 for 2 
days. A wet preparation of the cells on slides was performed and they were
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examined under the Phase contrast microscop (Labophot, Nicon, Japan). The 
photos were taken at x 40 magnification.
2.40.2 L. major parasites treated with gentamicin
Using the software IP lab in connection with a Zeiss Axioskop (Jena, Germany) L. 
major parasites treated with 0 and 100 j^g/ml gentamicin for 3 days were filmed. 
Every 2 seconds a picture was taken at x 63 magnification.
2.41 Statistics
To ensure that two data sets, e.g. ELISA, proliferation, footpad measurement data 
sets, were significantly different, groups of means were compared using the 2- 
sample Student’s t-Test or the Mann-Whitney test applying the MINITAB program 
(MINITAB Inc., Lancaster, UK). A p-value of <0.05 was considered significant.
Differences in ST2-Fc and hIgG binding to T helper cells, detected by anti-human 
IgGI antibody (section 2.35), were analysed using the K-S two-sample test 
(CELLQuest Software, Becton Dickinson). This test analyses the statistical 
significance of differences between overlaid histograms. The calculation obtains the 
greatest difference between the curves. D/s(n) is an index of similarity for two curves. 
If D/s(n)=0, then the curves are identical. D represents the greatest difference 
between the two curves.
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Chapter 3 Expression and purification of ST2
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To gain a tool, which can modulate ST2L mediated responses, ST2 was expressed and 
purified from baculovirus-infected insect cells and stably transfected Chinese hamster 
ovary (CHO) cells. While baculovirus-derived ST2 had no detectable biological function 
on Th cells and macrophages, 50-100 i^g/ml of CHO cell-derived ST2-Fc significantly 
inhibited IL- 6  and IL-12 production from LPS-stimulated macrophages. All purified 
batches of ST2-Fc protein showed similar levels of suppression and were used in 
chapter 4 to investigate the effect of ST2 on CD4(+) T cells. The inhibition of 
macrophage cytokine production by ST2 could be mimicked with fixed Th2, but not 
fixed Thi cells. In this chapter, the observation that ST2 has an anti-inflammatory 
action on macrophages was confirmed and extended. A detection system to assess the 
biological activity of ST2-Fc has also been developed and successfully used.
Introduction
The diversity in effector function of Thi and Th2 cells is caused by the differential 
expression of molecules such as cytokines, chemokines and cell surface molecules. 
ST2L, an IL-1 receptor family member, was shown to be a cell surface marker for Th2 
cells (Xu et a/., 1998). The functions of ST2L and its splice variant ST2, which lacks the 
transmembrane and intracellular domains, are still unclear. Administration of anti-ST2L 
antibodies or ST2-Fc fusion protein impaired Th2 cell effector functions in inflammatory 
diseases, suggesting that ST2L has an important functional role on Th2 cells (Xu et al., 
1998, Loehning et al., 1998). A current hypothesis suggests that in murine T helper 
cells, ST2 is an antagonist to membrane-bound ST2L. ST2 potentially binds the as yet 
unidentified ligand of ST2L and prevents signalling (Loehning et al., 1998; Senn et al.,
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2000). Therefore, ST2 is a valuable tool to investigate the in vivo and in vitro function of 
ST2L. In this investigation, viable cell expression systems were selected and 
established to produce and purify functional ST2, which was then tested in vitro and in 
vivo in different disease models. The expression of ST2 in an E.coli expression system 
produced insoluble protein, which therefore could not be used for functional assays (Xu 
D., unpublished results). A mammalian cell expression system, which would produce 
soluble, fully glycosylated protein was not available at the time. As another group (Rupp 
et a/., 1995) had already established a successful protocol for purification of ST2 using 
the baculovirus expression system, the same system was initially adopted in these 
studies. This group provided the expression construct for ST2. Later, a mammalian cell 
expression system (stably transfected Chinese hamster ovary cells) for the ST2 fusion 
protein (ST2-Fc) was applied (Kang D, Astra, Sweden). Dr. Kang provided the stably 
transfected CHO cells and the purification protocol. Methods were developed to detect 
successful expression and for purification of baculovirus-derived-ST2 and CHO cell 
derived-ST2-Fc. The biological function of ST2 and ST2-Fc was assessed by treatment 
of macrophages, based on the finding that ST2 suppresses inflammatory cytokine 
production by LPS-stimulated macrophages (Sweet et a/., 2000).
Baculovirus expression system
Baculoviruses belong to a diverse group of large double-stranded DNA viruses that 
infect many different species of insects as their natural hosts (Matthews, 1982). 
Infectious baculovirus particles enter susceptible insect cells by facilitated endocytosis 
or fusion, and viral DNA is uncoated In the nucleus. The baculovirus genome is 
replicated and transcribed in the nuclei of infected host cells where the large
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baculovirus DNA is packaged into rod-shaped nucleocapsids (Burgess, 1977). Since 
the size of these nucleo-capsids is flexible, recombinant baculovirus particles can 
accommodate large amounts of foreign DNA. The infected insect cells release 
extracellular virus particles by budding off from the cell membrane. In the late stage, 
occluded virus particles (OV) are assembled inside the nucleus and released when the 
infected cells lyse. The OV are embedded in a homogenous matrix made 
predominantly of a single protein, called polyhedrin (Rohrmann, 1986). Expression of 
the highly abundant polyhedrin gene is non-essential in tissue culture and its strong 
promoter can be used for the synthesis of foreign gene products. Insertional inactivation 
of the polyhedrin gene in baculovirus results in the production of occlusion body- 
negative viruses.
Rupp et al. (1995) described a ST2 expression system, based on recombinant 
baculovirus infection of insect cells. The complete open reading frame of the mature 
ST2 protein lacking its leader peptide was amplified by PCR from the cDNA clone 
pTI.10 (Klemenz et al., 1989). The amplified product of 1 kb was inserted into the 
baculovirus transfer plasmid pAcGP67B (BD Pharmingen) as a BamHI/Xbal fragment. 
The baculovirus transfer vector contained, beside the sequence of the mature secretory 
ST2 gene, an 5 .co//origin of replication, an ampicillin resistance marker, a promoter for 
polyhedrin and a large tract of baculovirus sequence flanking the cloning region to 
facilitate homologous recombination (Fig. 3.1). Purified recombinant vectors containing 
ST2 were co-transfected with baculovirus DNA into insect cells and recombinant 
viruses, which arose by homologous recombination between the transfer vector and 
baculovirus DNA, were selected. The recombinant ST2 produced in insect cells was 
slightly less glycosylated than the endogenous gene product of mammalian cells. To
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Fig.3.1 Map of pGP67T1S-Flag plasmid
The complete open reading frame of the mature ST2 lacking its leader peptide 
sequence was cloned (Rupp et al., 1995). At the 3’ terminal coding region a 
sequence for the FLAG peptide was fused and the 1 kb fragment was cloned via 
Xbal/BamHI site into the Baculovirus transfer vector pAcGP67-B.
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increase the yield of secretion of glycosylated protein in this system, the coding region 
of ST2 was fused in frame with the leader sequence of the highly expressed 
baculovirus protein GP67 glycoprotein. The recombinant ST2 protein was now directed 
into the secretory pathway. For facilitated purification, the sequence for an epitope of 
eight amino acids (Flag peptide) was added to the 3’ end of ST2.
CHO cell expression system
The extracellular part of ST2L fused to the constant region of human lgG1/Fc was 
stably transfected into a Chinese hamster ovary (CHO) cell line (Coyle et al., 1999; 
Fig.3.2). The cells secreted a protein with a molecular weight of 80-90 kDa. The 
expression in CHO cells ensured full O- and N- glycosylation. The ST2-Fc fusion 
protein has been reported to inhibit the production of Th2 cytokines and eosinophilic 
inflammation of the airways in Th2 driven mucosal response model (Coyle et.al., 1999). 
Further, ST2-Fc treatment of OVA challenged Th2 recipient mice led to suppression of 
the development of airway hyperresponsiveness (Coyle et.al., 1999).
Results 
3.1. Expression and purification of baculovirus-derived ST2
3.1.1. Ampiification of recombinant baculovirus in Sf9 cells
As summarized In Fig. 3.3 and as described in detail in section 2.37.1 and 2.37.2, Sf9 
cells were expanded in serum-containing medium and infected with recombinant 
baculovirus, which amplified in the cells and concentrated in the supernatant. To
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Fig.3.2 Eukaryotic expression of the ST2-Fc fusion protein
in Cos7 cells representative for ST2-Fc expression 
in CHO cells
(A) Schematic representation of the pT1-Hy1 expression vector. The 
vector bears the 1 kb fragment of ST2 and the constant chain 2 and 
3 (Ch2 and 0^3) domains.
(B) Schematic representation of the homodimeric disulphide-linked 
ST2-Fc fusion protein. Potential N-linked glycosylation sites are 
indicated by knobs. (Moritz et al., 1998a)
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Fig. 3.3 Production and purification of ST2 from baculovirus-infected 
insect ceils
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estimate levels of recombinant baculovirus, supernatant of infected Sf9 cells was 
assessed by PCR. Both PCR primers used bound within the sequence of the ST2 
gene. The brightness of PCR products from the tested supernatant in three different 
dilutions was compared to that of PCR products from supernatant with known virus 
contents of 10® pfu/ml (Fig. 3.4). if the amount of recombinant baculovirus in the tested 
supernatants was found to be lower than 10® pfu/ml, fresh Sf9 cells were infected with 
this supernatant to increase the virus titre. Infected Sf9 cells produced only small 
amounts of ST2 protein; therefore another insect cell line, HighS, was introduced to 
maximize the amount of expressed ST2 protein.
3.1.2. Infection of HighS cells and expression of ST2 protein
HighS cells were grown in serum-free medium to avoid later contamination of ST2 with 
other protein. HighS cells infected with virus containing Sf9 supernatant, released more 
55-65 kDa protein than Sf9 cells. ST2 expression was detected by Western Blot using a 
polyclonal anti-mouse ST2L antibody (Fig. 3.5). The yield of expressed ST2 and the 
timepoint of harvest of ST2 from HighS supernatant were optimized (Fig. 3.6). Maximal 
ST2 expression was found 3 to 4 days after infection with 10 pfu/ml recombinant 
baculovirus.
3.1.3. Purification of ST2 from HighS supernatants
The purification process was performed as described in section 2.37.3. Briefly, infected 
HighS supernatant was concentrated 5-10 fold in the Stirred Ultrafiltration Cell and 
samples of the supernatant before and after the concentration were run on a SDS gel 
and stained with Coomassie blue to show the success of the concentration. The main
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Fig 3.4 ST2-PCR to estimate the recombinant baculovirus titre in 
supernatants of infected Sf9 cells
Sf9 cells were infected with recombinant baculovirus at 0.1 pfu/cell (section
2.37.1 and 2.37.2). After 4 days the supernatant was analysed by PCR for ST2 
gene containing viruses as described in section 2.37.2). The PCR was run on a 
1% agarose gel. The three lanes run for each sample represent a 1:1, 1:5 and 
1:10 dilution of supernatant. The positive control is supernatant with 10® pfu/ml 
and the negative control is supernatant of uninfected High5 cells.
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Fig 3.5 Western Blot demonstrating ST2 expression In baculovirus- 
infected HIghS cells
High5 cells were infected with 10 pfu/cells of recombinant baculovirus (section 
2.37.3) and the supernatant harvested after 4 days. Western Blot for ST2 
detection was performed using 1 pg/ml polyclonal anti-ST2L antibody.
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Fig. 3.6 Optimisation of the infection of HighS ceiis with 
recombinant bacuiovirus
A) Western Blot of recombinant baculovirus-infected HighS cell supernatants. 
High5 cells were grown to a confluent layer (section 2.37.1) before being 
infected with different amounts of recombinant baculovirus (section 2.37.3). 
Supernatant was taken after 2, 3 and 4 days and the amount of ST2 was 
assessed by Western Blot using anti-Flag antibodies
(1:1000 dilution).
B) Coomassie blue-stained SDS gel of supernatants from baculovirus- 
infected and uninfected Sf9 and HighS cells. HighS cells were grown to 
confluency before being infected with different amounts of recombinant 
baculovirus and incubated for 4 days. Equal amounts of supernatant were run 
on a SDS gel and stained with Coomassie blue.
1: uninfected: 2: 100 pfu/ml; 3: 10 pfu/ml; 4: 1 pfu/ml; 5: 0.1 pfu/ml; X: not 
relevant sample
A)
day 2 day 3 day 4
<;=l 55-65 kDa
estimated 1 10 100 1 5 1 0 1 0 0  1 5 10 100
pfu/ml
B)
X 1 3 4
^=] 55-65 kDa
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fraction of the concentrated protein ran at approximately 60 kDa, suggesting that ST2 
was one of the main products of baculovirus-infected HighS celts. Only a marginal loss 
of protein due to binding to the filter membrane was observed (Fig. 3.7). ST2 protein 
was then dialysed against PBS and loaded onto an anti-FLAG column, washed and 
eluted by competition with Flag peptide. The volume was minimized again to ensure a 
high concentration of ST2. Samples of all purification steps were assessed for ST2 
enrichment by Western Blot, using a monoclonal anti-Flag antibody in a dilution of 
1:1000 (Fig. 3.8 A and B). The detected Flag containing protein ran at 50-60 kDa and 
was also detectable with polyclonal anti-ST2L antibody (data not shown). The protein 
bound specifically to the anti-FLAG column and the majority of it was eluted by Flag 
peptide competition. Only a small fraction remained bound to the column and this was 
subsequently released by Glycin/HCI treatment.
Only 300-400 pg ST2 per litre supernatant produced by 4x10^ High5 cells could be 
purified. The culture of Fligh5 cells in a spinner culture would allow the production of 
sufficient amounts of the protein, but was not available. The purification process worked 
out to be time and cost consuming. Hence, another ST2 expression system in OHO 
cells was chosen (chapter 3.3).
3.2. Biological activity of baculovirus-derived ST2
3.2.1 The effect of baculovirus-derived ST2 on polarised Th1 and Th2 cells and 
BALB/c spleen cells
Since ST2L is expressed on Th2 cells and ST2 may inhibit ST2L sinalling by binding to 
the as yet unknown ligand, ST2 was tested on purified polarised T helper cells.
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Fig 3.7 Concentration of HighS supernatant in the Stirred 
Ultrafiltration Cell
High5 supernatant was concentrated with the Stirred Ultrafiltration Cell 
containing a 30kDa membrane (section 2.37.4). After the concentration, the 
membrane was washed with PBS and water (wash 1,2) and all the protein 
solutions were run on a 10% SDS gel and stained with Coomassie blue.
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Fig 3.8 Anti-Flag antibody detection of ST2 in HighS supernatant 
and during the purification process
A) Dot Blot of titration of anti-Flag antibody binding to ST2-Flag in baculovirus- 
infected HighS supernatant.
B) Purification of ST2 over an anti-FLAG column. Western Blotting was 
performed on samples obtained during the purification process and ST2 was 
detected by anti-Flag antibody used at a 1: 1000 dilution.
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Furthermore, the possibility that other spleen cell types, including activated B cells and 
macrophages, may interfere with the function of ST2 on T cells e.g. by producing the 
ligand, was assessed. In all experiments Flag peptide was added as a control to 
determine the effect these eight amino acids had on the ST2 function. To exclude the 
possibility that IPS contamination might contribute to any observed effect, heat- 
denatured ST2 protein was added as a control. Since LPS is heat stable but proteins 
are generally not, any effect seen with the denatured ST2 preparation is likely to reflect 
effects of contaminating products such as LPS.
CD4(+) T cells were purified as described in section 2.37.4, stimulated with antigen, 
and either polarised towards Th1 or Th2 cells, or left unpolarised (Fig. 3.9) for 3 days. 
In a second experiment, BALB/c spleen cells were stimulated for 3 days with either 5 
pg/ml anti-CD3 or 2 pg/ml ConA to activate T cells, or 1 pg/ml LPS to activate B cells 
and macrophages. ST2 (10 pg/ml - 1 pg/ml) or the mentioned controls were added to 
both experiments at the time of stimulation. Proliferation and Thi and Th2 cytokine 
profiles were assessed after 3 days and found to be unchanged between ST2-treated 
cells and control cells.
3.2.2. The effect of baculovirus-derived ST2 on macrophages
Sweet et al. (2001) demonstrated binding of Cos7 cell-derived ST2-Fc fusion protein to 
primary bone marrow-derived macrophages and an inhibition of LPS-induced pro- 
inflammatory cytokine production, e.g. IL-6 and IL-12 but not IL-10, when ST2-Fc was 
added in concentrations of 50 - 100 pg/ml. Therefore, the effect of higher 
concentrations of baculovirus-derived ST2 on LPS-stimulated bone marrow 
macrophages (BMM) was tested. CSF-1-matured BMMs were treated with up to 50
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CD4(+) T cells were purified from 
spleens of DO11.10 mice as 
described in section 2.4 and 2.8. 
Cells (1x10®) were then stimulated 
with irradiated ARC (1:10) (section 
2.6) and 300 nM OVA antigen for 
3 days. A concentration range of 
baculovirus-derived ST2 or Flag 
peptide was added at the time of 
stimulation. Cell proliferation was 
assessed by ®(H)-Thymidine 
incorporation. The cytokine 
patterns were assessed by ELISA. 
IL-4 and IL-5 levels were below 
detection. The results (n=3) are 
shown as the mean ± 1 SD.
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|ag/ml ST2 or PBS as control for 1 h, and 100 ng/ml LPS were then added for a further 
8 h. ELISA analysis of the harvested supernatants revealed that baculovirus-derived 
ST2 was not able to suppress IL-6, IL-12 or TNF-a from LPS-stimulated macrophages 
and therefore did not show the biological activity that was apparent with the ST2~Fc 
fusion protein from Cos7 cells (data not shown).
3.3. Expression and purification of ST2-Fc from Chinese hamster ovary (CHO) 
ceils
3.3.1 Expression of ST2-Fc in CHO cells
As described in section 2.38.1 and in Fig. 3.10, ST2-Fc expressing CHO cells were 
expanded in medium, supplemented with serum containing high IgG, which provided 
optimal growth conditions. Upon confluency, CHO cells were transferred into medium 
containing serum with low IgG to minimize IgG interference during the ST2-Fc protein 
purification process via protein A sepharose. The release of ST2-Fc into culture 
medium was confirmed through Dot Blot and ST2-ELISA using monoclonal anti-ST2L 
antibodies. As shown in Fig. 3.11 A and B, both of these methods confirmed the 
presence of the ST2-Fc protein in supernatant of transfected CHO cells.
3.3.2 Purification of ST2-Fc protein
The purification of ST2-Fc protein from transfected CHO cell supernatants was based 
on the strong affinity of protein A to the Fc region of immunoglobulins, including IgG. 
The ST2-FC protein was bound by a protein A sepharose column and eluted by 
lowering the pH, which protonated carboxylic acid groups and allowed for release of the
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Expansion of CHO cells to confluency in complete medium
with serum
I
Change to complete medium with serum containing low amounts of IgG
i
Secretion of ST2-Fc into cell supernatant
Test of expression by Dot Blot 
and ELISA
ST2-Fc purification over Protein A sepharose column
i Sample monitoring by ODssonm ^  measurement and SDS-PAGE
Dialysis in 1x PBS
i
Concentration in Stirred Ultrafiltration Cell
i
Test for biological activity
Fig. 3.10 Production and purification of ST2-Fc from stabiy 
transfected CHO cel is
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Fig 3.11 Determination of successful ST2-Fc production in CHO cells 
supernatant
A) A Dot Blot of supernatants of transfected and untransfected CHO cells was 
performed. ST2-Fc was detected by 1 pg/ml of monoclonal blotinylated anti-ST2 
antibody.
B) ST2-FC was detected by ELISA using monolonal biotinylated anti-ST2 
antibody (section 2.23). The supernatant of untransfected CHO cells was used 
as negative control, the positive control consisted of ST2-Fc received from Dr. 
Kang, Astra. Sample 1, 2 and 3 were untested supernatants of transfected CHO 
cells. The error bars represent the standard deviation between the ELISA 
triplicates of one sample.
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fusion protein. Protein concentration in fraction eluates was monitored by OD280nm 
measurement (Fig. 3.12 A). Aliquots of fractions with the highest OD280nm were run on a 
denaturing SDS gel and stained with Coomassie blue (Fig. 3.12 B). A single band 
appeared around 90 kDa. Bands with molecular weights of 60-70 kDa, as seen in 
fraction 1-4 (Fig. 3.12 B), were minimized by more stringent washes (Fig. 3.12 0). The 
fractions with the highest protein contents were pooled, dialysed and concentrated. The 
purified protein preparation contained a single major band at 80-90 kDa (Fig. 3.13). 
One or two faint smaller bands were also observed that may have resulted from 
incomplete glycosylation or degradation of ST2-Fc protein. hIgG, the control used in in 
vitro experiments, ran with three bands at 25 kDa, 60 kDa and 80-90 kDa. The 25 kDa 
band represented the light chain, the 60 kD band represented the heavy chain and the 
large band may have been be due to incomplete dénaturation of the protein.
3.4 Assessment of the biological activity of CHO cell-derived ST2-Fc protein
3.4.1 The effect of ST2-Fc on macrophages
Cos7 cell-derived ST2-Fc protein, obtained from Astra, was able to suppress pro- 
inflammatory cytokines including TNF-a, IL-6 and IL-12 on LPS-stimulated BMMs 
(Sweet et a/., 2001). To test the biological activity of CHO cell-derived ST2-Fc protein, 
the protein was cultured with LPS-stimulated BMMs as described in 3.2.2. Human IgG 
was added as a control to determine the effect of the Fc part of the ST2 fusion protein. 
Every batch of ST2-Fc protein suppressed production of pro-inflammatory cytokines at 
a concentration range of 50-100 pg/ml (Fig.3.14). 50 pg/ml of ST2-Fc reduced IL-12 by 
72%, IL-6 by 80% and TNF-a by 61%. The expression of IL-10 was not affected. The
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Fig 3.12 Purification of ST2-Fc from supernatant of transfected 
CHO cells
The purification was conducted as described in section 2.38.2.
A) OD280 nm profile of purification. Different colours represent separately 
collected fractions of a volume of 3.5 ml. Fraction 4 contains the majority of 
the eluted ST2-Fc.
B) Run of fractions on a Coomassie blue-stained SDS gel. Fraction 4 contains 
the majority of the eluted ST2-Fc.
C) Coomassie blue-stained SDS gel of the collected fractions after prolonged 
washing with buffer A (20 mM sodium-phosphate pH 7.0). This figure shows a 
separate experiment. Here, fraction 3 contains the majority of the eluted ST2- 
Fc. (sn =supernatant, ft=flow through, w=wash, f=fraction)
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Fig. 3.13 Coomassie biue-stained SDS gei of purified ST2-Fc and the 
control higG
A) Purified ST2-Fc was run on a 10% SDS gel and stained with Commassie 
blue.
B) Purified ST2-Fc and higG (purified over the Protein A sepharose column, 
described in section 2.38.2) were run on 10% SDS gel and stained with 
Coomassie blue.
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Fig 3.14 ST2-Fc suppresses IL-6, IL-12 and TNF-a production by LPS- 
stimulated BMMs
BMMs were obtained as described in section 2.11. Matured BMMs (5x10®) were 
incubated with 50 pg/ml ST2-Fc or higG for 1h, then stimulated with 100 ng/ml 
LPS for 8 h. Control cells were left unstimulated. The cytokine production was 
measured by ELISA. The results (n=3) are shown as the mean ± 1 SD 
(**p<0.005) and are representative for 4 experiments.
(NA: not analysed)
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suppression of pro-inflammatory cytokines by ST2-Fc was not due to toxicity as it had 
no effect on the viability of RAW264 cells and BMMs as assessed by MTT assay, 
despite the fact that IL-6 and IL-12 levels decreased dramatically in these cells (Fig. 
3.15 and data not shown).
3.4.2. The effect of ST2L on macrophages
The suppressive effect of ST2-Fc might be mediated by its binding to the cell surface of 
macrophages (Sweet et al., 2001). The binding could be further enhanced by treatment 
of macrophages with LPS, indicating the upregulation of the putative ST2-binding 
protein. ST2L and ST2 share a common extracellular region, raising the question of 
whether membrane-bound ST2L functions in the same way on macrophages as its 
shorter splice variant. To address this question, the ability of fixed Th2 cells (which 
express ST2L) to inhibit LPS-stimulated macrophages to produce pro-inflammatory 
cytokines was assessed. Thi and Th2 clones were fixed with paraformaldehyde to 
inhibit their cytokine production and cultured with macrophages as described in section 
2.39. Neither of the fixed Th clones produced cytokines or showed signs of proliferation. 
However, fixed Th2 cells were able to decrease IL-6 expression to 39% and IL-12 
expression to 48% of the control level (Fig. 3.16). Fixed Thi cells, which do not express 
ST2L, did not alter the IL-6 release, and actually increased IL-12 production from LPS- 
stimulated macrophages.
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Fig 3.15 Dose-dependent effect of ST2-Fc on LPS-stimulated RAW cells
RAW264 cells (5x10®/well) were treated with a concentration range of ST2-Fc 
and higG for 1h before being stimulated with 100 ng/ml LPS. The cells were 
incubated for a further 8h. Control cells were not stimulated with LPS. The cells 
were tested for changes in mitochondrial activity (A) and the supernatants were 
analysed for IL-12 and IL-6 production by ELISA (B,C). The results (n=3) are 
shown as mean ± 1 SD (**p<0.005, *p<0.05) compared with the control (higG).
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Fig. 3.16 Fixed Th2, but not Thi cells reduce IL-6 and IL-12 production 
by LPS-stimulated BMMs
Thi and Th2 cell clones (5x10®) were fixed in 1% paraformaldehyde (section 
2.39) and incubated for 1h with matured BMMs (10:1) before 100 ng/ml LPS 
were added and the cells were incubated for a further 18h. Cytokine production 
was analysed by ELISA. The results (n=3) are shown as mean ± 1 SD 
( *p<0.05) and represent 2 experiments.
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Discussion
ST2 derived from baculovirus-infected insect cells did not show suppressive activity on 
LPS-stimulated macrophages, whilst ST2-Fc protein decreased pro-inflammatory 
cytokine production by LPS-stimulated macrophages. Rupp et al. (1995) reported the 
expression of the secreted, modified ST2 protein by baculovirus-infected insect cells, 
but no biological function of the protein had been shown. Meisel et al. (2001) 
demonstrated recently that Flag-ST2 could neutralize the effects of immobilized anti- 
ST2L antibody on Th2 cells but did not show an effect of Flag-ST2 itself on Th2 cells 
which is consistent with the results presented here. There may be several reasons for 
the lack of bioactivity of baculovirus-derived ST2. Firstly, the protein function may suffer 
from a lack of glycosylation and other post-translational modifications, which might be 
crucial for the biological function of ST2, e.g. for the interaction with its ligand/receptor. 
Several post-translational modifications such as N- and O-linked glycosylation, 
phosphorylation and proteolytic cleavage have been reported to occur in the 
baculovirus-infected insect cells (Hoss et al., 1990; Kloc et al., 1991). However, the 
baculovirus expression system can express the gene of interest at a high rate, which 
may overwhelm the ability of the cell to modify the protein product (Crossen and 
Gruenwald, 1997). Additionally, baculovirus-infected insect cells are impaired in their 
ability to sialylate proteins (Marchai et al., 2001). Secondly, ST2-Fc protein is likely to 
dimerise in solution (Gayle et al., 1996), due to the forming of two disulphide bridges. 
By using a non-denaturing gel, a number of bands above 150 kDa were detected, which 
could indicate the existence of ST2-Fc dimers (data not shown). Fc fusion proteins 
have been shown to dimerise and exhibit stronger biological activity than monomeric
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native receptors, e.g. the soluble TNF-a receptor fusion protein (Kuerschner et al., 
1992; Mohler et al., 1993). Baculovirus-derived ST2 carrying the Flag peptide was 
found to be monomeric (Gayle et. al., 1996). Whether dimérisation is critical for ST2 
function and whether natural ST2 is dimerising is still unclear and needs to be further 
investigated. Due to the lack of functional anti-ST2 antibodies for Western Blotting of 
non-denaturing gels, the question of whether natural ST2 forms dimers could not be 
fully addressed during this study. Flowever, Kuroiwa et al. (2001) using gel filtration and 
SDS PAGE under non-reducing conditions suggested the existence of ST2 multimers in 
human serum.
The suppressive effect of ST2-Fc on macrophages could be mediated by binding to a 
cell surface protein, which functions as a receptor (Fig. 4.1 B). Indeed, strong binding of 
ST2-Fc but not baculovirus-derived ST2 to macrophages was found (Sweet et. al., 
2001; data not shown). Fixed Th2 cells, expressing ST2L, but not fixed Thi cells were 
also able to reduce pro-inflammatory cytokine production on LPS-stimulated 
macrophages, indicating a role for ST2L similar to ST2. Monoclonal anti-ST2L 
antibodies were unable to neutralize the effect of fixed Th2 cells on macrophages, but 
induced a reduction of pro-inflammatory cytokines (data not shown). Testing fixed Th2 
cells, isolated from ST2L knockout mice (Townsend et al., 2000), should prove whether 
ST2L is important for altering IL-6 and IL-12 production by activated macrophages. It 
remains unclear, which of the Thi cell expressed molecules was responsible for the 
observed increase of IL-12 production by activated macrophages. For example, IFN-y is 
able to increase IL-12 production (Ma et al., 1996; Hayer et al., 1995), but IFN-y 
production by fixed Thi cells was not detected.
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The effect of the ST2-Fc fusion protein on T helper cells was next investigated and is 
described in chapter 4.
141
Chapter 4 The effects of ST2 on naïve but not on
committed CD4(+) T cells
142
Naïve CD4(+) T cells and polarised Th1 cells do not express the orphan receptor 
ST2L, whilst most CD4(+) T cells become ST2L(+) upon repeated antigenic 
stimulation under Th2 polarising conditions. The blockade of ST2L function on Th2 
cells through ligand competition with its shorter spliced variant, soluble ST2 (ST2), 
has been extensively studied. An analysis of the effect of ST2-Fc fusion protein, 
mimicking ST2, on ST2L(-) naïve and antigen-stimulated CD4(+) T cells is 
presented in this chapter. In vitro studies revealed that ST2-Fc suppressed 
cytokine expression by CD4(+) T cells, which had been primed with antigen. 
However, antigen-restimulated CD4(+) T cells were resistant to the suppressive 
effect of ST2-FC. ST2-Fc binding studies using these cells showed that only naive 
and freshly stimulated CD4(+) T cells bound the fusion protein, whilst restimulated 
CD4(+) T cells were unable to do so. This suggests that ST2 functions through 
binding to an unidentified receptor and suppressing the effector functions of the 
target cell. These data collectively demonstrate that ST2-Fc is unlikely to act on 
unpolarised CD4(+) T cells as an ST2L antagonist by competition for a soluble 
ligand but rather probably functions by binding directly to T cells and triggering 
signalling.
Introduction
The two ST2 gene products, a 5 kb mRNA coding for a membrane-bound receptor 
(ST2L) and a shorter 2.7 kb mRNA coding for the soluble receptor (ST2), were 
found to be expressed in several T cell lines (Roessler et al., 1995). The role of
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ST2L, an orphan receptor, in Th2 cells has been extensively examined. This 
molecule is stably expressed on Th2, but not Th1 cells (Xu et al., 1998; Loehning 
et al., 1998). Blockade of ST2L by anti-ST2L antibody resulted in increased 
resistance to Leishmania major infection in BALB/c mice and exacerbated 
collagen-induced arthritis in DBA/1 mice by modulation of the Th1/Th2 balance. 
Thus, ST2L was postulated to be involved in Th2 cell effector functions.
An important unanswered question is the role of ST2 in immune responses. It 
might, like other soluble cytokine receptors, act as an antagonist to ST2L by 
binding to its putative ligand and so preventing ST2L-mediated signalling (Fig. 4.1 
A, Fernandez-Botran et al., 1996). Alternatively, since ST2 was found to bind 
directly to macrophages and trigger anti-inflammatory responses (Sweet et al., 
2001), ST2 has the potential to act as a ST2L agonist on cells expressing the 
putative receptor for ST2 and ST2L and to induce signalling through this receptor 
(Fig.4.1 B). In support of the first model, a ST2-Fc fusion protein, consisting of the 
extracellular part of ST2L and the Fc part of human IgGI, suppressed both 
differentiation to and activation of Th2, but not Thi effector populations in vitro, 
and abrogated Th2 cytokine production in vivo (Coyle et al., 1999). Additionally, 
the ST2-FC protein attenuated eosinophilic inflammation of the airways, suggesting 
a crucial role for ST2L in Th2 effector functions (Coyle et al., 1999; Loehning et al., 
1998). Coyle's findings that ST2-Fc also had a priming effect on unpolarised Th 
cells raised the question, as to how ST2 functions on ST2L(-) Th cells, where a 
competition between the two ST2 splice variants for the unknown ligand is unlikely 
(Coyle et al., 1999). The effect of ST2-Fc on the cell viability and cytokine
A) Competition of ST2 and ST2L for their ligand
ligand
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ST2
B) Binding of ST2 or ST2L to their receptor
ST2 or ST2L
receptor for ST2 and ST2L
Fig.4.1 Models for ST2 function on T helper cells
A) ST2 competes with ST2L for their soluble ligand and therefore prevents 
signalling through ST2L.
B) ST2 or ST2L bind to their receptor on Th cells and thereby initiate signalling.
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expression of naïve and committed CD4(+) T cells was therefore examined. The 
possibility of ST2-Fc mediating its effects by binding to the cell surface was also 
investigated by flow cytometry.
Results 
4.1. The effect of ST2-Fc on T helper cells
4.1.1. The effect of ST2-Fc on naive CD4(+) I  cells during an antigen-driven 
immune response
At the time of this study little was known about the in vitro effects of ST2-Fc on T 
cells. ST2-FC or human IgG (100 pg/ml - 1 iig/ml) was added to spleen cells 
derived from D 011.10 mice. The cells were stimulated with antigen or plate-bound 
anti-CD3 to activate T cells, and LPS or LPS/IFN-y to activate macrophages, which 
may produce ST2 ligand or receptor and therefore provoke a cytokine response by 
Th cells. ELISA analysis of Thi and Th2 cytokines revealed no difference between 
ST2-Fc-treated and hIgG-treated control cells (data not shown). Next, CD4(+) T 
cells were enriched by negative selection as described in section 2.8 and polarised 
to Thi and Th2 cells (section 2.9). ST2-Fc (100 pg/ml - 1 pg/ml) added at the time 
of stimulation did not influence the cytokine expression profiles of either Thi or 
Th2 cells (data not shown). The effect of ST2-Fc on in vitro polarised Thi and Th2 
cells was then compared to an in vivo Th2 dominated disease model, Leishmania 
major in BALB/c mice. Spleen cells from infected animals were stimulated in vitro
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with L. mayor antigen (section 2.16) and ST2~Fc or hIgG (100 pg/ml -1 pg/ml). Thi 
and Th2 cytokine expression profiles were not altered by the addition of ST2-Fc 
(data not shown). In summary, ST2-Fc at concentrations of 100 pg/ml -1 pg/ml did 
not alter T helper effector functions in the applied models.
Coyle et al. (1999) described a shift from Th2 to Thi cytokines in antigen 
restimulated Th cells, when the first antigenic stimulation was administered in the 
presence of 100 pg/ml ST2-Fc. Th2, but not Thi cells were susceptible to ST2-Fc 
effects. To examine the effects of these doses of ST2-Fc on antigen-stimulated T 
helper cells, CD4(+) T spleen cells derived from DO11.10 mice and purified by 
negative selection as described in section 2.8, were stimulated with 300 nM OVA 
peptide antigen in the presence of irradiated ARC in a ratio of 1:10 (T cells : ARC). 
ST2-FC or human IgG control (100 pg/ml) was added at the time of stimulation and 
the culture incubated for 3 days (Fig.4.2 A). Unexpectedly, the production of both 
Thi and Th2 cytokines was significantly suppressed by the ST2-Fc protein. IL-2 
expression was almost completely abolished and IFN-y production was decreased 
by 70%; IL-5 expression levels were low, but a 75% decrease was observed. IL-6 
expression was decreased by 85% in comparison to hIgG-treated cells and IL-4 
expression was below the limit of detection of the ELISA (Fig. 4.3). ST2 did not 
significantly decrease cell proliferation, suggesting that toxicity due to the high 
concentration of ST2-Fc was not the reason for the observed suppression of 
cytokine release. Only ST2-Fc concentrations above 10 pg/ml proved to be 
effective in decreasing Thi and Th2 cytokine production by antigen-stimulated Th 
cells (Fig. 4.4).
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Fig. 4.2 Experimental protocols to investigate the effect of ST2-Fc 
on T helper cells
A) CD4(+) T cells, purified from DO11.10 mice as stated in section 2.4 and 
2.8, were stimulated with either irradiated ARC (1:10) and 300 nM OVA 
antigen or 4 pg/ml plate-bound anti-CD3. ST2-Fc (100 pg/ml) or human IgG 
(hIgG) were added for 3 days. Afterwards cell viability and cytokine 
expression were assessed by ^(H)-Thymidine incorporation and ELISA.
B) Rurifled CD4(+) T cells, purified from DO11.10 mice, were stimulated 
with irradiated ARC (1:10) and 300 nM OVA antigen for 3 and 6 days before 
the cells were restimulated with 4 pg/ml anti-CD3 and the addition of 100 
pg/ml ST2-FC or hIgG. Three days later, cell viability and cytokine 
expression were assessed.
C) Ru rifled CD4(+) T cells, purified from DO11.10 mice, were stimulated 
with 4 pg/ml anti-GD3 for 3 days. The cells were then incubated in 10 ng/ml 
IL-2-containing medium for 48h, before they were restimulated with 4 pg/ml 
anti-GD3 and 100 pg/ml ST2-Fc or hIgG. Three days later, cell viability and 
cytokine expression were assessed.
A)
day 0 day 3
• anti-CD3 or APC+Ag • Proliferation assay
• 100 pg/ml ST2-FC and hIgG • ELISA 
as control
B)
day 0
APC+Ag
day 3 (6)
• anti-CD3 
•100 pg/ml ST2-FC 
and hIgG as control
day 6 (9)
Proliferation assay 
ELISA
C)
day 0
►anti“CD3
day 3 day 5 day 8
IL-2 • anti-CD3 • Proliferation assay
• 100 pg/ml ST2-FC • ELISA 
and hlgG as control
148
Fig 4.3 The effect of ST2-Fc on antigen-stimulated Th cells
CD4(+) T cells were obtained from DO11.10 mice (section 2.4 and 2.8) 
and 1x10® cells/well were stimulated with APC (5x10®) and 300 nM OVA 
antigen for 3 days together with 100 pg/ml ST2-Fc and hlgG as control. 
Cytokine expression was assessed by ELISA. The detection level of the 
IL-5 was 20 pg/ml, the detection level of IL-6 was 10 pg/ml. IL-4 levels 
were below detection. Proliferation assays were performed to estimate 
cell viability. hIgG-treated samples were compared with ST2-Fc-treated 
samples: * p<0.05, ** p<0,005. These results (n=3, ELISA triplicates) are 
shown as the mean ± 1SD and are representative of 6 experiments.
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Fig 4.4 Dose dependent effect of ST2-Fc on antigen-stimulated Th 
ceils polarised under neutral conditions
Purified CD4(+)T cells (1x10®/well) were cultured for 3 days with APC (5x10®) 
and 300 nM OVA antigen and ST2-Fc or hlgG in graded concentrations. 
Cytokines and proliferation profiles were assessed by ELISA and proliferation 
assay respectively. The detection level of the IL-6 was 5 pg/ml. hIgG-treated 
samples were compared with ST2-Fc-treated samples:
* p<0.05, ** p<0.005. Results (n=3) are shown as the mean ± 1 SD and are 
representative of 2 experiments.
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4.1.2 The effect of ST2-Fc on naïve CD4(+) T cells primed with plate-bound 
antl-CD3
Next, the question of whether ST2-Fc-mediated suppression requires the presence 
of antigen presenting cells (APC) or whether it acts directly on the CD4(+) T cells 
was addressed. ST2-Fc might interact directly with the APC and thereby alter 
costimulatory signals for CD4(+) T cells or induce the expression of soluble 
factors, which mediate the cytokine suppression on CD4(+) T cells. CD4(+) T cells 
were stimulated with 4 jLig/ml plate-bound antl-CD3 for 3 days and incubated from 
the time of stimulation with 100 ^ig/ml ST2-Fc protein or hlgG (Fig. 4.2 A and Fig. 
4.5). ST2-FC significantly decreased Thi and Th2 cytokine release. IL-2, IL-4 and 
IL-5 production was almost completely suppressed by ST2-Fc treatment; IFN-y 
expression was decreased to 45% of the control level, while cell viability, as 
measured by ^(H)-Thymidine incorporation, was not affected. ST2-Fc 
concentrations lower than 10 juig/ml had no effect (Fig. 4.6). Thus, ST2-Fc has a 
suppressive effect on Thi and Th2 cytokine release by T cell receptor stimulated 
CD4(+) T cells, irrespective of whether APC are present.
4.1.3 The effect of ST2-Fc on primed CD4(+) T cells during an anti-CD3- 
drlven secondary response
Naïve and primed CD4(+) T cells might have a very different susceptibility to the 
suppressive effect of ST2-Fc. For example, another molecule with a suppressive 
effect on Th cells, TGF-p1, has been found to inhibit the proliferation and cytokine
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Fig. 4.5 The effect of ST2-Fc on antl-CDS-stlmulated CD4(+) T cells
CD4(+) T cells (1x10®/well), purified from DO11.10 mouse spleen cells by 
negative selection, were stimulated with 4 [ng/ml anti-CD3 in the presence of 100 
|ag/ml ST2-FC or hlgG for 3 days. Proliferation was assessed by ^(H)-Thymidine 
incorporation and cytokine production was assessed by sandwich ELISA. 
hIgG-treated samples were compared with ST2-Fc-treated samples: * p<0.05,
** p<0.005. Results (n=3) are shown as mean ± 1 SD and representative of 4 
experiments.
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Fig. 4.6 Dose-dependent effect of ST2-Fc on antl-CDS-stlmulated Th cells
Purified CD4(+) T cells (IxlO^/well) were stimulated with 4 pg/ml anti-CD3 and 
treated for 3 days with graded concentrations of ST2-Fc or hlgG. Cell 
proliferation and cytokine expression were determined by ^(H)-Thymidine 
incorporation and ELISA. IL-5 levels were below detection. hlgG- treated 
samples were compared with ST2-Fc-treated samples: * p<0.05, ** p<0.005. 
Results (n=3) are shown as mean ± 1 SD.
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expression of antigen-stimulated naïve Th cells, but not of antigen-stimulated 
memory Th2 cells (Ludviksson et al., 2000).
To examine whether primed CD4(+) T cells are susceptible to ST2-Fc, CD4(+) T 
cells were derived from DO11.10 mouse spleen and purified by negative selection. 
They were primed with 300 nM OVA antigen in the presence of irradiated APC 
(1:10 ratio) for 3 or 6 days, and then restimulated with plate-bound anti-CD3 (4 
pg/ml) for a further 3 days in the presence of 100 pg/ml ST2-Fc or hlgG (Fig. 4.2
B). ST2-FC had no effect on either the proliferation or Thi and Th2 cytokine 
production of restimulated T helper cells, indicating that restimulated T helper cells 
are resistant to ST2-Fc (Fig. 4.7 and 4.8). To assess whether the strong response 
of primed Th cells to the secondary anti-CD3 stimulation could have masked the 
suppressive effect of ST2-Fc, CD4(+) T cells were stimulated for 3 days with 
antigen in the presence of APC and subsequently incubated with 100 pg/ml ST2- 
Fc or hlgG for a further 3 days. Cell proliferation levels were low but similar 
between ST2-Fc- and hIgG-treated cells. Thi and Th2 type cytokines could not be 
detected (data not shown).
4.1.4 The effect of ST2-Fc on CD4(+) T cells, twice stimulated with plate- 
bound anti-CD3
To investigate whether the engagement of the T cell receptor was responsible for 
this resistance to ST2-Fc, or whether the interaction with the APC or soluble 
factors expressed by APC was also essential, CD4(+) T cells were stimulated with 
plate-bound anti-CD3 (4 pg/ml) for 3 days, incubated with 10 ng/ml IL-2 for 48 h
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Fig. 4.7 The effect of ST2-Fc on restimulated Th cells (1)
Purified CD4(+) T cells (1x10®/well) were stimulated with Irradiated APC (5x10®) 
and 300 nM OVA antigen for 3 days before being restimulated with 4 pg/ml anti- 
CD3 for a further 3 days. At the time of the restimulation with anti-CD3 
100 pg/ml ST2-FC or hlgG were added. Then proliferation and cytokine pattern 
were assessed. Results (n=3) are shown as mean ± 1 SD and representative of 
3 experiments.
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Fig. 4.8 Effect of ST2-Fc on restimulated Th cells (2)
Purified CD4(+) T cells (1x10®/well) were stimulated with APC (5x10®) and 300 
nM OVA antigen for 6 days before being restimulated with 4 pg/ml anti-CD3 for 
3 days. At the time of restimulation with anti-CD3 (day 6), 100 pg/ml ST2-Fc or 
hlgG were added. The cytokines released were measured by ELISA and the 
proliferation determined by ®(H)-Thymidine uptake. Results (n=3) are shown as 
mean + 1 SD and represent 2 experiments.
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and then restimulated with anti-CD3 in the presence of 100 pg/ml ST2-Fc or hlgG 
for a further 3 days (Fig. 4.2 0; Fig. 4.9). The fusion protein did not suppress 
cytokine production or proliferation of the Th cells, confirming that triggering of the 
T cell receptor sends a sufficient signal to the T cell to undergo changes that 
prevent ST2-Fc action.
4.1.5 The effect of ST2-Fc on cloned Thi and Th2 cells
To further confirm that primed T helper cells are resistant to ST2-Fc, the effect of 
the fusion protein on the responses of fully committed Thi and Th2 clones was 
examined. D10 (Th2) cells produced IL-4 and IL-5 but not IFN-y when stimulated 
with antigen in the presence of APC, whilst Dorris (Thi) cells produced IFN-y but 
not IL-4 and IL-5 (Fig.4.10). The presence of ST2-Fc did not affect cytokine 
production or proliferation of antigen-stimulated Th clones (Fig. 4.11). Interestingly, 
although ST2L is expressed on Th2 cells but not on Thi cells (see Fig. 5.1), Th2 
clones did not exhibit differential susceptibility to ST2-Fc.
4.1.6 Analysis of ST2-Fc binding to CD4(+) T cells and cloned T helper cells
The results presented above demonstrate that ST2-Fc has a suppressive effect on 
freshly stimulated CD4(+) T cells, but not restimulated cells. To investigate 
whether this phenomenon is due to the differential expression of a ST2 binding 
protein on the Th cells, ST2-Fc binding to naïve, freshly stimulated and 
restimulated CD4(+) T cells was analysed by flow cytometry. CD4(+) T cells were 
separated by negative selection and cultured with OVA antigen or anti-CD3 (as
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Fig 4.9 The effect of ST2-Fc on anti-CD3-restimulated Th cells
Purified CD4(+)T cells (1x10®/well) were stimulated with 4 pg/ml anti-CD3 for 3 
days, then incubated for 2 days with 10 ng/ml IL-2 and afterwards restimulated 
with anti-CD3 for a further 3 days. At the time of the restimulation with anti-CD3, 
100 pg/ml ST2-FC or hlgG were added. The proliferation and cytokine pattern 
were determined by ®(H)-thymidine uptake and ELISA respectively. Results 
(n=3) are shown as mean ± 1 SD.
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Fig. 4.10 Typical cytokine profile of T helper clones
Thi clones (Dorris, X4) and Th2 clones (D10, X I2) were stimulated with their 
respective antigen in the presence of APC (1:10) for 3 days as described in 
section 2.7. The supernatants were analysed for IFN-y, IL-4 and IL-5 by ELISA. 
Results (n=3) are shown as mean ± 1 SD.
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Fig. 4.11 Dose-dependent effect of ST2-Fc on Th cell clones
D10 (Th2) and Dorris (Thi) T cell clones (1x10®/well) were stimulated with APC 
(1:10 ratio) and antigen for 3 days, ST2-Fc or hlgG at indicated concentrations 
were added. Proliferation and cytokine release was determined. Results (n=3) 
are shown as mean ± 1 SD.
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described in Fig. 4.12) prior to incubation for 30 min with ST2-Fc fusion protein or 
hlgG (100 pg/ml) at 4°C to allow binding but prevent receptor-mediated 
endocytosis (Huang et al., 1999; Ikushima et al., 2000). ST2-Fc was detected by a 
FITC-labelled anti-human IgGI antibody. In two separate experiments, 10-15% of 
naïve CD4(+) T cells stained positive for anti-hlgGI, suggesting binding of ST2-Fc 
to these cells (Fig. 4.12 A). Freshly stimulated CD4(+) T cells exhibited a similar 
percentage of ST2-Fc binding (Fig. 4.12 B), while restimulated CD4(+) T cells 
showed no binding of ST2-Fc (Fig. 4.12 C and D). Thi and Th2 cell clones did not 
exhibit binding of the ST2-Fc fusion protein (Fig. 4.13).
Next, naïve CD4(+) T cells were double stained for ST2-Fc binding and CD4 to 
exclude the possibility that the fusion protein bound to the 5-10% CD4(-) cells not 
excluded by negative selection. As demonstrated in Fig.4.14, ST2-Fc bound to 
approximately 9% of the CD4(+) T cell population and no ST2-Fc positive staining 
could be detected in the 9.5 % GD4(-) cells. Hence, there was a direct correlation 
between cell populations that bound ST2-Fc and cell populations in which ST2-Fc 
exerted a suppressive effect on cytokine production and proliferation.
Discussion
To investigate the effects of ST2 on CD4(+) T cells, a fusion protein expressed in 
CHO cells and consisting of the extracellular part of ST2L and the Fc part of IgG I, 
K , was used. Its biological function had been tested on LPS-stimulated 
macrophages and 50 - 100 jj.g/ml ST2-Fc proved to suppress pro-inflammatory
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Fig. 4.12 Binding studies of ST2-Fc versus hlgG on purified 
CD4(+) T ceils
Purified CD4(+)T cells, which were derived from DO11.10 mice, were 
treated as described below and incubated with 100 pg/ml ST2-Fc or 
hlgG and stained with monoclonal FITC-anti-human IgGI antibody 
(1:100 dilution) as described in section 2.35. A gate was set to exclude 
dead cells.
A) naïve GD4(+)T cells
B) GD4(+)T cells stimulated for 24 h with 4 pg/ml anti-GD3
C) GD4(+) T cells stimulated for 3 days with 4 pg/ml anti-GD3, then 
incubated for 48 h with 10 ng/ml IL-2 and then restimulated with anti-
GD3 for 36 h
D) GD4(+) T cells stimulated for 6 days with (1:10) APG and 300 nM 
OVA Ag and then for 2 days with anti-GD3
These results are representative of 2 experiments.
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FL1-H
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hlgG + control antibody
ST2-Fc + anti-hlgG1 antibody
FL1-H
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FL1-H
hlgG + anti-hlgG1 antibody
hlgG + control antibody
ST2-FC + anti-hlgG1 antibody 
Fig. 4.13 ST2-Fc binding studies on Th cell clones
Th2 cell clone X I2 (A) and Th1 cell clone X4 (B) were tested for ST2-Fc binding 
by incubating them with 100 |jg/ml ST2-Fc or hlgG and staining with monoclonal 
anti-human IgGI antibody (section 2.35). A gate was set to exclude dead cells 
These results are representative of 2 experiments.
Statistics 
of Fig. 4.12, 
and 4.13
Treatment D/s(n)
Naïve CD4(+) 15.42
T ceils (A)
CD4(+) T 
ceils (B)
CD4(+) T 
ceils (C)
CD4(+) T 
ceils (D)
X4
13.72
4.2
1.56
6.32
0.29
0.22
0.04
0.03
0.08
<0.001
<0.001
<0.001
<0.001
<0.001
X12 6.68 0.09 <0.001
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Fig. 4.14 ST2-FC binding to CD4(+) T cells
Naïve CD4(+) T cells from lymph nodes of DO. 11.10 mice were purified by 
negative selection. They were incubated with 100 pg/ml ST2-Fc or hlgG for 30 
min at 4°C and then washed before staining with monoclonal anti-human IgGI 
antibody and anti-CD4 antibody as described in section 2.35. The cells were 
then analysed by flow cytometry. (A) shows CD4 expression among live cells 
and (B) shows CD4(+) cells (M2), which stained positive for anti-hlgGI.
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cytokines such as IL-6 and IL-12. Kuroiwa et al. (2000) reported a serum 
concentration of 1.2 ng/ml ST2 in normal human blood and an enhanced ST2 
concentration of up to 5 ng/ml in sera from patients with bronchial asthma. These 
results suggest a function for ST2 in Th2-mediated diseases, but do not indicate a 
physiologically relevant ST2 concentration, because local concentrations might be 
much higher than the measured serum levels. Suppressive ST2-Fc doses 
exceeded the serum ST2 levels dramatically, suggesting the need for a high local 
ST2 concentration or a differing function of ST2-Fc function from in vivo occurring 
ST2.
The results presented here showed that ST2-Fc suppressed both Thi and Th2 
cytokine production by naïve CD4(+) T cells in the absence of APC, e.g. T cell 
stimulation by anti-CD3, and such suppression was equal to, or even greater than, 
that observed in the presence of APC. This implies that ST2-Fc is not primarily 
acting via effects on APC, but instead can act directly on CD4(+) T cells. After 
restimulation through the TCR, CD4(+) T cells lost the ability to respond to ST2-Fc, 
which further confirms that the observed suppression of cytokines on freshly 
stimulated CD4(+) T cells was not due to a toxic effect of the high concentration of 
ST2-Fc on the cells. In addition, Coyle et ai. (1999) reported that CD4(+) T cells 
treated with ST2-Fc during priming and then restimulated with antigen still 
exhibited a suppression of Th2 cytokines, while Thi cytokines were upregulated. 
These findings suggest that the suppressive effects of ST2-Fc are maturation-and 
differentiation-dependent.
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TGF-pi has been shown to have similar suppressive effects, dependent on the 
maturation and differentiation state of the CD4(+) T cells (Ludviksson et al., 2000). 
It has a profound inhibitory effect on the cytokine production and proliferation of 
antigen-stimulated, naive CD4(+) T cells undergoing differentiation under neutral 
(antigen stimulation only), Th1 and Th2 priming conditions. ST2-Fc also inhibited 
the cytokine production of antigen-stimulated, naive CD4(+) T cells undergoing 
differentiation under neutral, Th1 and Th2 priming conditions (Th1 and Th2 cell 
data not shown). Furthermore, memory Th1 cells remain susceptible to TGF-pi 
suppression, while memory Th2 cells are not subject to ST2-Fc suppression 
(Ludviksson et ai., 2000). Only memory Th2 cells remain susceptible to ST2-Fc 
(Coyle et al., 1999). Both TGF-p and ST2 are upregulated upon UV irradiation 
(Kumar et a!., 1997, Dissanayake and Mason, 1998) and might limit immune 
responses at an initial differentiation stage, and later control the balance between 
Thi and Th2 cells.
To investigate how ST2-Fc modulated the effector function of I  cells, ST2-Fc 
binding studies by flow cytometry were performed. The results revealed that ST2- 
Fc bound only to naïve and freshly stimulated CD4(+) T cells, but not to 
restimulated CD4(+) T cells. This is consistent with the fact that naïve but not 
committed CD4(+) T cells responded to ST2-Fc. This may be the result of 
downregulation of the putative ST2 binding protein. There are several candidate 
ST2 binding molecules on GD4(+) T cells. Binding of ST2 to the myeloma-derived 
RPMI8226 cell line (Yanagisawa et a i, 1997), BALB/c 3T3 cell line and human 
vein endothelial cells (Kumar et a!., 1995), macrophages, activated B cells, DCs
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and naïve Th ceils (Sweet et al., 2001; Lambrecht et al., 2000, Coyle et al., 
unpublished data; own data) has been reported. A putative ligand called ST2 
binding protein (SBP) was cloned by Gayle et al. (1996). However, SBP was not 
able to induce signal transduction by ST2L in murine fibroblasts. The expression of 
SBP on T helper cells was investigated by RT-PCR. Naïve CD4(+) T cells 
expressed the short form of SBP (670 bp), which was previously demonstrated to 
bind ST2-FC. Whether TCR activation of naïve CD4(+) T cells causes 
downregulation or loss of SBP expression has still to be investigated. However, 
strong evidence from polarised Thi cells suggest that this might be the case. Th 
cells polarised for 7 days towards the Thi phenotype lost the expression of the 
670 bp fragment but expressed a larger transcript of 1.2 kb. SBP, which contains 
only a short intracellular sequence, is unlikely to induce a signalling response on 
its own. Addition of other components forming a receptor complex similar to the IL- 
1R complex might be necessary for a response to ST2, if indeed SBP really is 
involved in signalling in response to ST2.
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Chapter 5 Regulation of ST2 and ST2L expression
by Th1 and Th2 type cytokines
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This chapter addresses the question of whether the cytokine environment that 
determines the pathway of differentiation for the Th cell subsets also affects the 
ST2L expression pattern. Further, the expression of both ST2 and ST2L gene 
transcripts were monitored under the influence of IL-4 and IFN-y to investigate 
whether ST2 and ST2L are differentially regulated in Th cells. The Th2 cytokine 
IL-4 upregulated ST2L expression at the promoter activity, gene transcript and 
protein levels. Furthermore, ST2 message was also upregulated by IL-4 but 
peaked earlier than ST2L mRNA. IFN-y on the other hand, decreased the level of 
ST2L expression, indicating a potential mechanism for cross-regulation of Th2 cell 
function by Th1 cells. These results suggest differential regulation of ST2 and 
ST2L in CD4(+) T cells and may offer an explanation for the selective expression 
of ST2L on Th2 but not Th1 cells.
Introduction
ST2L is selectively expressed on Th2 cells but not naïve CD4(+) T cells or Th1 
cells (Xu et a/., 1998; Coyle et a/., 1999; Meisel et al., 2001). The expression 
pattern for its shorter splice variant ST2 on CD4(+) T cells has not been analysed. 
Treatment with antibodies against ST2L decreased Th2 effector functions in vivo 
(Xu et al., 1998; Loehning et al., 1998; Coyle et al., 1999). This raised the 
question of whether ST2L expression is influenced by Type 2 (IL-4, IL-5, IL-10) 
and Type 1 cell cytokines (IFN-y, IL-2). So far, the regulation of murine ST2L and 
ST2 expression in T helper cells is largely unknown apart from the observation 
that expression of ST2L was upregulated by serum stimulation (Xu et al., 1998).
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Very recently, Meisel et a!. (2001) reported that exogenous IL-6, IL-5 and TNF-a 
enhanced the expression of ST2L on Th2 cells. Monitoring the expression of ST2 
and ST2L in response to such stimuli could provide further information as to 
whether ST2 and ST2L are differentially regulated, as suggested by observations 
in fibroblasts and mast cells (Kumar et a/., 1997; Gaechter et al., 1998). This may 
help answer the question of whether ST2 acts as an agonist and/or antagonist in T 
cells. Therefore, in this study the expression patterns of ST2 and ST2L in naïve 
GD4(+) T cells as well as polarised Thi and Th2 cells were determined, and the 
effects of Thi and Th2 type cytokines on ST2/ST2L promoter activity, gene and 
protein expression were examined.
Results
5.1. Alteration of the cell surface expression of ST2L by IL-4 and IFN^
Although ST2L is clearly an important marker and functional receptor on Th2 cells, 
an analysis of factors influencing ST2L/ST2 expression in this cell type has not 
previously been performed. To address this question initially, regulation of protein 
levels in response to Th1 and Th2 cytokines was analysed.
5.1.1 Surface expression of ST2L
ST2L protein expression was detected by flow cytometry using a biotinylated 
monoclonal anti-ST2L antibody as described in section 2.34. As shown in Fig. 5.1 
and 5.2, the antibody detected ST2L on Th2 cell clones and three times polarised 
Th2 cells, but not on Thi cell subsets as expected.
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Fig. 5.1 Expression of ST2L on Th2 but not Thi cell clones
Thi and Th2 clones (1x10®/well) were stained as described in section 2.34 with 
250 ng/ml biotinylated anti-ST2L antibody or biotinylated control-antibody (rat 
IgGI, k) and afterwards labelled with FITC-labelled streptavidin (1:1000) before 
being analysed by flow cytometry. A gate was set to exclude dead cells.
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Fig. 5.2 Expression of ST2L on fuiiy poiarised Th2 but not on Th1 ceiis
CD4(+) T cells were purified by negative selection and polarised three times 
towards the Th1 or Th2 phenotype as described in section 2.8 and 2.9. Five 
days after the last stimulation, the Th cells were stained with 250 ng/ml 
biotinylated anti-ST2L antibody or the biotinylated control-antibody (rat lgG1, 
k) and FITC-streptavidin (1:1000 dilution) as secondary antibody. Samples 
were analysed by flow cytometry. A gate was set to exclude dead cells.
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5.1.2 Regulation of ST2L expression on cioned Th2 ceiis by IL-4 and IFN^
When Th2 clone cells (X I2) were treated with 10 ng/ml IL-4 overnight, these cells 
showed a 50% increase in the proportion of ST2L positive cells compared to 
control cells treated with medium alone. Among the Th2 cells treated with 100 
U/ml IFN-y the proportion of ST2L positive cells was decreased by 30-50% (Fig. 
5.3).
5.1.3 Regulation of ST2L expression on polarised Th2 ceils by IL-4 and IFN^
In vitro polarised Th2 cells exhibit, like Th2 cell clones, all effector functions 
specific for this cell subset, but do not have the limitation of immortalised cloned 
cells. Hence, the results obtained in T cell clones were confirmed using long-term 
polarised resting Th cells. Overnight IL-4 treatment (10 ng/ml) doubled the 
proportion of ST2L positively stained cells in twice polarised Th2 cells. However, 
100 U/ml (10 ng/ml) IFN-y did not alter the cell surface expression of ST2L on 
these cells (Fig. 5.4). it is possible that Th cell clones and polarised Th cells might 
have different response thresholds to IFN-y. This was not further investigated, but 
Carter et al. (2001) reported that IFN-y (50 ng/ml) could suppress ST2L 
expression in antigen-stimulated, polarised Th2 cells. In addition, they reported an 
increase in ST2L expression on Th2 cell clones and semi-committed Th2 cells 
upon antigen and IL-4 (50 ng/ml) stimulation which is consistent with the results 
above (Carter etal., in press EJl, 2001).
5.2 Regulation of ST2 and ST2L gene expression by IL-4 and IFN^
Since both IL-4 and IFN-y regulated cell surface expression of ST2L, the 
quantitative technique of Real time PCR was employed to analyse ST2L gene
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Fig.5.3 Regulation of ST2L expression on cioned Th2 ceiis by iL-4 
and IFN-7
Th2 clone (X12) (1x10®/well) was treated overnight with 10 ng/ml IL-4 (A) or 
100 U/ml IFN-y (B) or medium alone and the expression of ST2L was assessed 
by flow cytometry staining with 250 ng/ml biotinylated anti-ST2L antibody or with 
biotinylated isotype control. A gate was set to exclude dead cells. IL-4 increases 
the ST2L expression by 50%, while IFN-y drecreased ST2L expression by 30%.
174
A)
FL -H
medium-treated + control Ab 
medium-treated + anti-ST2L Ab 
IL-4 - anti-ST2L Ab
B)
\r>
o -
o -
FL1-H
medium-treated + control Ab 
medium-treated + anti-ST2L Ab 
IFN^ - anti-ST2L Ab
Fig.5.4 IL-4-increased ST2L expression on polarised Th2 cells
CD4(+) T cells were purified by negative selection and polarised twice towards 
Th2 cells as described in section 2.8 and 2.9. Three days after the last 
stimulation 1x10®/24 well Th2 cells were treated overnight with 10 ng/ml IL-4 (A) 
or 100 U/ml IFN-y (B) or medium alone and the expression of ST2L was 
assessed by staining with 250 ng/ml biotinylated anti-ST2L antibody or the 
biotinylated isotype control and FITC-streptavidin as secondary antibody 
(1:1000). A gate was set to exclude dead cells.
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expression in response to these stimuli. In addition, this method was also used to 
analyse the effects of IL-4 and IFN-y on ST2 gene expression to investigate 
whether both transcripts are similarly regulated.
5.2.1 ST2 and ST2L mRNA expression patterns
ST2 and ST2L mRNA expression were assessed by TaqMan Real time PCR after 
total RNA had been extracted, DNAse-treated and reverse transcripted (section 
2.29-2.32). ST2L mRNA was strongly expressed in twice polarised Th2 cells, three 
days after the last stimulation. Very low levels of ST2L mRNA were detected in 
naïve Th and twice polarised resting Th1 cells (Fig. 5.5 A). ST2 mRNA was found 
to be expressed at a low but detectable level in differentiated restingTh2 cells, was 
hardly detectable in Th1 cells and below the level of detection in naïve Th cells 
(Fig. 5.5 B). Hence, the expression pattern was as expected for ST2L. The 
expression pattern of ST2 in differentiated Th1 and Th2 cells and naïve Th cells 
has not previously been reported. The low expression levels of ST2 suggest that 
this soluble factor has no function in resting Th cells and is likely to react only to 
appropriate stimuli, e.g. IL-4.
5.2.2 Regulation of ST2 and ST2L mRNA expression in cloned Th2 cells by 
IL-4 and IFN^
When the Th2 clone (X I2) was treated with 10 ng/ml IL-4, levels of ST2L mRNA 
increased after 4h to 170% of the control level, before decreasing to basal levels. 
IFN-y (100 U/ml) reduced the amount of ST2L mRNA after 1h, and after 4-8h to 
50-60% of its control level (Fig. 5.6 A). IL-4 enhanced ST2 mRNA levels after 1h 
of treatment, whilst IFN-y had little effect on ST2 gene expression (Fig. 5.6 B).
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Fig. 5.5 Expression of ST2L and ST2 mRNA in naïve Th, Th1 and Th2 ceiis
CD4(+) T cells were purified from D011.10 mice by negative selection (section 
2.8) and twice polarised towards the Thi orTh2 phenotype (section 2.9). Three 
days after the last stimulation, total RNA was extracted from 2x10® naïve Th, Thi 
and Th2 cells and reverse transcripted after DNAse treatment. Real time PCR 
was performed using specific primers for ST2L (A) and ST2 (B). The error bars 
represent the standard deviation between triplicate results obtained from one 
cDNA sample.
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Fig. 5.6 IL-4 and IFN^ after ST2L and ST2 mRNA expression levels in 
cloned Th2 cells.
Th2 cell clone X12 (2x10®/well) were treated with either 100 U/ml IFN-y or 10 
ng/ml IL-4 for 24 h, RNA was extracted and reverse transcripted after DNAse 
treatment and Real time PCR performed with specific primers for ST2L (A) and 
ST2 (B). The results (n=3) are shown as mean ± 1 SD. The IFN-y- and IL-4- 
treated sample was compared with the medium control: *p<0.05.
A) ST2L expression
L_ 3000
2500
a:
CL
X
2
S
2000
Of
E 1500
(/) 1000 
500 
0  1 1 1 1----------
2 4 8 12 24
B) ST2 expression
DC0_
X
S
g
'Ë<D
DC
E
H
C/D
medium
IL-4
IFN-y
25
1 2 4 8
hours after stimulation
178
These findings corroborate the findings of cell surface expression of ST2L in 
response to IL-4 and IFN-y. Furthermore, these data indicate that differences 
between ST2 and ST2L gene expression exist. For example, IFN-y selectively 
suppressed ST2L but not ST2 mRNA.
5.2.3 Regulation of ST2 and ST2L mRNA expression in polarised Th2 cells 
by IL-4 and IFN^
The results obtained with cloned Th cells were confirmed with fully polarised Th2 
cells, originally derived from D011.10 mouse spleen cells.
Addition of IL-4 to twice polarised Th2 cells led to a 2.5 fold increase in ST2L 
mRNA expression 2 h - 8 h after stimulation (Fig. 5.7 A). ST2 mRNA in IL-4- 
treated cells increased 4 fold after 2 h and decreased to control level thereafter 
(Fig. 5.7 B). In agreement with the protein expression results, no significant 
changes of ST2 gene expression in response to IFN-y were observed (data not 
shown).
5.2.4 Regulation of ST2 and ST2L mRNA expression in naïve T helper cells 
by IL-4
Potential effects of IL-4 on the ST2L gene expression at the early stage of Th cell 
differentiation might explain the Th2 phenotype specific expression pattern. For 
this reason, the effects of IL-4 on ST2/ST2L gene expression in naïve Th cells 
were assessed. Low ST2L gene expression was found in unstimulated, naïve T 
helper cells (Fig. 5.8 A). IL-4 increased this amount after 4 h -  24 h by about 50%. 
Remarkably, IL-4 dramatically enhanced the expression of ST2 at 1 h post- 
stimulation; subsequently ST2 mRNA returned to basal levels (Fig. 5.8 B).
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Fig.5.7 IL-4 alters ST2L and ST2 mRNA expression In polarised Th2 cells.
CD4(+) T cells were purified by negative selection (section 2.8) and polarised 
twice towards a Th2 phenotype (section 2.9). Three days after the last 
stimulation the cells were treated with 10 ng/ml IL-4 for 24 h. RNA was extracted 
and reverse transcribed after DNAse treatment and Real time PCR performed 
with specific primers for ST2L (A) and ST2 (B). The results (n=3) are shown 
as mean ± 1 SD. The IL-4-treated sample was compared with the medium 
control: **p<0.005, *p<0.05.
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Fig. 5.8 IL-4 alters ST2L and ST2 mRNA expression in naïve Th cells.
CD4(+) T cells were purified by negative selection as described in section 2.8, 
treated with 10 ng/ml IL-4 for 24 h. RNA was extracted and reverse transcribed 
after DNAse treatment and Real time PCR was performed with specific primers 
for ST2L (A) and ST2 (B). The results (n=3) are shown as mean ± 1 SD. The 
IL-4 treated sample was compared with the medium control: **p<0.005.
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5.3 Influence of IL-4 and IFN^ on the ST2/ST2L promoter
After establishing that IL-4 and IFN-y regulate ST2L expression in an opposing 
manner, the mechanism of this phenomenon was investigated. This work was 
done primarily by Dr. Matthew Sweet but was in collaboration with the work 
described above on ST2 gene regulation.
There are various mechanisms (e.g. different promoter usage, mRNA stability, 
alternative splicing, alternate poly A site etc.) by which cells can regulate 
ST2/ST2L expression. Alternate usage of distal and proximal promoters, which 
are 10.5 kb apart, is thought to control haematopoietic and non-haematopoietic 
specific ST2/ST2L expression respectively. For example, while in murine mast 
cells ST2 and ST2L gene transcription is initiated from the distal promoter, in 
murine fibroblasts both variants are transcribed from the proximal promoter 
(Gaechter et al., 1998, Gaechter et al., 1996). However, in rat fibroblasts ST2L is 
transcribed from the distal promoter, while ST2 is transcribed from the proximal 
promoter (Bergers et al., 1994), which suggests that these cells differentiate 
between the two forms through alternate promoter usage. In initial studies the 
question about promoter usage of ST2L in murine Th2 cell clones was addressed 
using primer extension analysis. It was shown that ST2L transcription was initiated 
from distal exon 1 (corresponding to upstream promoter usage) and not from 
proximal exon 1 (corresponding to downstream promoter usage, data not shown). 
To confirm these findings and to assess the relative importance of different 
transcription factors and signalling pathways in ST2/ST2L gene expression, four 
separate ST2/ST2L promoter/reporter gene constructs as well as a negative 
control plasmid were generated (Fig. 5.9). These constructs encompassed both 
the upstream and downstream promoters. Constructs were transiently transfected
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Fig.5.10 Luciferase assay to test activity of ST2/ST2L promoter 
contructs in Thi and Th2 ciones
Different length promoter contructs were cloned and transiently transfected into 
X4 (Thi) and X12 (Th2) cells. The luciferase activity was assayed to determine 
the active promoter. The error bars represent the standard deviation between 
triplicate samples.
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into Th1 (X4) and Th2 (X12) ceil clones and reporter gene expression (luciferase 
activity) was analysed (Fig. 5.10). These experiments revealed that the 
downstream (pST2down-luc) promoter was very weakly activated in both Thi and 
Th2 cell clones, while the upstream (pST2up-luc) promoter was 60 fold more 
active inTh2 cells than in Th1 cells. Hence, these results corroborate the findings 
from primer extension experiments and suggest that the upstream (distal) 
promoter is responsible for Th2-specific ST2L expression. Deletion of the 6.3 kb 
upstream promoter to a 2.7 kb fragment (pST2up2.7-luc) reduced the promoter 
activity approximately 5-fold, indicating that the elements within the depleted 
regions are important for the expression of ST2L in Th2 cells. A further depletion 
to 0.3 kb (pST2-0.3-luc) reduced promoter activity still further, although this 
minimal promoter still displayed Th2 cell-specific activity. The activity of the 
upstream ST2/ST2L promoter was modulated by IL-4 and IFN-y, which confirmed 
the findings made at the mRNA level (Fig. 5.11). IFN-y suppressed luciferase 
expression 2.2-fold and treatment with IL-4 upregulated expression 2.3-fold. 
These data suggest that the IL-4 and IFN-y regulate ST2L expression by 
modulation of the upstream promoter activity. The downstream promoter was not 
regulated in Th2 cells by the addition of these cytokines, providing further 
evidence that the upstream promoter and not the downstream promoter is the 
functional promoter in Th2 cells.
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Fig.5.11 Influence of IL-4 and IFN-y on upstream ST2/ST2L promoter in 
cloned Th2 cells
Th2 clone (X12) was transiently transfected with a promoter contruct containing 
the full length upstream ST2/ST2L promoter fused to the luciferase gene. Cells 
were treated overnight with either 100 U/ml IFN-y or 10 ng/ml IL-4 and analysed 
for luciferase activity. These results represent two pooled experiments and are 
expressed as mean ± 1 SD. The IFN-y- or IL-4-treated sample were compared to 
the medium control: ** p<0.005.
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Discussion
Regulation of ST2L expression in T helper cells by IL-4 and IFN-y 
The cytokine environment in which naïve CD4(+) T cells are primed determines 
whether the cell differentiates towards a Th1 or Th2 phenotype. Th2 cells 
differentiate and proliferate through IL-4 stimulation, while IL-12 is essential for 
Th1 development and IFN-y for Th1 cell effector functions (O’Garra and Arai, 
2000).
ST2L was found to be expressed on Th2, but not on Th1 cells and its inhibition led 
to an attenuation of essential Th2 effector functions (Loehning et al, 1998; Coyle 
et al., 1999). Furthermore, ST2L expression is closely linked to Th2 type cytokine 
expression as analysed by four-colour single-cell cytometry (Loehning et al.,
1999). These results indicate a strong link between ST2L expression and Th2 
effector functions; however, the molecular mechanisms are still unknown.
IL-4 increased the ST2L expression on naive and polarised Th2 cells in a similar 
manner, suggesting either a conserved mechanism of ST2L gene regulation to 
which naïve and later, polarised Th2 cells respond due to their cytokine 
environment (Fig. 5.12 A), or an IL-4-induced increase in proliferation of the small 
number of ST2L-expressing Th2 cells among naïve Th cells (Fig. 5.12 B). CD4(+) 
T cells purified from DO11.10 TCR transgenic mice contain cells able to react to 
antigens other than OVA peptide and therefore contain activated, differentiated Th 
cells (Saparov et al., 1999). The former hypothesis was supported by findings that 
IL-4 expression preceded the surface expression of ST2L and therefore ST2L 
expression is indicative of advanced Th2 commitment (Meisel et al., 2001).
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Fig. 5.12 Models of IL-4 effect on ST2L expression in Th2 ceiis
(A) Naïve Th cells are driven towards a Th2 phenotype by IL-4. The expression 
of IL-4 (and IL-4 R) precedes the expression of ST2L as a marker of advanced 
Th2 cell development.
(B) Among naïve Th cells there a small amount of already differentiated Th2 cells 
which are responsive to IL-4 and expressing ST2L. IL-4 addition enhances the 
proliferation of this subset.
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Furthermore, only very low ST2L expression could be detected among naïve Th 
cells purified from TCR transgenic mice (Fig. 5.5).
IL-4 gene-targeted mice expressed similar ST2L levels as the wild type mice, 
whereas ST2L expression was reduced three fold in IL-5 knockout mice (Loehning 
et al., 1998). These data suggest that ST2L is not sufficient to drive Th2 cell 
functions, assuming that IL-4 and IL-5 knockout mice develop impaired and 
normal Th2 responses respectively (Jankovic et a i, 2000, Pearce et a i, 1996; 
Noben-Trauth et a i, 1996; Xu et a i, 2000; Vajdy et a i, 1995; Burdach et ai, 
1998).
Following priming of CD4(+) T cells under Th2-polarising conditions, the 
expression of ST2L was not dependent on further addition of exogenous IL-4 
during subsequent rounds of stimulation (Meisel et a i, 2001). Flowever, the 
neutralisation of endogenous IL-4 in these celis resulted in a delayed increase in 
ST2L expression (Meisel et a i, 2001). Hence, the ST2L expression does not 
seem to be absolutely dependent on Th2 cytokines such as IL-4 and IL-5, 
although ST2L expression can be upregulated by these cytokines as 
demonstrated in this chapter and by Meisel et a i (2001).
IFN-y, which is released by Thi cells and known to decrease Th2 cell proliferation 
(Fitch et a i, 1993), might suppress ST2L expression on Th2 celis, thereby 
potentially inhibiting ST2L-mediated Th2 effector functions, such as Th2 celi 
proliferation and IL-4 and IL-5 production (Meisel et a i, 2001).
In summary, ST2L expression correlates with the differentiation of naïve Th celis 
to Th2 cells and is positively regulated by Th2 type cytokines and negatively 
regulated by Thi type cytokines. This level of regulation provides not only an
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obvious mechanism for Th2-specific ST2 expression but also a mechanism by 
which Th1 cells can suppress Th2-type responses.
Differentially regulation of ST2 and ST2L by Th1 type and Th2 type cytokines 
ST2 and ST2L are derived from the same gene, which raises the question of 
whether the two forms are similarly or differentially expressed and regulated. ST2 
and ST2L expression were extensively studied in rat and mouse. ST2L was found 
in major haemopoietic organs such as spleen and liver, whilst ST2 was expressed 
in non-haemopoietic organs, e.g. embryonic bone and skin (Roessler et al., 1995). 
Unstimulated murine fibroblasts predominantly express ST2, whilst unstimulated 
mast cells and Th2 cells express mainly ST2L (Gaechter et al., 1998; Berger et 
al., 1994). Gaechter and colleagues also reported that calcium ionophore 
stimulation of mast cells resulted in upregulation of ST2/ST2L gene expression 
and a switch from the long to the short transcript. These findings suggest that ST2 
and ST2L are differentially expressed and regulated depending on the cell type 
and species.
In this chapter, IL-4 was shown to increase the expression of both transcripts. 
Timecourse experiments indicated that ST2L and ST2 mRNA were not co- 
ordinately regulated by IL-4. That is, IL-4 induced an early peak of ST2, which 
rapidly declined, whilst ST2L was induced more slowly over a prolonged period, 
demonstrating that the two isoforms are independently regulated by this cytokine. 
It is not inconceivable that ST2 and ST2L could also regulate the expression of 
each other in response to IL-4. For example, the rapid increase in ST2 expression 
in response to iL-4 might enhance ST2L expression or alternatively ST2L 
expression might suppress ST2 expression. These possibilities were not
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investigated during the course of these studies. The hypothesis of differential 
regulation of ST2 and ST2L was supported by the findings in murine fibroblasts 
treated with pro-infiammatory cytokines such as IL-1 and TNF-a (Kumar et al., 
1997). The short form of the ST2 gene was strongly upregulated by these 
treatments, while ST2L gene expression was not affected.
Alternate promoter usage has been suggested as a mechanism for the differential 
expression of ST2 and ST2L in rat fibroblasts (Berger et al., 1994). In order to 
investigate the ST2/ST2L promoter usage in Th2 cells primer extension 
experiments were performed (data not shown) and transient transfection analysed 
(Fig. 5.10). Both confirmed the distal promoter as the one being responsible for 
Th2 cell-specific ST2L expression as suggested in murine mast cells (Gaechter et 
al., 1998). These data were further corroborated in promoter regulation studies 
where cytokines that regulated ST2L mRNA and protein (IL-4 and IFN-y) acted in 
a similar manner on the upstream but not the downstream ST2/ST2L promoter.
In promoter analysis experiments, luciferase activity was only assayed after 24 h. 
Since luciferase is a relatively unstable enzyme (Sweet et al., 1995), it is possible 
that the acute effect of IL-4 on ST2 expression was not observed in promoter 
analysis experiments. Timecourse experiments examining the effect of iL-4 on 
both the upstream and downstream promoters would therefore be warranted. 
However, in the rodent system, differential expression of ST2L and ST2 has been 
previously reported as a consequence of alternative splicing at exon 8 (Berger et 
al., 1994, Gaechter et al., 1996). Hence, it is likely that the effects of IL-4 on 
production of ST2 would not be observed using this technique.
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Chapter 6 Immunomodulating effects of G418 and
gentamicin in  v i t r o  and i n  v iv o
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During transfection studies I discovered that Th1, but not Th2 cells were resistant 
or less susceptible to the toxic effects of G418, the selection marker used for 
these transfections. In vivo applications for G418 are limited due to its overali 
toxicity to eukaryotic celis. Therefore, its structural analog and commonly used 
antibiotic, gentamicin, was tested in vitro for its ability to differentially inhibit Th 
cells and was found to behave in a similar manner to G418. According to these 
findings, the in vivo effects of gentamicin on L  major infections in susceptible 
BALB/c mice were assessed. Aminoglycosides such as paromomycin in 
combination with gentamicin have been linked to successful treatment of L  major 
infections in mice and humans, but the mechanism remained unclear. When 
susceptible BALB/c mice were treated with injections of 50 mg/kg of gentamicin 
for 12 days (twice per day) from the time of infection, the onset of the disease was 
completely prevented. This extensive treatment with gentamicin provoked a 
general suppression of the L  major antigen-specific responses among immune 
ceils, e.g. Th and B lymphocytes, whilst shorter treatment, in agreement with in 
vitro results, showed that this antibiotic altered the Th1/Th2 type balance, which is 
known to determine the outcome of L  major infections. Further, gentamicin at 
estimated in vivo concentrations partially decreased the cell viability of 
macrophages and of parasites in vitro. The same gentamicin dose induced shape 
and activity changes in the parasite, which might influence the parasite - 
macrophage interaction. Parasites, short-term pretreated with high doses of 
gentamicin, did not loose their infectivity in vivo.
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Taken together, these results suggest an immunomodulative ability of gentamicin 
given for a short period of time or at low doses and a immunosuppressive ability of 
the drug on parasites and immune cells when given for longer periods at high 
doses.
Introduction
In studies described in this chapter, Th2 cells were due to be transfected with a 
plasmid encoding antisense ST2 and a neomycin resistance gene. G418 is widely 
used as selection marker for transfection experiments since expression of 
neomycin resistance gene in mammalian cells confers resistance to the otherwise 
toxic antibiotic. G418 toxicity dose-response experiments on untransfected Th1 
and Th2 cell clones were therefore performed to determine the concentration of 
G418 required to select stable transfectants. Surprisingly, Th1 but not Th2 cells 
were resistant to the toxicity of G418.
G418 (geneticin sulfate), exhibiting toxicity towards both eukaryotic and 
prokaryotic cells, belongs to the family of aminoglycoside antibiotics. 
Aminoglycosides, including streptomycin, neomycin, paromomycin, gentamicin 
and geneticin (G418) are characterized by the presence of an aminocyclitol ring 
linked to aminosugar (Fig. 6.1). They have established effects against prokaryotic 
ceils, and some are widely used against aerobic and facultative aerobic Gram- 
negative bacilli and some Gram-positive bacteria (Mingeot-Leclercq et a/., 1999). 
Their bactericidal activity is attributed to the irreversible binding to the ribosomes,
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leading to mistranslation (Mingeot-Leclercq et al., 1999). At higher concentrations 
these antibiotics have also known effects against eukaryotic, mammalian cells 
(Mingeot-Leclercq et a!., 1999). In eukaryotic cells G418 and its structural 
analogue gentamicin have been shown to reduce the efficiency of translation 
termination by a mechanism that alters the ribosomal proof-reading process. This 
leads to the misincorporation of an amino acid through the pairing of a near­
cognate aminoacyl tRNA with the stop codon. Intact cells have to be exposed to 
50-200 pg/ml aminoglycosides to facilitate a significant level of read-through of a 
translation termination codon. However, due to the poor permeability of these 
charged compounds across the plasma membrane, the actual intracellular 
concentration required to facilitate read-through during translation is unclear 
(Manuvakhova et a!., 2000). The interference of G418 with the ribosomes during 
eukaryotic protein synthesis causes the synthesis of stress proteins and other 
abnormal proteins as shown in fibroblasts (Eustice et a!., 1984; Wilhelm et a!., 
1978; Buchanan et al., 1987). This may lead to loss of fidelity and a shortening of 
cellular life span.
Apart from resistance to G418 by transfection with a plasmid encoding the 
neomycin resistance selectable marker, others have reported that mammalian 
cells can display inherent resistance to G418. Sweet et al. (1996) demonstrated 
that the murine macrophage cell line RAW264 became resistant to the toxic 
effects of G418 after treatment with bacterial Npopolysaccharide (LPS). It was 
suggested that LPS might induce expression of a membrane transport system 
such as multidrug resistance proteins (MDR) or an organic anion transporter.
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G418 is toxic towards pro- and eukaryotic cells, excluding the possibility for clinical 
usage, but gentamicin, a structural analogue of G418, is widely used in humans 
as an antibiotic against diseases caused by aerobe bacteria such as septicaemia, 
meningitis, endocarditis (caused by viridans streptococci or Enterococcus faecalis) 
and pneumonia (British National Formulary, BNF, 1997).
Gentamicin is a multiple charged compound that interferes with prokaryotic protein 
synthesis by binding to the 16S rRNA and inhibiting several catalytic RNAs such 
as self-splicing group I introns, RNase P and small ribozymes (Schroeder et al., 
2000). Similar to G418, gentamicin is known to interfere also with eurkaryotic cells. 
In single eukaryotic cells like Tetrathymena thermophlla, gentamicin inhibits 
protein synthesis by progressive depletion of polysomes (Eustice et al., 1984). 
Gentamicin can suppress translation termination signals in mammalian cells 
similar to G418, but at a 2-14-fold lower level of read-through (Manuvakhova et 
al., 2000). These findings may explain why long term treatments with gentamicin 
can produce dose-related adverse effects in humans, such as ototoxicity and 
nephrotoxicity (BNF, 1997; Wilhelm et al., 1978, Buss et al., 1985). Gentamicin as 
a polycation has been reported to induce the release of soluble Intermembrane 
mitochondrial proteins and therefore support apoptosis (Mather and Rotten berg,
2000), offering another mechanism for gentamicin to interfere with eukaryotic 
cells. Negative effects of gentamicin on cytokine production of T cells, delayed- 
type hypersensitivity (DTH) response, NK cell activity, phagocytosis and antibody 
response have been reported (Van VIem et al., 1996; Ohya et al., 1998). Due to
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its ability to selectively kill or suppress Th2 cells, but not Th1 cells as shown in 
results, L  mayor-infected mice were treated with gentamicin.
Leishmaniasis is a widespread and debilitating protozoal disease of humans and 
animals. Leishmania major parasites cause cutaneous leishmaniasis, which can 
leave disfiguring scars upon healing or, alternatively, lead to long-term chronic 
infections. Hence, extensive research has been done on murine Leishmaniasis 
models such as BALB/c mice, that are highly susceptible to the disease. This led 
to the Identification of a number of treatments that are now partly used in humans. 
Among aminoglycosides, paromomycin is the only one with clear antiprotozoal 
and antileishmanial activity (El-On and Greenblatt, 1983). However, early work by 
El-On et al. (1984) demonstrated that 12% gentamicin had a modest activity in L. 
major infections when used topically. Others reported gentamicin as part of a 
successful topical treatment (15% paromomycin, 0.5% gentamicin) for L. major 
infections (GrogI et al., 1999). Nevertheless, the mechanism of action of 
gentamicin during L  mayor infections remains unclear.
In this chapter the effect of gentamicin on Thi and Th2 cells activity was 
investigated and the question addressed whether the beneficial effect of 
gentamicin in L. major infection in mice is due to its ability to modulate the 
Th1/Th2 cell balance.
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Results
6.1 Cloned Thi cells but not Th2 cells are resistant to G418
The original experiment leading to the observations in this report involved the 
stable transfection of Thi and Th2 cell clones with a plasmid containing antisense 
ST2 and a neomycin resistance gene, a selectable marker conferring G418 
resistance, followed by selection in the presence of G418. The aim was to switch 
off ST2L and ST2 expression in Th2 cells. In a pilot experiment different 
concentrations of G418 were tested in Thi and Th2 clone cells for their ability to 
select stable transfectants. Thi and Th2 cells were cultured with 20-800 |ig/ml 
G418 and 10 ng/ml IL-2 for 3 days. Thi cells showed no changes in cell shape 
even at 800 jug/ml G418 (Fig. 6.2), whilst Th2 cells that did survive at a dose of 
200-800 |ig/ml G418 were severely affected as was evident by irregular cell shape 
that is indicative of cell death (Fig. 6.3).
To quantify the phenomenon, both proliferation assays and MTT cell viability 
assays were employed. Since absolute values for proliferation and succinate 
dehydrogenase activities varied between Thi and Th2 cells, all results are 
displayed as a percentage of control cells, that did not receive G418, to allow a 
direct comparison between Thi and Th2 cells. Thi cells generally exhibited a 
lower proliferation rate than Th2 cells (Fig. 6.4, basal levels). The selective toxicity 
of G418 for two sets of Th2 but not Thi cell clones is apparent in Fig. 6.4. The 
proliferation as well as the mitochondrial activity of Th2 cells decreased 
dramatically with 50-200 p.g/ml G418, whereas Thi cells were only slightly
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Fig. 6.2 and 6.3 The effect of G418 on cloned Th1 and Th2 cells
Th1 cell clone X9 (Fig. 6.2) and Th2 cell clone X12 (Fig. 6.3) were stimulated 
with 10 ng/ml IL-2 and treated with 0, 400 and 800 jag/ml of G418 for 3 days. A 
wet preparation of the cells on slides was performed which was examined 
under a phase contrast microscope. Photographs were taken at x40 
magnification.
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Fig. 6.4 Differential effect of G418 on cloned Thi and Th2 ceiis
Thi (X9, Dorris) and Th2 (X I2, DIO) cell clones (IxlO^/well) were treated with 10 
ng/ml IL-2 and a concentration range of G418 for 3 days. MTT assays (A) and 
proliferation assays (B) were performed to assess the cell viability. The basal 
levels of proliferation (in cpm) and mitochondrial activity are given in brackets. 
The results are presented as percentage of untreated cells. Data (n=3) are 
shown as the mean ± 1 SD and are representative of 3 experiments.
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affected by 600-800 |ig/ml G418. In fact, treatment with 50-400 fag/ml G418 
caused a two to three fold increase in the proliferation of Th1 cell clones. To 
determine whether the enhanced susceptibility of Th2 cell clones to G418 was 
associated with an increase in apoptosis, Th cell clones were treated with G418 
for 2 days and then stained for propidium iodide and annexin V as described in 
section 2.36. After 2 days of G418 treatment, no early apoptotic cell population 
(annexin V(+)/PI(-)) could be detected (data not shown). Instead, G418 increased 
the number of annexin V(+)/PI(+) cells, which either undergo necrosis or are at the 
late stage of apoptosis (Fig. 6.5 A). At a concentration of 500 i^g/ml, G418 induced 
11% more annexin V(+)/PI(+) cells among Th2 than among Thi cells. The 
PI(+)/annexin V(-) cell population, characteristic for necrotic cell death, was also 
more evident in Th2 cells (47%) in comparison to Thi cells (38%) after treatment 
with 1000 i^g/ml G418 (Fig. 6.5 B). Earlier timepoints have to be investigated to 
answer the question, whether G418 kills Th cells by apoptosis or necrosis.
6.2 G418 affects primary polarised Th2 ceiis but not Thi ceils
Since G418 appeared to have a selective toxicity for cloned Th2 cells over Thi 
cells, the effect of G418 on primary Thi and Th2 cells was next investigated.
The proliferation rate of Thi cell clones was usually lower than the proliferation 
rate of Th2 cell clones (D10 versus Dorris, X12 versus X9) (Fig. 6.4), which might 
offer one explanation for the differential effect of G418 on Th cell clones. To 
assess whether other mechanisms apart from a differing proliferation rate might 
play a role in the selective killing process, G418 was added to polarised Thi and
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Fig. 6.5. G418 induces more ceii death in Th2 ceiis than in Th1 ceiis
Thi (X4) and Th2 (X I2) clones (1x10®/well) were treated for 2 days with 
a concentration range of G418 and were stained with PI and annexin V 
in order to detect apoptotic/necrotic cells.
(A) shows the percentage of PI(+)/annexinV(+) stained cells against 
G418 concentration.
(B) shows PI(+)/annexinV(-) stained cells.
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Th2 cells at a timepoint (day 3 after antigen stimulation) when both cell types 
exhibited similar cell viability as assessed by proliferation and MTT assay (Fig. 
6.6). The levels of proliferation and succinate dehydrogenase activities of 
polarised Th1 and Th2 cells, restimulated with anti-CD3, varied depending on 
length of time these cells had been stimulated with antigen presenting cells (APC) 
before. Th1 and Th2 cells, which were taken 3 days after antigenic stimulation and 
restimulated with anti-CD3, exhibited similar cell viability (Fig. 6.6). Cells taken 
after 5 days antigenic stimulation differed dramatically in the cell viability 
measures when restimulated with anti-CD3. The proliferation rate in Th1 cells 
decreased to 60% of its level on day 3 and the MTT assay showed a 70% 
decrease compared to day 3, whilst Th2 cells showed equal or higher cell viability 
measures. Hence, Th1 cells taken on day 5 after antigenic stimulation exhibited 
only 18% of the cell viability of Th2 cells. According to these findings, CD4(+) T 
cells were stimulated with plate-bound anti-GD3 (4 pg/ml) and incubated with 5- 
100 i^g/ml G418 on day 3 after the second restimulation. The cell viability was 
then assessed by proliferation and MTT assays. Thi cells, treated with 100 |ig/ml 
G418 showed 80-100% higher proliferation and succinate dehydrogenase 
activities than Th2 cells, which showed severe signs of cell death (Fig. 6.7).
6.3 G418 reduces Th2 type cytokine production by BALB/c spleen ceils
The results from both T cell clones and polarised T cells suggested that G418 was 
selectively toxic to Th2 cells. The effect of G418 on BALB/c spleen cells was next 
investigated to determine whether a similar phenomenon could be observed in a
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Fig. 6.6 The effect of anti-CD3 stimulation on cell viability of 
polarised Th cells
Purified CD4(+) T cells were polarised twice as described in section 2.9 and 
stimulated at 3, 5, 7 days after the second antigenic stimulation for 3 days with 4 
jag/ml anti-CD3. The cell viability was then assessed by MTT (A) and proliferation 
assay (B). Results (n=3) are shown as mean ±1 SD and and are representative 
of 4 experiments. (* p<0.05)
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Fig. 6.7 The effect of G418 on twice polarised Th1 and Th2 cells
CD4(+) T cells were purified from DO11.10 mice spleen by negative selection 
and twice polarised as described in sections 2.8 and 2.9. The cells were 
collected three days after the second stimulation, treated with a concentration 
range of G418 and stimulated with 4 pg/ml anti-CD3 for 3 days. MTT assay (A) 
and proliferation assay (B) were then performed. The basal levels of proliferation 
(in cpm) and of mitochondrial activity are given in brackets. The results (n=3) are 
shown as mean ± 1 SD and as percentage of untreated cells (** p< 0.005,
* p< 0.05). Data are representative of 5 experiments.
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mixed cell population. Spleen cells, stimulated with anti-CDS and incubated with 
100-800 jig/ml G418, showed impaired proliferation and cytokine production (Fig. 
6.8). 100 pg/ml G418 reduced the output of Th2 type cytokines IL-4 to 34% and 
IL-5 to 24%, but Thi type cytokines IFN-y and IL-2 were affected only marginally. 
These results suggest that among the spleen cell population G418 selectively 
inhibited or depleted cells secreting Th2 type cytokines and only higher G418 
concentrations were able to reduce cells secreting Thi type cytokines.
6.4 Gentamicin decreases the celi viability and cytokine production of 
Th2 celis over Th1 ceiis
Although these results obtained using G418 as a compound to favour survival of 
Thi over Th2 cells, G418 can not be used in vivo because of its universal toxicity 
to mammalian cells. Therefore, the possibility that gentamicin, an antibiotic which 
is related to G418, might share this feature of Th2-specific toxicity was next 
explored. Thi and Th2 cell clones were cultured with 10 ng/ml IL-2 and 200-1000 
pg/ml gentamicin for 3 days, lower gentamicin concentrations did not affect cell 
viability (data not shown). As demonstrated by both proliferation and mitochondrial 
activity assays, 600-1000 pg/ml gentamicin reduced the cell viability of Th2 cells to 
20-30% whilst the same doses of gentamicin had little effect on Thi cells which 
remained at 55-95% of their untreated cell viability (Fig. 6.9). The selective effect 
of gentamicin was then tested on twice polarised Thi and Th2 cells. Proliferation 
of Th2 cells was reduced by 70% in response to 1000 pg/ml gentamicin whilst Thi 
cells had only a 15% impairment in proliferation (Fig. 6.10). These findings clearly
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Fig. 6.8 The effect of G418 on BALB/c spleen cell cytokine production
BALB/c spleen cells (1x10®/well) were stimulated with 4 pg/ml anti-CD3 and 
treated with a concentration range of G418 for 3 days. Cytokine production was 
measured by ELISA and cell viability was assessed by proliferation assay. The 
basal cytokine and proliferation levels are given in brackets. Results (n=3) are 
shown as percentage of untreated cells (100%) and presented as mean ±1 SD 
(*p<0.05; **p<0.005). These data are representative of 5 experiments.
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Fig. 6.9 The effect of gentamicin on cioned Thi and Th2 ceils
Thi (Dorris) and Th2 cell (DIO) clones (IxlO^/well) were treated for 3 days with 
a concentration range of gentamicin and 10 ng/ml IL-2. Cell viability was 
assessed by MTT assay (A) and proliferation assay (B). The basal levels of 
proliferation and MTT are shown in brackets. The results (n=3) are shown as 
percentage of untreated cells (100%) and presented as mean ± 1 SD (* p<0.05). 
Data are representative of 2 experiments.
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Fig. 6.10 The effect of gentamicin on polarised Thi and Th2 ceils
Purified CD4(+) T cells were polarised twice as described in section 2.9. Three 
days after the second stimulation they were stimulated with 4 pg/ml anti-CD3 
and with a concentration range of gentamicin for 3 days. Cell viability was 
assessed by proliferation assay. Basal proliferation levels are given in brackets 
(in cpm). The results (n=3) are presented as percentage of untreated cells 
(100%) and shown as the mean ± 1 SD (** p<0.005; *p<0.05). Data are 
representative of 3 experiments.
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indicate a similar killing specificity of gentamicin as seen with G418, suggesting 
that Th1 cells were less susceptible to the aminoglycoside than Th2 cells. In the 
mixed cell population of BALB/c spleen cells, a three-day gentamicin treatment 
(50-1500 |Lig/ml) decreased production of Th2 cytokines much more dramatically 
than Thi cytokines (Fig. 6.11). For example, 1000 pg/ml gentamicin caused a 
21% reduction of IL-2 and a 33% reduction of IFN-y, whilst the Th2 cytokine IL-4 
was reduced by 75% and IL-5 by 95%. Summarizing the findings, gentamicin was 
able to selectively kill or suppress Th2 cell clones, polarised Th2 cells and Th2 
cytokine producing spleen cells compared with Thi cells.
6.5 Gentamicin inhibits the progress of Leishmania major in susceptible 
BALB/c mice
Both G418 and gentamicin altered the balance between Th cells in favour of Thi 
cell survival and cytokine production in vitro. Whether this observation could be 
applied to modulation of Th1/Th2 responses in vivo was assessed next, 
leishmaniasis is caused by the intracellular parasite Leishmania, which infects 
macrophages, multiplies in their vacuoles and thereby escapes immune detection. 
Disease progress is exacerbated by strong Th2 responses in infected organisms, 
while a strong Thi response is protective (Scott et a!., 1988). Healing is mediated 
by the Thi type cytokine IFN-y, that activates macrophages to produce nitric oxide 
which has been shown to kill intracellular parasites in vitro (Liew et ai., 1991; Nacy 
et a!., 1985). Disease progression correlates with production of Th2 type cytokines 
such as IL-4, which decreases macrophage expression of NO synthase and NO
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Fig. 6.11 The effect of gentamicin on BALB/c spieen ceii cytokine 
production
BALB/c spleen cells (1x10®/well) were stimulated with 4 pg/ml anti-CD3 and 
treated with a concentration range of gentamicin for 3 days. Cytokine release 
was assessed by ELISA and cell viability by proliferation assay. The basal levels 
are shown in brackets. The results (n=3) are presented as percentage of 
untreated cells (100%) and shown as the mean ± 1 SD (** p<0.005; * p< 0,05). 
Data are representative of 4 experiments.
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and therefore favors parasite survival (Liew et a/., 1989; Liew, 1991). BALB/c mice 
are susceptible to the disease due to development of a Th2 type response after 
infection with Leishmania major. Low doses of gentamicin as part of a successful 
topical treatment for murine cutaneous Leishmaniasis have been described by 
Grog I et ai. (1999), but gentamicin treatment alone did not induce healing of the 
lesions. Hence the effect of gentamicin on both disease progression (footpad 
swelling) and immunological parameters was assessed in L. mayor-infected 
BALB/c mice.
6.5.1 High doses of gentamicin prevent Leishmania disease progression 
(trial 1)
Using doses of gentamicin that are applied clinically to treat bacterial infections (3 
and 6 mg/kg body weight, BNF, 1997; Sakaeva et a/., 1998), no effect was 
observed on L. mayor-mediated disease progression (data not shown). To 
examine the possibility that the low dose of gentamicin did not overcome the high 
dose infection of parasites, higher concentrations of gentamicin were used. Three 
groups of 6 BALB/c mice were infected with 1x10^ L. major parasites/mouse by 
footpad injection and treated i.p. with PBS as a control, 10 mg/kg gentamicin or 50 
mg/kg gentamicin for 12 days, twice a day. At 10 mg/kg, gentamicin did not inhibit 
disease progression. However treatment with 50 mg/kg gentamicin completely 
inhibited disease progression over 80 days (Fig. 6.12 A). Two mice treated with 50 
mg/kg of gentamicin were kept to observe the long-term effect of gentamicin
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Fig. 6.12 Gentamicin treatment of L. mayor-infected BALB/c mice (trial 1)
Three groups of 6 BALB/c mice were infected in the left footpad on day 0 with 
1x10® parasites/mouse. From day 0 - 1 2  they received i.p. injections of PBS, 10 
mg/kg or 50 mg/kg of gentamicin twice per day. The footpad swelling data show 
the difference between the infected left and the uninfected right footpad and are 
presented as the mean ± 1 SD ( ** p<0.005, * p< 0.05 comparing PBS control 
with 50 mg/kg treatment). A) shows the early development of foot pad swelling of 
6 mice per group till 80 days after infection, B) shows the late development till 
200 days after infection, monitoring footpad swelling of 2 mice which had been 
treated with 50 mg/kg of gentamicin.
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injections. One mouse developed obvious lesions 180 days after the parasite 
infection, while the second mouse showed no signs of swelling (Fig. 6.12 B).
6.5.2 Investigation of the mechanism of the protective effect of high dose 
of gentamicin in Leishmaniasis during trial 1
After establishing that high doses of gentamicin prevented L. major infection in 
BALB/c mice, I next addressed the mechanism by which this occurred. Hence, I 
assessed the immunological parameters after L  major infection (with or without 
gentamicin treatment). The parasite load in the infected foot, antigen specific 
antibody production, cell proliferation in response to L  mayor antigen and cytokine 
production were measured. Further, the effect of gentamicin on leukocyte subsets 
in BALB/c mice was analysed by flow cytometry to determine which cell types 
were affected by this treatment regime.
Three groups of BALB/c mice had been infected with L  major parasites and 
injected i.p. twice daily with PBS, 10 mg/kg or 50 mg/kg of gentamicin between 
day 0 and day 12. On day 79, three out of the six mice in each group were 
sacrificed, the popliteal lymph node cells, spleen cells, serum and the infected 
footpads were pooled and analysed for parasite antigen-specific responses.
The analysis of the parasite load by serial limiting dilution assay (section 2.15) 
confirmed that no parasites were found in the infected footpad of mice treated with 
50 mg/kg gentamicin. Comparable numbers of parasites were seen in the 
footpads of mice treated with the lower dose of gentamicin and PBS (Fig. 6.13 A). 
Despite this, neither dose of gentamicin had any effect on the L  major antigen-
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Fig 6.13 Assessment of parasite load and parasite antigen-induced 
proi iteration at a late state of gentamicin-treated L. major 
infection in BALB/c mice
Three mice of trial 1 were sacrificed at day 79. The infected footpads were 
analysed for parasite load (A) by serial limiting dilution assay (section 2.15), 
culturing the parasites for 3 days in dilutions in complete Schneider’s medium. 
Proliferation (B) was assessed by stimulating 1x10® spleen cells with increasing 
doses of parasite antigen for 3 days and pulsing them with IpCi ^(H)-Thymidine. 
Basal levels are given in brackets. These results (n=3) are shown as the mean ± 
1 SD and presented as fold increase in comparison to untreated cells.
A)
15
1
■Oroo
(/}
2 
CD 
CL
10
0
B)
2.5
co
2a.
c
0)(/)
CD
2Üc
p
o
LL
0.5
o o oo
PBS control 
(22020±24 cpm)
10 mg/kg, dO-12 
{16473 ±993 cpm)
50 mg/kg, dO-12 
{56294 ± 5864 cpm)
concentration/-, mayor antigen (parasite/ml)
216
specific proliferation response of spleen cells in vitro (Fig. 6.13 B). The cytokine 
response of spleen cells to parasite antigen was analysed by ELISA. Infected 
mice injected with PBS responded to increasing parasite antigen doses with 
increasing production of IFN-y as well as IL-4, which agrees with previous findings 
by Morris et ai. (1992). Spleen cells of mice treated with 10 mg/kg of gentamicin 
responded with a higher IFN-y and IL-4 cytokine production than spleen cells from 
control mice. Spleen cells of mice treated with 50 mg/kg gentamicin responded to 
increasing parasite antigen doses with no alteration in IFN-y production, while the 
IL-4 production was slightly reduced in the presence of the antigen, reaching only 
34% of the level of control spleen cells when stimulated with the highest antigen 
dose (Fig. 6.14).
L  mayor-specific IgGI and lgG2a antibodies in the serum were also measured. 
Thi cells promote lgG2a antibody production while Th2 cells are capable of 
stimulating B cells to produce IgGI. Therefore the lgG1/lgG2a ratio is generally 
accepted as an approximate measure for Th1/Th2 cell activity. As figure 6.15 
shows, both isotypes were detectable in serum from the PBS-treated group. 
Levels of IgGI were higher than levels of lgG2a. Serum from 10 mg/kg 
gentamicin-treated mice contained similar amounts of both antibodies (data not 
shown). Serum of mice that had been treated with 50 mg/kg gentamicin contained 
significant lower amounts of both IgGI and lgG2a than the serum from control 
mice.
At this very late state of disease no sign for a biased Thi or Th2 response could 
be found and the defective T cell response could reflect either the lack of sufficient
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Fig. 6.14 Cytokine production of gentamicin-treated L. mayor-infected 
spleen cells taken at a late state of disease in response to 
parasite-antigen
Three mice from each treatment group of trial 1 were sacrificed on day 79 and 
spleens were collected and pooled. Spleen cells (1x10®/well) were stimulated 
with increasing doses of parasite antigen for 3 days. Cytokine production was 
analysed by ELISA. Results (n=3) are shown as mean ± 1 SD. (** p<0.005, 
comparing PBS control with 50 mg/kg gentamicin treatment)
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Fig. 6.15 Parasite antigen-specific serum antibody production of a iate 
state of L. mayor infection, treated with gentamicin
Three mice from each treatment group of trial 1 were sacrificed on day 79 and 
serum was collected, pooled and analysed for parasite antigen-binding lgG2a (A) 
and IgGI (B) antibodies by ELISA (section 2.23). The error bars represent the 
standard deviation between ELISA triplicates.
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antigen to stimulate effector T cells differentiation or toxicity of 50 mg/kg 
gentamicin to T cells. Therefore, during the following experiment the effects of 
lower gentamicin concentrations and delayed treatment with the aminoglycoside 
were analysed during a more acute stage of the disease.
6.5.3 The effects of high doses of gentamicin appiied at different stages of 
Leishmania major infection (triai 2)
After establishing that 50 mg/kg reproducibly prevented the onset of L. major- 
mediated disease progression in BALB/c mice, the ability of gentamicin to act as a 
therapeutic agent after L. major infection was examined next. Most successful 
treatments of L. major infection in mice start each prior to or at the time of 
infection suggesting that they function to influence initial events in T cell 
differentiation, rather than reversing established T cell responses. For example, 
IL-12 has to be administered within one week after the infection but not later, 
leading to a complete cure of Leishmaniasis in susceptible BALB/c mice (Sypek et 
al., 1993).
Here, five groups of 6 BALB/c mice were treated i.p. as follow:
1. From the day of infection for 12 days with PBS.
2. From the day of infection for 12 days with 25 mg/kg of gentamicin.
3. From the day of infection for 12 days with 50 mg/kg of gentamicin.
4. From day 7 post-infection for 7 days with 50 mg/kg of gentamicin.
5. From the day that swelling became visible for 12 days with 50 mg/kg of 
gentamicin.
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50 mg/kg of gentamicin prevented the growth of L. major if administered from the 
day of infection (Fig. 6.16 A). A lower dose (25 mg/kg) controlled the infection over 
100 days, after which rapid swelling of the footpads (indicative of parasite 
multiplication) occurred (Fig. 6.16 B).
If Thi cells had been involved in protection elicited by gentamicin to L  major 
parasites, one might expect that memory Th1 cells could prevent a reinfection. 
Therefore, mice that had been treated with 50 mg/kg of gentamicin from day 0 
onwards and had overcome an initial challenge were reinfected with the parasite 
on day 91 (Fig. 6.16 B). After 3 weeks an increase in swelling was apparent, which 
increased steadily to the level seen in the PBS-treated mice, suggesting the 
absence of L  mayor specific memory Thi cells.
A transient protection was achieved if mice were injected with 50 mg/kg of 
gentamicin from day 7 after infection. This treatment regime delayed detectable 
footpad swelling for 55 days, but after this period the increase in footpad swelling 
was similar to the PBS group (Fig. 6.17 A). Next, the ability of gentamicin to act 
therapeutically was examined. Mice were infected with the parasite and treated 
with gentamicin only after footpad swelling had reached 0.5 mm. The treatment 
decreased the swelling dramatically, but after the end of injections the disease 
progressed again as shown in Fig. 6.17 B. The trial was repeated using a 5 x 
higher parasite dose (trial 3). As shown in Fig. 6.18, the results were nearly 
identical. Gentamicin injections, started when open lesions had already appeared, 
decreased the swelling dramatically and closed the lesions. However, the swelling
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Fig. 6.16 Gentamicin treatment of L. mayor-infected BALB/c mice (trial 2)
Three groups of 6 mice were infected in the left footpad on day 0 with 1x10® 
parasites/mouse and injected (i.p.) from day 0 - 1 2  with PBS, 50 mg/kg (A) or 25 
mg/kg of gentamicin (B) twice a day. After 87 days, the group treated with 50 
mg/kg of gentamicin was reinfected with the same parasite dose. The footpad 
swelling data show the difference between the infected left and the uninfected 
right footpad and are presented as the mean ± 1 SD ( ** p<0.005, * p< 0.05 
comparing PBS control with gentamicin treatment).
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Fig. 6.17 Gentamicin treatment of L. major-infected BALB/c mice (trial 2)
Three groups of 6 mice were infected in the left footpad on day 0 with 1x10^ 
parasites/mouse and injected (i.p.) twice per day from day 7 - 1 4  with PBS and 
50 mg/kg gentamicin (A) or when swelling appeared for 12 days with 50 mg/kg of 
gentamicin (B). The footpad swelling data shown are the difference between the 
infected left and the uninfected right footpad and the mean ± 1 SD (* p< 0.05 
comparing PBS control with gentamicin treatment).
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Fig 6.18 Gentamicin treatment of L. major-infected BALB/c mice (trial 3)
Four groups of 12 mice were infected in the left footpad on day 0 with 5x10% 
parasites/mouse and injected (i.p.) twice per day from day 0 - 1 4  with PBS or 50 
mg/kg gentamicin or from day 7 - 1 4  with 50 mg/kg gentamicin or when lesions 
appeared for 12 days with 50 mg/kg gentamicin twice a day. The footpad 
swelling data show the difference between the infected left and the uninfected 
right footpad and are presented as the mean ± 1 SD.
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increased and the lesion relapsed soon after cessation of the gentamicin 
treatment.
6.5.4 Assessment of immunological parameters during the acute state of 
gentamicin-treated Leishmaniasis (trial 3)
BALB/c mice were infected with L  major and treated twice daily with PBS or 
gentamicin (50 mg/kg) from day 0-12 or from day 7-14 or when the swelling 
became visible (day 51-63). On day 54, three mice of the PBS group, 50 mg/kg 
(dO) group and the 50 mg/kg (d7) group were sacrificed and immunological 
parameter analysed. On day 67, three mice of the PBS group and the lesion 
treatment group were sacrificed and the response of spleen, lymph node cells and 
serum antibody levels against parasite antigen was analysed. Changes in cell 
populations (CD4(+), GD8(+) T cells, CD19(+) B cells or macrophages) under the 
influence of gentamicin were monitored by flow cytometry.
At this point, footpad swelling of the PBS group was strongly increasing, while 
footpad swelling of the 50 mg/kg gentamicin group was not detectable. Mice 
treated after day 7 of infection showed signs of footpad swelling. Mice with open 
lesions that had subsequently received gentamicin showed lesion healing and a 
reduction in swelling.
The parasite load in all gentamicin-treated groups was considerably lower than in 
the PBS control group. Mice that received 50 mg/kg of gentamicin from day 0 had 
a 10-fold lower parasite number than their control litter mates. When this 
treatment regime started from 7 day post-infection, a 3-fold reduction in parasites
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was achieved. Gentamicin treatment given just after lesions had become apparent 
reduced the number of parasites 5-fold in comparison to the PBS control group 
(Fig. 6.19).
In Fig. 6.20, the response of popliteal lymph node cells to parasite antigen was 
examined. In a parallel experiment, spleen cells responded in a similar fashion 
(data not shown). No proliferative response to increasing doses of L. major 
antigen was seen with lymph node cells treated with 50 mg/kg gentamicin from 
day 0. Proliferation of lymph node cells from mice that were treated with 
gentamicin 7 day post-infection was similar to that of cells from PBS-treated mice 
(Fig. 6.20 A). Lymph node cells from mice that were treated with gentamicin after 
the appearance of open lesions had approximately a 3-fold increase in 
proliferation compared to cells from the control group (Fig. 6.20 B).
To test whether gentamicin treatment caused a general impairment of T cells 
proliferation, independent of their ability to react to parasite antigen, lymph node 
cells of mice treated with gentamicin or PBS were stimulated with 4 |ig/ml plate 
bound anti-CD3 (Fig. 6.21). No difference in response to anti-CD3 between the 
PBS group and mice treated with 50 mg/kg from day 0 was detected. These data 
show that gentamicin had a selective effect on parasite antigen-reactive T cell 
expansion.
To exclude the possibility of a non-specific T cell response to parasite antigen, 
cells of uninfected mice were compared to cells of L. mayor-infected, PBS-treated 
mice (Fig. 6.22). Proliferation of lymph node cells from uninfected mice increased 
slightly in response to parasite antigen but reached only 10% of the proliferation
226
12.5o
1073
§
1
2
CN2
o■o■o
coCÛo_
g
t
s
I
E
olO
c
8
co
CÛ
CL
C0)
E
I
c0
1
Fig. 6.19 Assessment of parasite ioad of gentamicin-treated L. major- 
infected BALB/c mice at a iate state of infection (triai 3)
Three mice of each treatment group from trial 3 were sacrificed on day 54 and 
the parasites in the infected footpads were pooled and analysed by the serial 
limiting dilution assay (section 2.15). The results (n=3) are shown as the 
mean ± 1 SD.
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Fig. 6.20
L. mayor antigen concentration (parasites/ml)
T cell proliferative response of gentamicin-treated, L. major- 
infected BALB/c mice to parasite antigen (trial 3)
Three mice from each treatment group of trial 3 were sacrificed on day 54. The 
popliteal lymph node cells of each group were pooled and stimulated with 
increasing doses of parasite antigen for 3 days before ^(H)-Thymidine uptake 
was measured. The basal levels of proliferation are shown in brackets. Results 
(n=3) are shown as mean ± 1 SD and as fold increase in comparison 
to unstimulated cells.
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Fig. 6.21 T ceil proliferative response of PBS versus gentamicin-treated 
popliteal lymph node cells derived from L. mayor-infected 
BALB/c mice (trial 3) to anti-CD3
Lymph node cells (1x10®/well) of 3 mice, sacrificed on day 54 of trial 3, were 
pooled and stimulated with 4 pg/ml anti-CD3 Ab for 3 days before the cells were 
pulsed and ^(H)-Thymidine uptake was measured. The results (n=3) are shown 
as the mean ± 1 SD.
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Fig. 6.22 Proliferative response of L. /nayor-infected and uninfected 
lymph node cells to parasite antigen
Lymph nodes of three uninfected and three L  mayor-infected BALB/c mice, 
sacrificed on day 54 of trial 3, were stimulated for 3 days with increasing doses 
of parasite antigen. Cell proliferation was measured by ^(H)-Thymidine uptake. 
Data (n=3) are mean ± 1 SD (**p<0.005).
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level of infected cells. This indicates a small non-antigen-specific response did 
occur but the magnitude of the response was not sufficient to interfere with 
parasite-specific responses.
Both parasite-specific IgGI and Ig02a antibody levels were found in serum of the 
PBS group (Fig. 6.23). In serum from mice treated with the high dose of 
gentamicin from day 0 no lgG2a and significant lower amounts of IgGI were 
detected compared to control serum or serum from mice treated from day 7. The 
serum of mice treated when lesions had appeared, showed no significant 
difference in IgGI or tgG2a levels compared with the PBS controls (Fig. 6.24). 
Therefore, early gentamicin treatment diminished both IgGI and lgG2a antigen- 
specific antibody responses.
To monitor the effect of gentamicin on the Th1/Th2 cell balance, Th1 and Th2 cell- 
specific cytokines were measured. All measured cytokines were produced by 
infected lymph node and spleen cells after culture with L  major antigen. Th1 
cytokines (IFN-y and IL-2) and Th2 cytokines (IL-4 and IL-6) were expressed at 
similar levels in cells from the PBS control group and the 50 mg/kg gentamicin- 
treated group (d7). Only IL-10 expression was decreased by gentamicin treatment. 
However, cells from mice injected with 50 mg/kg gentamicin from day 0 showed 
no expression of the above cytokines. To investigate whether the suppression of 
cytokines was due to regulatory T cells (Tr1, Th3), the production of IL-10 and 
latent TGF-p were examined (Groux et a/., 1997). IL-10 was not expressed by 
lymph node cells treated early with gentamicin, whilst de novo TGF-p synthesis 
was not affected by an increasing L  major antigen concentration (Fig. 6.25).
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Fig. 6.23 Assessment of parasite-specific antibody production at an 
acute state of gentamicin-treated L. major infection in BALB/c 
mice (trial 3)
Sera of 3 mice of each indicated treatment group, sacrificed on day 54 (trial 3), 
were pooled and analysed for parasite-specific lgG2a (A) and IgGI (B) 
antibodies (section 2.23). The error bars represent the standard deviation 
between ELISA triplicates.
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Fig. 6.24 Assessment of parasite-specific antibody production at an 
acute state of gentamicin-treated L. major infection in BALB/c 
mice (trial 3)
Three mice of each treatment group of trial 3 were sacrificed on day 67 and the 
sera pooled. The serum was analysed for parasite antigen-binding lgG2a (A) and 
IgGI (B) antibodies by ELISA (section 2.23). The error bars represent the 
standard deviation between ELISA triplicates.
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Fig. 6.25 Cytokine production of gentamicin-treated 
L. mayor-infected mice in response to parasite 
antigen (trial 3)
□  PBS control 
S  50 mg/kg, d7 
■  50 mg/kg, dO
Three mice each treatment group were sacrificed on day 54 of trial 3 and 
popliteal lymph nodes and spleens were collected and pooled. 1x10® lymph node 
cells or spleen cells (for IL-6) were stimulated with parasite antigen for 3 days 
and culture supernatants assayed for cytokines by ELISA. The error bars 
represent the standard deviation between ELISA triolicates.
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These results suggest that the involvement of regulatory T cells in the suppression 
process was unlikely. Further, they suggest that treatment of mice with the high 
dose gentamicin at the time of infection eliminated parasite-specific T cells. 
Parasite-specific IL-2 produced by lymph node cells from mice treated with 
gentamicin after lesion onset was found to be 1.4-2.6 times higher than the IL-2 
level of the PBS-treated group. Thi and Th2 type cytokines including IFN-y, IL-4, 
IL-6, IL-10 were expressed to a lower level in the gentamicin-treated mice than in 
the PBS controls. TGF-p expression was not significantly different between the 
two groups and did not alter with an increasing antigen concentration (Fig. 6.26). 
Early gentamicin treatment reduced L. mayor-specific proliferation and antibody 
response as well as cytokine production. Flow cytometry analysis was used to 
investigate whether these changes were due to changes in spleen cell subsets 
such as CD4(+) T cells, CD8(+) T cells, B cells (CD19(+)) or macrophages 
(FA11 (+)). Pooled spleen cells from three PBS-injected and L. mayor-infected mice 
were compared with those from three L  mayor-infected mice treated with 
gentamicin from day 0. Gentamicin did not alter the percentage of CD4(+) cells or 
CD8(+) cells. The percentage of CD19(+) cells increased slightly by 5 % (38.74% 
in PBS-treated group compared to 43.76% in gentamicin-treated group), and the 
percentage of FA11(+) cells increased by 10% (20.06% in PBS-treated group 
compared to 30.49% in gentamicin-treated group) (Table 6.1). To check, whether 
gentamicin functioned by inducing cell death spleen cells were double stained for 
annexin V and cell surface markers. This revealed a 10% increase in apoptotic B
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Fig. 6.26 Cytokine production of gentamicin-treated 
L. mayor-infected mice in response to parasite 
antigen (trial 3)
Three mice per group were sacrificed on day 54 of trial 3 and popliteal lymph 
nodes and spleens were pooled. 1x10® lymph node cells or spleen cells (for IL-6) 
were stimulated with parasite antigen for 3 days before ELISA was performed. 
Data (n=3) are shown as mean ± 1 SD (**p<0.005; * p< 0.05).
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Cell surface marker PBS-treated Gentamicin-
treated
CD4(+) 9.48 % 10.19%
CD8(+) 21.47% 19.9%
CD19(+) 38.74 % 43.76 %
CD19(+)/annexinV(+) 15.44% 26.58 %
FA11(+) 20.06 % 30.49 %
Table 6.1. The effects of gentamicin on cell populations of L. major- 
infected BALB/c at an acute state of the disease (trial 3)
BALB/c mice were infected on day 0 with 5x10® L  major parasites/mouse. 
Gentamicin (50 mg/kg) was injected i.p. twice daily from day 0 to day 12. On 
day 54, three mice were sacrificed and their spleen cells analysed for cell 
surface marker staining.
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cells among gentamicin-treated cells (gated for CD1 G '^^VannexinV" '^^ ,^ 15.44% in 
PBS-treated group versus 26.58% in gentamicin-treated group, Table 6.1).
When comparing size (FSC) and granularity (SSC) of the spleen cell population of 
gentamicin-treated versus PBS-treated cells, a lower number of bigger sized cells 
with higher granularity in region 2 (R2) and region 3 (R3) was observed in cells 
from gentamicin-treated mice (Fig. 6.27). In spleen cells from PBS-treated mice, 
three times more cells accumulate in R2 and R3 than in spleen cells from 
gentamicin-treated mice (14.59% in PBS-treated mice versus 5.51% in 
gentamicin-treated mice). According to the expression of their cell surface marker 
the population in R2 consisted mainly of MHCII(+) cells, CD4(+) and CD8(+) T 
cells and some CD19(+) B cells. Region 3 contained mainly MHCII(+) cells (Fig. 
6.28). Taken together, these results suggest that gentamicin treatment might have 
suppressed proliferating MHCII expressing cells, CD4(+) and CD8(+) T 
lymphoblasts and CD19(+) B cells (Longobardi, 1992; Komai-Koma and 
Wilkinson; 1997).
6.5.5 Analysis of early events in gentamicin-treated L. mayor infection
The analysis of the late state of gentamicin-treated L  major infection suggested a 
general suppression of antigen-specific immune responses. To determine whether 
there was any in vivo evidence for selective suppression of Th2 over Thi cells by 
gentamicin, mice were treated with the aminoglycoside for a shorter time period 
and were analysed at early timepoints after infection with L  major parasites. Two 
groups of 6 mice were infected with 1x10^ parasites per mouse and injected i.p.
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Fig. 6.27 Gentamicin treatment 
suppresses cell populations of 
bigger size and granularity
On day 54 after L. major infection 
(trial 3) pooled spleen cells of 3 
mice treated with PBS or 50 mg/kg 
gentamicin (dO-12) were analysed 
by flow cytometry. The figure 
shows Forward Scatter (FSC) 
and Side Scatter (SSC) 
representing size and granularity of 
cells.
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Fig. 6.28 Flow cytometry analysis of cell surface marker expression of 
cells in R2 and R3
Spleen cells, gated in region 2 and 3, were analysed for cell surface marker 
expression. Cells were analysed for CD19 (B cells ), CDS (Tc cells ), CD4 (Th 
cells), FA11 (macrophages) and MHCII (APC) expression.
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with either gentamicin (50 mg/kg) or PBS for 7 days twice a day. Two mice of each 
group were sacrificed on day 3, 7 and 10. No footpad swelling was apparent at 
any of these timepoints.
When spleen and lymph node cells were stimulated with L  major antigen, no 
production of Th1/Th2 cytokines could be detected. However, when stimulated 
with 4 f^g/ml plate-bound anti-CD3, proliferation levels of spleen cells, treated with 
gentamicin and taken on day 10 after infection, were similar to proliferation levels 
of PBS-treated spleen cells (23% increase in gentamicin-treated group). IL-2 
levels in the gentamicin-treated group were twice that of the control group. IFN-y 
levels were comparable between control and treated group. Th2 cytokines were 
downregulated in mice injected with gentamicin, IL-4 to 74% and IL-5 to 33% of 
their control levels (Fig. 6.29). Similar results were achieved with spleen cells 
taken after 7 days of gentamicin treatment (data not shown).
10 days after infection L  mayor-specific serum antibodies were detectable. IgGI 
antibodies were impaired (to 36% of the control level at a 1/16 dilution), while 
lgG2a antibodies were expressed equally in both groups (Fig. 6.30).
As assessed by flow cytometry, gentamicin did not alter the number of CD4(+), 
CD8(+) T cells or B cells in the spleen 10 days after infection and only a slight 
decrease in the number of macrophages was apparent as a result of gentamicin 
treatment. Among popliteal lymph node cells, situated close to the infection, an 
11% decrease in B cells and small decrease in macrophages was detectable 
(Table 6.2).
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Fig. 6.29
PBS
gentamicin
Cytokine and proliferative response of gentamicin-treated 
L. mayor-infected BALB/c mice at an early state of disease 
(trial 4)
Spleen cells of 2 groups of three mice, infected with 5x10^ parasites/mouse and 
treated for 7 days twice a day with PBS or 50 mg/kg gentamicin, were collected 
on day 10, pooled and stimulated with 4 pg/ml anti-CD3 Ab for a further 3 days. 
Cytokines were assessed by ELISA and cell proliferation by ®(H)-Thymidine 
uptake. Results (n=3) are shown as mean ± 1 SD (* p<0.05).
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Parasite antigen-specific antibody response of gentamicin- 
treated L. mayor-infected BALB/c mice at an early state of 
disease (trial 4)
Sera of two groups of 3 mice, infected with 5x10% parasites/mouse and treated 
for 7 days twice a day with PBS or 50 mg/kg of gentamicin were collected on day 
10 of infection and the lgG2a (A) and the IgGI (B) antibody production were 
analysed by ELISA (section 2.23). Results (n=3) are shown as mean ± 1 SD 
(* p<0.05).
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Cell
surface
marker
Uninfected
spleen
Gentamicin (%)
Uninfected
LN
Gentamicin {%)
Infected
spleen
Gentamicin (% )
Infected
LN
Gentamicin (%)
- + - + - + +
CD4{+) 22.61 26.24 NA NA 27.29 26.76 41.0 44.86
CD8(+) 40.87 39.83 NA NA 10.79 10.14 13.36 15.82
CD19(+) 10.43 10.65 NA NA 45.91 48.34 40.87 29.81
FA11(+) 17.55 13.13 NA NA 28.33 22.21 14.67 11.39
Table 6.2. Comparison of the effect of gentamicin on L. mayor-infected 
and uninfected BALB/c mice
BALB/c mice were infected with 5x10^ parasites/mouse or were kept uninfected. 
50 mg/kg of gentamicin was injected twice daily for 7 days. On day 10, three 
mice were sacrificed and spleen and lymph node (LN) cells were pooled and 
analysed for the expression of cell surface markers by flow cytometry. (NA: not 
analysed)
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Using size and granularity, a 56% smaller population of enlarged cells in lymph 
nodes from infected and gentamicin-treated mice was found (Fig. 6.31). Analysis 
of cell surface markers in this subset (R2) revealed, these cells were mainly 
CD19(+) and CD4(+) cells. Consequently, early after L  mayor infection gentamicin 
appeared to cause impairment in the recruitment of activated CD4(+) T 
lymphoblasts and B effector cells (Longobardi, 1992; Komai-Koma and Wilkinson; 
1997).
6.5.6 Analysis of early events in gentamicin-treated uninfected BALB/c mice
The analysis of early immunological parameters in L  mayor-infected BALB/c mice 
showed that gentamicin induced suppression of Th2 cell-associated markers 
(IgGI, IL-4, IL-5) and either enhanced or did not affect Thi cell function. 
According to in vitro results presented earlier in this chapter, gentamicin 
selectively suppressed stimulated Th2 cells over Thi cells. To address the 
question of whether gentamicin can suppress immune cells in the absence of an 
infection, two groups of 3 BALB/c mice were injected with 50 mg/kg of gentamicin 
or PBS for 7 days twice a day. On day 10, the spleens were pooled and analysed. 
Spleen cells were stimulated with 4 pg/ml anti-CD3 and cytokine release and 
proliferation responses were assessed. The effect of gentamicin on different cell 
population was also analysed by flow cytometry.
The proliferation and the IFN-y expression in response to anti-CD3 were similar 
between spleen cells from PBS-treated and gentamicin-treated mice. Flowever, 
spleen cells treated with gentamicin expressed significantly less IL-4 (decrease by
245
Fig. 6.31 Gentamicin treatment of L. mayor-infected mice suppresses 
CD4(+) and CD19(+) cell population of bigger size and 
granularity
Pooled popliteal lymph node cells, taken on day 10 after L  major infection from 
three mice which had been treated with PBS or 50 mg/kg of gentamicin, were 
analysed by flow cytometry. Cells gated in region 2 (R2) were stained for CD4, 
CDS. CDIOand FA11.
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34%) and marginally less IL-5 (decrease by 18%) (Fig. 6.32). Assuming, that the 
BALB/c mice used were free of infections and therefore did not contain any 
proliferating, antigen-specific Th1 and Th2 cells, other sources of IL-4 such as 
NK1.1(+) CD4(+) T cells (Skold et al., 2000) might have been suppressed by 
gentamicin treatment.
Gentamicin did not alter the number of CD4(+) T cells, CD8(+) T cells and B cells 
in spleen cells of treated mice whilst the number of macrophages was reduced 
marginally by 4.4% (Table 6.2). The analysis of size and granularity of gentamicin 
treated and untreated cells revealed no differences (data not shown). These 
results suggest, that gentamicin mainly affected the antigen-specific immune 
responses.
6.6 Metabolism of serum gentamicin
It was vital to establish the levels of gentamicin that were present in vivo after 
gentamicin administration to BALB/c mice so similar doses could be used in in 
vitro experiments. Therefore, 6 mice were injected with a single dose of 
gentamicin (50 mg/kg) and the sera of 2 mice were collected after 4 h, 10 h and 
24 h. The serum content was analysed for levels of gentamicin by fluorescence 
polarisation immunoassay as described in section 2.3. As shown in Fig. 6.33 the 
gentamicin concentration had decreased after 4 h to 45 jig/ml and after 10 h only 
19 jag/ml were detected. One day after the injection the concentration decreased 
further to 13.5 jiig/ml gentamicin. In human individuals with normal renal function 
the estimated half-life in serum is 2-3 h (BNF, 1997). A maximum of two half-1 if es
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Fig. 6.32 The effect of gentamicin treatment on cytokine production of 
spleen cells from uninfected BALB/c mice
Three BALB/c mice were injected for 7 days twice daily with PBS or 50 mg/kg 
gentamicin and sacrificed on day 10. Spleen cells were pooled and stimulated 
with 4 pg/ml anti-CD3 Ab for 3 days. Cytokine release was assessed by ELISA 
and the cell viability by ^(H)-Thymidine uptake. Results (n=3) are shown as mean 
± 1 SD. (** p<0.005; *p<0.05)
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Fig. 6.33 Gentamicin serum concentration decreases over time.
BALB/c mice (n=9) were injected with 50 mg/kg gentamicin and three mice were 
sacrificed after 4, 10 and 24 h. The serum of 3 animals was pooled and the 
concentration of gentamicin was determined by fluorescence polarisation 
immunoassay (section 2.3).
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passed before the first measurement was undertaken. Consequently, a maximal 
concentration of about 200 jig/ml gentamicin reached the serum and spleen cells. 
After 6 h, when the next injection was administered, only 10-20 |ag/ml gentamicin 
remained in the circulation.
6.7 In vitro analysis of effects of gentamicin on parasites and ceils of the 
immune response
After observing that gentamicin prevented the infection with L  major in the BALB/c 
mouse model, in vitro analysis was performed to determine whether the effect of 
gentamicin was a direct effect on parasites or affected specific cells of the immune 
system such as macrophages and Th cells.
6.7.1 The effect of gentamicin on L. mayor parasites in vitro
As shown in L  mayor-infected BALB/c mice, gentamicin reduced the parasite 
number in the infected footpad independently of the state of disease. To further 
investigate the function of gentamicin on L. major parasites, parasites in their log 
phase were cultured with increasing concentrations of gentamicin for three days in 
complete Schneider’s medium, fixed and counted afterwards. To document any 
effects of gentamicin on shape and activity changes, photographs of the parasites 
were taken every 2 seconds under x 63 magnification. Gentamicin (1000 pg/ml) 
reduced the number of L  major parasites to 15% of the control level, while 100 
pg/ml did not affect the parasite number significantly (Fig. 6.34 A). Untreated 
parasites moved quickly in direction of their flagellum and had a slim, elongated
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Fig. 6.34 The effect of gentamicin on mature BMMs and L. mayor parasites
A) L  major promastigotes were grown in complete Schneider’s medium and 
cultured for 3 days with a concentration range of gentamicin, before being 
counted.
B) BMMs, matured with 10 ng/ml CSF-1 for 6 days, were cultured for 3 days 
with a concentration range of gentamicin and the MTT activity was assessed. 
The results (n=3) are shown as mean ± 1 SD (* p<0.05; ** p<0.005, comparing 
treated and untreated cells).
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shape (6.35 A). Parasites incubated with 100 pg/ml gentamicin had a much 
shorter round body, a shorter flagellum and moved very slowly (Fig. 6.35 B). 1000 
pg/ml gentamicin drastically altered morphology to a round body without flagellum, 
and greatly inhibited parasite mobility (Fig. 6.35 C). Cell debris was apparent, 
implying that a great percentage of parasites died in this concentration of 
gentamicin.
Zakai et al. (1998) reported that changes in Leishmania parasite morphology 
occurred at a lower pH of 5.5 increasing the infectivity of the parasites. To assess 
whether the observed shape and activity changes were due to lowering the pH in 
the medium, the pH changes caused by gentamicin were assessed. Only a 
concentration of 5 mg/ml gentamicin, which was never reached in in vivo 
experiments, altered the pH by one unit (Fig. 6.36). Therefore, gentamicin as an 
active component caused the changes described above.
6.7.2 The effect of gentamicin on the infectivity of L. major parasites in vivo
To examine whether gentamicin had a direct effect on the infectivity of L. major, 
parasites were incubated with 0, 50 and 500 pg/ml gentamicin for 48 h and then 
injecting into the footpad of 5 BALB/c mice. The swelling of the footpads was 
monitored over 70 days. Fig. 6.37 shows that parasites treated with different 
doses of the drug were similarly efficient in infecting BALB/c mice according to 
footpad swellings, suggesting that observed shape and activity changes at these 
drug concentrations given over 2 days did not affect the infectivity of parasites in 
vivo. These in vitro treatments were done with high doses of gentamicin for a short
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Fig. 6.35 A
Untreated L. major parasites
L. major parasites were grown 
for 3 days in complete Schneider’s 
medium. Pictures were taken every 
2 s with X 63 magnification.
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Fig. 6.35 B
Gentamicin-treated L. major parasites
L  major parasites were grown 
for 3 days in complete Schneider’s 
medium and incubated with 100 pg/ml of 
gentamicin. Pictures were taken every 
2 s with X  63 magnification.
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Fig. 6.35 C
Gentamicin-treated L. mayor parasites
L  major parasites were grown 
for 3 days in complete Schneider’s 
medium and treated with 1000 pg/ml 
of gentamicin. Pictures were taken every 
2 s with X  63 magnification.
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Fig. 6.36 Infiuence of gentamicin on the pH value of RPMi1640 medium
A concentration range of gentamicin was added to complete RPMI medium and 
the pH value was measured by pH meter.
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Fig. 6.37 Short-term gentamicin pretreatment does not affect infectivity 
of L. major parasites.
L  major parasites were cultured for 48 h with 0, 50 and 500 pg/ml gentamicin in 
vitro. Afterwards 5 x10^ parasites of each group were injected into the left 
footpad of 5 mice. The foot pad swelling was measured starting from day 35. 
Results (n=5) are shown as the mean ± 1 SD.
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period of time. During the in vivo trials, the parasites were exposed to gentamicin 
concentrations up to 200 p,g/ml twice per day for 12 days, which might have 
affected the infectivity much more dramatically than Fig. 6.37 suggests.
6.7.3 The effect of gentamicin administration on T helper cells
Next, cells of the immune system involved in Leishmaniasis disease progression 
were examined for effects of gentamicin. The suppressive effect of gentamicin on 
polarised T helper cells had been investigated in chapter 6.2. Gentamicin 
concentration of 200-300 pg/ml had marginal effects on the proliferation and 
cytokine production of Thi cells, but decreased Th2 cell proliferation and cytokine 
production (Fig. 6.10 and 6.11).
6.7.4 The effect of gentamicin on macrophages
As macrophages are hosts for L  major parasites, an effect of gentamicin on these 
cells could strongly influence the progression of the disease. Therefore, peritoneal 
macrophages, obtained from BALB/c mice, were stimulated in vitro with 10 ng/ml 
IPS and 0, 100, 500 and 1000 jug/ml gentamicin for 2 days. The mitochondrial 
activity as well as the cytokine expression (IL-6, IL-12 and TNF-a) was analysed. 
LPS stimulation of macrophages was chosen, because no cytokine release was 
detected in response to infecting parasite (data not shown), which has also been 
described by Chakkalath et al. (1994) and Belkaid et al. (1998).
Gentamicin reduced the cell viability of peritoneal macrophages stimulated with 
LPS in a dose-dependent manner (Fig. 6.38). The addition of 500-1000 |ag/ml
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Fig. 6.38 Suppression of LPS- stimulated peritoneal macrophage effector 
functions by gentamicin
Peritoneal macrophages were obtained from BALB/c mice (section 2.12). 1x10® 
cells were stimulated with 100 ng/ml LPS and a concentration range of 
gentamicin for 2 days. The cell viability was assessed by MTT assay (A) and the 
cytokine release by ELISA (B-D). The results (n=3) are shown as mean ± 1 SD 
(* p<0.05).
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impaired the succinate dehydrogenase activity by 77%. Unstimulated and parasite 
infected macrophages cultured with gentamicin showed similar pattern in MTT 
assays (Fig. 6.34 B, data not shown). LPS activates inflammatory cytokine 
production in peritoneal macrophages. Gentamicin decreased IL-6 and TNF-a 
expression in a dose dependent manner (Fig. 6.38). Incubation with 500 jig/ml 
gentamicin caused a 60% decrease in IL-6 expression and TNF-a expression. 
The IL-12 production was not affected by gentamicin treatment, only 1000 jag/ml 
gentamicin decreased the IL-12 release marginally. NO was not detectable by 
Griess reaction due to requirement for additional IFN-y combined with LPS 
stimulation. Unstimulated peritoneal macrophages and parasite-infected 
macrophages did not produce detectable cytokine levels. A primary function of the 
macrophages is to process and present antigen in the context of MHC class II 
molecules to T cells. MHC class II expression on viable cells did not change by the 
treatment with gentamicin, suggesting that the activation state of these cells was 
not affected (data not shown). In summary, gentamicin reduced viability and 
cytokine production of LPS-stimulated macrophages but did not affect their MHC II 
expression.
6.7.5 The effect of gentamicin on parasite-infected macrophages
Gentamicin is as a polycationic molecule water soluble, but poorly lipid soluble. It 
is therefore relatively ineffective at crossing biological membranes (Lutwyche et 
al., 1998). Hence, cells might use active pump mechanisms or pinocytosis to 
absorb the drug. To determine whether sufficient amounts of gentamicin can enter
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macrophages to affect intracellular parasites, macrophages were infected with 
parasites in a ratio of 1:10 (macrophage : parasite). Gentamicin was either added 
24 h prior infection, at the time of infection or 24 h after infection with L. major. 
After 3 days the macrophages were lysed and the parasite number assessed by 
serial limiting dilution assays as described in sections 2.15 and 2.17. As a control, 
L  mayor parasites were kept under macrophage growth conditions (RPMI 1640 + 
10% PCS, 37°C, 5% C02) and treated with 10 - 2000 i^g/ml gentamicin. Similar 
results as shown in Fig. 6.34 A were obtained. 10 and 100 |ag/ml gentamicin did 
not reduce the parasite number, but the parasites appeared less active, while 
1000 ng/ml seemed to have killed most parasites (data not shown).
Fig. 6.39 A shows that even 100 jug/ml gentamicin added to L  mayor-infected 
macrophages for 3 days killed all intracellular parasites. In photographs of the 
cells treated with 0 or 100 ng/ml gentamicin, taken before the parasites were 
washed away, no extracellular parasites were found in the 100 ng/ml culture, while 
numerous parasite were observed in the untreated culture (Fig. 6.40). To assess 
the ability of gentamicin to kill intracellular parasites, macrophages were infected 
with parasites for 24 h and remaining parasites were washed off before 
gentamicin was added (Fig. 6.39 B). No parasites were found in cells treated with 
100 ng/ml or higher concentrations of gentamicin. Finally, when macrophages that 
had been pretreated with gentamicin for 24 h, were washed and challenged with 
parasites for further 3 days, 100 ng/ml of the drug did not change the number of 
invading parasites in macrophages. 1000 ng/ml gentamicin decreased the
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Fig.6.39 The effect of gentamicin on 
macrophage infecting L. major parasites
A) Mature BMMs were obtained as described 
in section 2.11. Cells were infected with 
parasites (1:10) and different gentamicin 
concentrations were added for 3 days. 
Macrophages were lysed and parasite 
dilutions were cultured in complete 
Schneider's medium for 2 days and assessed 
by serial limiting dilution assay (section 2.15).
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B) Mature BMMs were pretreated with L  
major {  ^AO). Free parasites were washed off 
after 24 h. Different concentrations of 
gentamicin were added for 3 days. The cells 
were lysed and the remaining parasites were 
counted by serial limiting dilution assay.
C) Mature BMMs were pretreated with 
gentamicin for 24 h, then washed and 
infected with L. major (1:10) and incubated 
for 3 days. The cells were lysed and the 
intracellular parasites were analysed by serial 
limiting dilution assay.
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Fig. 6.40 The effect of gentamicin on macrophages infected with L. major
Mature BMMs were incubated with L  major (1:10) and without (A) or with 100 
pg/ml of gentamicin (B) for 3 days. Arrows indicate extracellular parasites.
(x 40 magnification)
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parasite number by 40 %, 2000 pg/ml decreased the number further to 40% (Fig. 
6.39 C).
Discussion 
G418 and gentamicin - potential tools to select Th1 over Th2 cells
The effect of G418 on T helper cell subsets
G418 is known to have varying effects on different eukaryotic cell types. In order 
to use this selection marker on transfected cells, a dose response of toxicity must 
be performed on untransfected cells to determine the minimum dosage required 
for such selection. In the course of these experiments, it was found that in 
response to G418, Th1 cells exhibited a significantly higher survival rate than Th2 
cells, as shown on Th cell clones and polarised Th cells (Fig. 6.2-6.7). 
Furthermore, higher Th1 type cytokine levels in comparison to Th2 type cytokines 
were observed after exposure of activated spleen cells to G418 (Fig. 6.8). Th1 
type cytokines are also expressed by NK1.1(+) T cells and CD8(+) Tc1 cells upon 
TCR stimulation (Skold et al., 2000; Harty et al., 2000), while Th2 type cytokines 
are expressed by NK1.1(+) T cells and mast cells (Skold et al., 2000; Bradding et 
al., 1995). Thus, these cell types may also be affected by the gentamicin 
treatment. However, the results on Th cell clones and polarised Th cells suggest 
strongly a selective suppression of gentamicin on T helper cell subsets. Propidium 
iodide and annexin V staining of G418-treated T cell clones implied that G418
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induced cell death either by apoptosis, supported by shrunk appearance of cells 
(Fig. 6.3), or necrosis more effectively in Th2 cells than in Th1 cells. Although the 
mechanism of Th1 cell resistance to G418 was not investigated, the most likely 
explanation, given the ability of aminoglycosides to interfere with the protein 
synthesis of eukaryotic cells (Manuvakhova et al., 2000), is that the Th2 cell 
proliferation rate is higher than that of Th1 cells. This was evident on Th cell 
clones (Fig. 6.4, basal levels), where BALB/c mice derived Th1 cells (X9) 
proliferated 3-4 fold less than Th2 cells (X12) from the same genetic backround. 
Polarised Th2 cells, stimulated with anti-CD3 proliferated 5 days after stimulation 
much stronger than polarised and anti-CD3 stimulated Th1 cells (Fig. 6.6). Indeed, 
it is known that stimulation with anti-CD3 antibodies inhibits IL-2 dependent 
proliferation in Th1 but not in Th2 cells (Gajewski et al., 1989; Williams et al., 
1990).
Another explanation may be that Thi cells express a transport activity, which 
exports intracellular G418. One possible candidate of a membrane transport 
system promoting the efflux of cytotoxic drugs on Th cells is the P-glycoprotein, 
encoded by the mdr (multiple drug resistance) genes. Indeed, the expression of P- 
glycoprotein has been reported to identify a subset of activated CD4(+) T cells 
characterized by an augmented rate of proliferation and increased IL-2 and IFN-y 
secretion in response to various polyclonal stimuli (Bommhardt et al., 1994). 
However, it was also reported that the multiple drug resistance protein 1 (MDR1 or 
MRPI) transmembrane pump, which is encoded by mdr1, is highly expressed by 
resting Th2, but not by Thi cells and is induced to equal expression level in both T
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cell subsets after antigenic stimulation in vivo (Lohoff et a!., 1998; PrechtI et a!.,
2000). Blockage of MDR1 with a monoclonal antibody did not increase the 
cytotoxicity of G418, suggesting that G418 resistance may not be associated with 
mdr1 expression (Metchetner et a!., 1992). Additionally, when using Taxol and 
Doxorubicin, which are substrates of the mdr1 coded P-glycoprotein (Sweet et al., 
1996), no selective suppression of cell viability of Th2 cells over Thi cells was 
observed (data not shown). Although the expression pattern of this particular MDR 
member does not correlate with the selective resistance of Thi cells but not Th2 
cells to G418, it may be that other MDR members are expressed in a Th2-specific 
manner. Indeed, others have reported complimentary patterns of expression of 
the ABC transporters CFTR and MDR1 in vivo (Anderson et a!., 1991; Trezise et 
a/., 1992). Hence, it is conceivable that certain MDR members are expressed in a 
Thi-restricted manner while other family members, such as MDR1, are expressed 
in a Th2-specific manner.
LPS stimulated macrophages (like TOR stimulated Thi cells) exhibit resistance to 
G418 (Sweet et a/., 1996), which might be mediated by an increased expression 
of the P-glycoprotein. An antibody blockade of P-glycoprotein on alloreactive 
CD4(+) T cells and CD14(+) monocytes resulted in diminished IFN-y secretion by 
CD4(+) T cells and in diminished IL-12 export and/or secretion by activated 
monocytes (Frank et a/., 2001). IFN-y upregulates the expression and activity of P- 
glycoprotein in human peripheral macrophages (Puddu et a/., 1999) and may thus 
increase IL-12 secretion of stimulated macrophages which then leads to further 
Thi cell development. These findings link stimulated macrophages and Thi cells
266
and suggest similar regulation of the P-glycoprotein expression in the two cell 
subsets.
Resistance to aminoglycosides and specifically to G418 is known from aerobic 
bacteria through the expression of enzymes from three classes; phosporylases, 
acetylases and adenyl transferases. These can inactivate aminoglycosides by 
cleavage or modification (Coppoc, 1996). No resistance is known from eukaryotic 
cells thought to express similar enzymes.
The observation that Thi cell are more resistant to G418 killing than Th2 cells is 
of technical interest to immunologists. A refined method might be used to isolate 
Thi cells out of mixture of activated T helper cells, or Th cells could be biased 
towards Thi phenotype by adding low doses of G418 to the culture.
The in vitro effect of gentamicin on T helper subsets
Gentamicin, commonly used as antibiotic, has well known function against 
prokaryotic cells (Schroeder et al., 2000). Side effects such as damage to sensory 
cells of the cochlea, the vestibular apparatus and on proximal tubular cells of the 
kidney on patients during long-term treatment suggest that gentamicin might also 
have adverse effects on eukaryotic cells (Lima da Costa et al., 1998; God ber et 
al., 1995; English et al., 2001). Several groups reported an impairment of the 
immune response by gentamicin, suppressing the production of different 
cytokines, DTH responses, lymphocyte proliferation, NK cell activity and 
phagocytosis (Van VIem et al., 1996). Rats treated with 225 mg/kg of gentamicin 
twice per day for 12 days showed a decrease in body weight, especially the
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thymus weight. DTH response and IFN-y production were suppressed in a dose 
dependent manner (Exon et al., 1989). Gentamicin (50 i^g/ml) decreased the IL-2 
production by mouse spleen cells in vitro (Ibrahim et al., 1988). The findings 
outlined in this chapter corroborate these previous reports. That is, gentamicin 
affects T lymphocytes negatively at higher dosage by decreasing cell viability and 
cytokine production. The data in this thesis have further extended the knowledge 
about the function of gentamicin on T lymphocytes. It selectively suppressed Th2 
type cytokine production and proliferation at moderate dosage and has therefore a 
potential as an agent to modulate Th1/Th2 function without universal toxicity to 
eukaryotic cells. Interestingly, 10-fold higher levels of gentamicin than of G418 
were needed to achieve a similar suppression pattern. This finding correlates with 
the results of Manuvakhova et al. (2000), that 2-14-fold higher levels of gentamicin 
were needed to achieve the amount of G418-induced suppression of translation 
termination signals. The mechanism of the selective suppression of gentamicin is 
unclear. It is likely that, given the similarities of G418 and gentamicin, the same 
mechanisms - differential protein synthesis rate or differential expression of an 
ABC transporter protein - which directs Th2-selective toxicity of G418 are also 
responsible for the effects of gentamicin.
The in vivo effects o f gentamicin on L. major infected BALB/c mice 
L. major infections in susceptible BALB/c mice lead to the development of locally 
severe lesions that do not resolve spontaneously. This is due to the inability of 
their immune system to mount an effective protective Thi response (Bradley,
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1977). The disease progresses because antigen-specific Th2 cell response 
dominates due to an early outburst of IL-4 and other, partly genetic factors. The 
high IL-4/IFN-y ratio prevents the activation of infected macrophages to destroy 
the parasites (Lehn et al., 1989; Liew et al., 1989). Resistant mice, such as CBA 
mice, exhibit a dominant Thi cell response when infected with L  mayor parasites 
and are able to resolve the locally small lesions that occur (reviewed by Launois et 
al., 1997). Therefore, progress of cutaneous leishmaniasis mainly depends on the 
Th1/Th2 cell ratio and their cytokine production. CD8(+) T cells can support Thi 
cells by producing IFN-y and TNF-a (Fong and Mosmann, 1990), that enables 
macrophages to kill the parasites in their phagosomes by increased NO 
production (Liew et al., 1990). B cells have not been reported to play a major role 
in L. mayor infections (reviewed by Liew, 1986). Successful treatments of L. major 
in BALB/c mice have been based on a direct suppressive effect on the parasite, 
the alteration of the Th1/Th2 balance, the activation or suppression of 
macrophages or the general suppression of the early immune response (reviewed 
by Bogdan and Roellinghoff, 1998).
Gentamicin was shown to be a potential tool to alter the Th1/Th2 type balance in 
vitro. To test whether gentamicin could alter the Th1/Th2 balance in vivo the 
murine model for L  major infections in susceptible BALB/c mice was applied, 
where gentamicin has been reported as part of a successful topical treatment 
(15% paromomycin, 0.5% gentamicin. Grog I et al., 1999). However, the 
mechanism of gentamicin in parasite killing had not been addressed.
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Consistent with the result of other groups I found that low dose gentamicin 
treatment of L. mayor-infected mice did not prevent the onset of the disease (data 
not shown; Carter and Alexander, 1989; Neal and Croft, 1984). Therefore, high 
doses of gentamicin, administered at different stages of the disease, were used to 
treat parasite-infected BALB/c mice. BALB/c mice, injected with 50 mg/kg of 
gentamicin from the time of L  major infection for 12 consecutive days, did not 
show footpad swelling. When gentamicin treatments were started later in the 
disease progression, the onset of the disease was delayed or the swelling of the 
lesions was reduced but these treatments were unable to prevent the disease 
progression. Analysis of immunological parameter at this acute state of infection 
revealed a general suppression of the parasite-specific T and B cell immune 
response by gentamicin when administered from the day of infection (Fig. 6.20- 
6.25). Further, the number of B and T lymphoblasts was reduced by gentamicin 
treatment (Fig. 6.28 and 6.31) which might provide an explanation for the lack of 
L  mayor-specific antibody and cytokine response. Gentamicin could have 
prevented the onset of the disease by either shifting Th2 cell to Thi cell 
dominance and therefore creating a Thi cell memory phenotype or by nonspecific 
depletion of antigen responding CD4(+) T cell, which were mainly of a Th2 
phenotype. Mice that had been cured of an initial infection by treatment with high 
dose gentamicin still succumbed to a subsequent reinfection, which could not be 
prevented by potentially existing memory Thi cells, suggesting that gentamicin 
might not favor Thi cell survival but rather selectively deplete Th2 cells. In such a 
case, disease progression would be prevented as long as the drug was present
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but would not allow for development of a protective memory. Therefore, 
gentamicin was most effective at preventing disease progression only when 
administered in high doses at the time of infection with parasites.
In conclusion, long-term treatment with a high dose of gentamicin led to a 
complete suppression of the L  mayor-specific immune response. However, when 
L. mayor-infected BALB/c mice were treated with gentamicin from the time of 
infection for a shorter period (7 instead of 12 days) and analysed soon after the 
treatment finished, it was possible to show that gentamicin can shift the Th1/Th2 
type cytokine balance in vivo as in vitro results had already suggested (Fig. 6.29). 
In gentamicin-treated L. mayor-infected BALB/c mice a decreased Th2 cytokine 
and IgGI antibody production and a reduction of the CD4(+) T and B lymphoblast 
population could be detected. It is likely, that the ability of gentamicin to suppress 
Th2 type responses occurred dependently of L  major infection. Further 
experiments have to be performed to ensure that this treatment regime still 
efficiently cures L  major infections by altering the Th1/Th2 type balance. When 
BALB/c mice were treated from day 7 to 14 post-infection, a delayed onset but no 
prevention of the disease was achieved (Fig. 6,14 A and 6.15). At this stage, the 
treatment might have been unable to suppress the already strong Th2 immune 
response and the growing number of parasites. A treatment, starting at the time of 
infection stands better chances to interfere with the disease progress as shown for 
example with IL-12 (Sypek et a!., 1993). Spleen cells isolated from gentamicin- 
treated mice up to 10 days after the L  mayor infection responded only to anti-CD3 
stimulation, not to stimulation with L  mayor antigen. Additionally, when uninfected
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mice underwent similar treatment, a suppression of IL-4 production by gentamicin 
was observed (Fig. 6.32). Therefore it can not be excluded that other IL-4 
producing cells such as splenic NK1.1(+) CD4(+) T cells and Fcy(+) CD4(+) cells 
with intermediate expression levels of TCR (TCR '"^ ) also contributed to the 
cytokine profile upon primary TCR stimulation (Moodycliffe et al., 1999). A 
possible suppression of these cells by gentamicin would have to be investigated. 
The achieved prevention of leishmaniasis could be also due to a direct effect of 
gentamicin on the parasite or its ability to infect its host cell and/or suppress the 
immune response of macrophages. First, the in vivo concentration of gentamicin 
had to be measured to be able to test this concentration on the parasites. The 
estimated serum concentration in mice for gentamicin peaked at 200 |ig/ml and 
deceased quickly, but a potential damage of the renal absorbency could lead to 
higher local concentrations and more damage to the immune cells.
Gentamicin was able to reduce dramatically the parasite number in the infected 
footpads (Fig. 6.13 A, 6.19 A). Grog I et al. (1999) observed a 24% suppression of 
L. donovani parasites in mice liver after injection with 700 mg/kg of gentamicin for 
4 days. Further, in collaboration with Dr. Carter (University of Strathclyde, 
Glasgow), the high dose treatment of gentamicin (day 0 -  day 12, i.p. injections of 
50 mg/kg twice per day) was tested on hamsters infected with L  donovani. 
Gentamicin reduced the parasite number in spleen and bone marrow by 50%, in 
liver by 78%, while sodium stibogluconate, a clinically used drug, was unable to 
reach parasites in the bone marrow but reduced the parasites in the liver to 2%. 
As demonstrated in this chapter, gentamicin at high concentrations was able to kill
Ill
L  major parasite in vitro, modulating body shape and activity at lower doses (Fig. 
6.34 A, 6.35 A-C). This might have been caused by gentamicin interacting with 
ribosomes of Leishmania and so promoting the association of the subunits which 
prevents protein synthesis as reported for paromomycin, another structural related 
aminoglycoside (Maarouf ef a/., 1995). However, L. ma/or parasites, treated prior 
infection for 48 h with gentamicin concentrations, which exceeded the estimated 
concentrations used for in vivo experiments, did not loose their infectivity in 
BALB/c mice. One could argue that during the in vivo trial the parasites were 
exposed to gentamicin for a longer period, which might then interfere with the 
protein synthesis causing the parasites to loose their vital functions. Other findings 
suggest that the success of gentamicin treatment in L  major infections was not 
only due to its suppressive effect on parasites. If high gentamicin concentrations 
had only led to a reduction in the number of parasites, BALB/c mice would have 
developed resistance and Thi type responses as shown following the inoculation 
of very low numbers of L  major promastigotes (Li et a/., 1997). Furthermore, dead 
parasites are used as a vaccine to induce a protective Thi response (Bebars et 
ai., 2000). A reinfection of mice, which had been successfully cured by high dose 
gentamicin treatment, was not precluded by a memory Thi cell response (Fig. 
6.16 A).
Macrophages act as host cells for L  major parasites and are therefore an 
attractive target for ant\-Leishmania drugs. The induction of Thi type cytokine IFN- 
y can confer resistance by activating macrophages to destroy their intracellular 
parasites (Nacy et a!., 1985; Doherty and Coffman, 1999). In contrast to this
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mechanism of resistance, suppression of the host cell viability by gentamicin 
would destroy the parasite’s ability to transform into amastigotes and to replicate. 
Gentamicin reduced the cell viability of uninfected, parasite-infected and LPS- 
stimulated macrophages in a dose-dependent manner (Fig. 6.34 and 6.38). 
Although the estimated in vivo doses did not decrease macrophage viability to a 
great extent, the long-term treatment during the in vivo trial might have done so. 
The antibiotic, given at 40 mg/L, has been reported to significantly inhibit 
macrophage activation in response to filtrates of lymphocytes in culture (Sacha et 
a/., 1999). Whether defense mechanism of macrophages such as oxygen burst 
and NO production are also negatively affected by gentamicin treatment remains 
to be investigated. When L  mayor-infected macrophages were treated with the 
estimated in vivo doses of gentamicin (100 |ag/ml), which would harm neither 
parasites nor macrophages alone, a complete clearance of intracellular parasites 
was observed (Fig. 6.39 A). This might have been caused by the altered ability of 
the parasite to enter the macrophage or by the increased ability of the 
macrophage to take up gentamicin and therefore enhance the local concentration 
inside the cell. Bray et al. (1983) reported an increased ability of macrophages to 
pinocytose when infected with amastigotes of Leishmania mexicana mexicana. 
Macrophages, when preincubated with gentamicin, which was removed before 
infection, showed less ability to clear parasites. This result could be interpreted 
with the reduced ability of macrophages to pinocytose in the absence of parasites. 
Consequently, the presence of L. major parasites could increase the uptake of
274
gentamicin into the host cell where high local concentrations could destroy the 
parasite.
Several parasite surface molecules (lipophospoglycan, promastigote surface 
protease) are involved in the attachment of promastigotes to macrophages via 
CR1 or CR3 (Puentes et al., 1988). Entering the macrophage via these receptors 
does not trigger an oxygen burst (Wright and Silverstein., 1983). Interference of 
gentamicin as a charged molecule with the attachment process or with the 
synthesis of the cell surface molecules could prevent the entry of the parasite 
without inflammatory response from the host cell and rather promote phagocytosis 
and clearance.
In agreement with others I observed a suppressive effect of gentamicin on 
activated B cells and antigen-specific antibody production (Villa et al., 1986; Van 
VIem, 1996). Extensive gentamicin treatment caused suppression of both Thi and 
Th2-specific antibody isotypes which might have been due to the lack of antigen 
or activated helper T cells or the killing of B cells by gentamicin. Shorter treatment 
favoured Thi cell-specific lgG2a over IgGI production, which corresponds with 
the findings on Th cells.
However, healing of an established L. major infection in mice is thought to be 
independent of the specific anti-leishmanial antibody response elicited during 
infection (reviewed by Liew, 1986). As shown in mice lacking B cells due to a 
disruption of the IgM locus, B cells do not have vital functions for the development 
of polarised T helper response by direct antigen presentation or costimulation or
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antibody-mediate effector functions during a L. major infection (Brown et al., 
1999).
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Chapter 7 General Discussion
Ill
This thesis is separated into two major parts, both investigating molecules that are able 
to modulate Th1/Th2 type responses. The balance between Thi and Th2 cells 
responses determines the outcome of many infections and autoimmune diseases. 
Hence, the possibility to modulate this balance is crucial for a successful treatment. 
Firstly, ST2-FC was expressed in insect and mammalian cells and used to investigate the 
function of ST2 on T helper cells. Then, the regulation of ST2 and ST2L expression by 
Th1 and Th2 cytokines was assessed. The second part of this project focused on the 
ability of gentamicin to modulate Th1/Th2 responses in vitro and in vivo.
The orphan receptor ST2L, with which ST2 shares a common extracellular domain, is 
preferentially expressed on the surface of Th2 cells and is important for Th2 effector 
functions in vivo (Kropf et ai., 1999; Xu et al., 1998, Loehning et al., 1998; Coyle et al., 
1999; Chan et al., 2001). Evidence was obtained from studies with anti-ST2L antibodies 
and ST2-FC fusion protein, mimicking the effects of ST2. Both treatments decrease Th2 
type responses (Xu et al., 1998; Coyle et al., 1999). One hypothesis suggests that anti- 
ST2L antibodies and ST2-fusion protein block the binding of the ligand and ST2L 
signaling and therefore prevent crucial Th2 cell effector functions, such as Th2 type 
cytokine production (Meisel et al., 2001). The effect of ST2 on ST2L expressing cells has 
been studied and the search for a soluble ligand is continuing. Only recently first 
attempts were made to reveal the effect of ST2 on ST2L(-) cells. An anti-inflammatory 
effect of ST2 on LPS-stimulated macrophages has been described (Sweet et al., 2001), 
which was also seen with fixed Th2 cells expressing ST2L, but not Thi cells. This thesis 
accumulated more evidence for a function of ST2 on ST2L(-) T helper cells. Naïve and
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primed T helper cells do not express ST2L (own observations; Meisel et al., 2001 ; Carter 
et al., in press EJI, 2001). Here I show that ST2-fusion protein can suppress cytokine 
expression of antigen stimulated naïve T helper cells, but not on re-stimulated Th cells. 
As with macrophages, this effect was mediated by binding of ST2 to an unidentified cell 
surface protein on naïve Th cells. Coyle et al. (1999) also reported an effect of ST2 on 
ST2L(-) cells. Naïve Th cells were antigen stimulated in the presence of ST2 for three 
days, followed by a restimulation, which led to a dominant Thi type cytokine expression. 
Hence, ST2 treatment results in cytokine gene expression changes and Th2 and Thi 
type cytokine promoters might be differently affected.
Apart from macrophages and naïve Th cells, ST2 was found to bind to activated B cells 
and dendritic cells (DC) (Yanagisawa, 1997; Coyle et al., 1999; Lambrecht et al., 2000). 
The expression profile of one ligand candidate, the membrane bound SBP (Gayle et al., 
1996), in Thi and Th2 cells is currently being investigated. ST2 may bind to antigen 
presenting cell subsets such as B cells and DCs and activate cell signaling. The obvious 
experiment to perform would be to assess the effect of ST2 on effector function of the B 
cells and DCs by measuring the cytokine and antibody production as well as the change 
of surface activation markers. Preliminary data suggest that ST2 increases IL-12 and 
TNF-a production by DCs while activation markers such as MHCII, CD80, CD86 and 
CD40 were not significantly affected (data not shown). Further, ST2 injections in ST2L- 
deficient mice (Townsend et al., 2001) will show whether ST2 has an effect on ST2L(-) 
cells. As seen on macrophages and Th cells the expression of the ST2 binding molecule 
can be altered by LPS stimulation and TCR stimulation, suggesting an activation-
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dependence. Similar binding studies with and without activation stimulus ought to be 
performed on B cells and DCs.
Another unsolved question is whether ST2 and ST2L act as agonists, which bind to a 
membrane-bound receptor and induce signaling as suggested on ST2L(-) cells 
(macrophages and naïve Th cells), or as antagonists, competing for a soluble ligand as 
assumed on ST2L(+) cells (Th2 cells) (Fig. 4.1). Soluble cytokine receptors (sCR) act 
mainly as antagonists to their membrane-bound homologue (reviewed in Fernandez- 
Botran et al., 1996a). On the other hand, soluble cytokine receptor can enhance the 
concentrations of active cytokines in vivo via several mechanisms including increasing 
cytokine stability, decreasing proteolytic degradation and altering pharmacokinetics (e.g. 
prolonged half life) (Aderka et al., 1992; Ma et al., 1996; Mohier et al., 1993) and 
therefore act as agonists. Whilst it is clear that in the studies outlined in this thesis, the 
major effect of ST2-Fc appeared to be a direct one, it is also likely that in other situations 
ST2 may act as a sCR. Whether ST2 would act as an antagonist or agonist in such 
circumstances awaits the identification of a putative ligand/receptor for ST2.
I next asked whether cytokines produced by Thi and Th2 cells influence ST2L and ST2 
expression. ST2L is known as a selective stable cell surface marker for Th2 cells, but the 
mechanism of Th2 cell-specific expression has not been addressed. Here I show that IL- 
4, a main player in Th2 cell polarisation, induces ST2L expression on naïve Th cells and 
polarised Th2 cells. A crucial role for IL-4 on ST2L expression was also suggested by 
Carter et al. (2001) and Meisel et al. (2001), reporting that IL-4 expression proceeds 
ST2L expression on polarising Th2 cells. ST2L expression also increases due to other
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Th2 cell proliferation stimuli such as IL-5, IL-6, IL-1 and TNF-a expressed by ARC and 
Th2 cells (Meisel et a i, 2001; own data). Although ST2L expression can be modulated 
by Th2 cytokines, studies on IL-4-, IL-5 and IL-10-deficient mice demonstrated that ST2L 
expression is not dependent on the presence of these cytokines. Double or triple knock­
out mice might demonstrate the importance of Th2 cytokines. On the other hand IFN-y, 
the main Thi cytokine, is able to reduce ST2L expression on cloned Th2 cells. IL-2, 
another Thi cell cytokine, decreased ST2L expression on cloned Th2 cells but to a much 
lesser extend than IFN-y at similar concentrations (data not shown). These results 
suggest another way of cross-regulation between Thi and Th2 cells. Interestingly, the 
expression of IL-18R, a cell surface marker for Thi cells, is up regulated by IL-12 and 
IFN-y, while the presence of IL-4 results in a downreguiation of the IL-18R a chain 
(Sareneva et a i, 2000; Smeltz et a i, 2001 ).
By assessing the expression pattern of ST2 and ST2L in response to IL-4, I found 
evidence that the two forms are differentially regulated. This was not due to alternative 
promoter usage but might be explained by different mRNA stability, which will have to be 
assessed. Differential regulation of ST2 and ST2L expression had already been 
suggested in mast cells, where calcium ionophore stimulation resulted in a switch from 
the long to the short transcript (Gaechter et a i, 1998).
When more information on the biological activity and regulation of ST2 is revealed, ST2- 
Fc may move to be an attractive therapeutic agent due to its specificity, affinity and lack 
of immunogenicity. Further, the ST2-Fc fusion protein has the added advantage of an 
increased half-life as a result of its dimeric nature. Indeed, its ability to trigger anti­
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inflammatory responses is of considerable interest as a therapeutic strategy for septic 
shock and autoimmune diseases such as rheumatoid arthritis.
Gentamicin, a broadly used antibiotic of the aminoglycoside family, had been reported to 
decrease the severity of L. major infection in mice when used topically in combination 
with paromomycin (GrogI et al., 1999). However, the mechanism for this effect remained 
unclear. In the second part of this thesis I demonstrate that the aminoglycosides G418 
and its structural analogue gentamicin are able to selectively suppress Th2 cells 
compared with Thi cells. Gentamicin inhibits prokaryotic and to a lesser extend 
eukaryotic cells by binding to ribosomes and perturbing the elongation of the nascent 
chain by impairing the proof-reading process controlling translational accuracy (Mingeot- 
Leclercq et a/., 1999, Manuvakhova et a!., 2000). There are several possible 
mechanisms for the differential suppression of Th2 and Thi cells. Firstly, presuming a 
faster rate of proliferation and therefore an increased protein synthesis of Th2 cells 
compared to Thi cells, the same amount of gentamicin will lead to more nonsense 
mutation and loss of viability in Th2 cells. Secondly, Th2 cells might have an increased 
amount of gentamicin in the cell due to lower expression of an active pump, transporting 
gentamicin out of the cell. Members of the mdr family, coding for P-glycoprotein, are 
differentially expressed in Thi and Th2 cells. Although mdr has yet to be shown 
differentially expressed in Thi but not in Th2 cells, the increased expression of P- 
glycoprotein has been reported in Thi type responses such as rheumatoid arthritis 
(Yudoh et a!., 1999). Additionally, IFN-y upregulates the expression and activity of P- 
glycoproteins in macrophages (Puddu eta!., 1999).
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Extrapolating these findings in vivo, high gentamicin concentrations prevented the onset 
of a L  major infection in BALB/c mice if the injections started at the time of infection. 
However, treatment with high concentrations of gentamicin caused a general 
suppression of L. mayor-specific Th and B cell immune responses. A suppressive effect 
of the applied gentamicin concentration was also observed on macrophage viability and 
parasite shape and activity. The latter might be explained by the fact that L  major 
ribosomes are also a target for aminoglycosides (Maarouf et ai., 1995). Although a short­
term gentamicin treatment did not affect the infective ability of the parasite in vivo, a 
longer treatment might generate a parasite mutant unable to infect macrophages and 
can therefore be used for active immunisation.
When a shorter gentamicin treatment was used, gentamicin suppressed Th2 type 
responses while Thi type responses were up regulated or not affected. Further 
experiments using a short term or lower dose of gentamicin treatments would have to 
establish whether the modulation of the Th1/Th2 balance is sufficient to prevent the 
development of leishmaniasis. This treatment regime should also limit the side effects of 
gentamicin on other cell types such as kidney cells. Attempts are made to find the active 
ring of gentamicin which is most important for binding to the ribosomes (Cashman et a!.,
2001). This could lead to improved drug devoid of side effects such as oto- and 
nephrotoxicity.
Gentamicin and G418 could be useful tools to influence Th1/Th2 type balance in in vitro 
culture systems. Further, the in vivo ability of gentamicin to shift the Th1/Th2 type 
balance towards a Thi biased phenotype and to decrease antigen-specific IgGI 
antibody production might be used in murine disease models like CIA, schistosomiasis
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mansoni or bacterial infections, where moderate doses of gentamicin may attenuate the 
disease (reviewed in Spellberg and Edwards, 2001; Boros and Whitfield, 1999). In 
contrast, helminth infections require a strong Th2 phenotype to clear the worm burden 
(Spellberg and Edwards, 2001). Here gentamicin might exacerbate the disease by 
promoting a Thi phenotype.
Finally, the ability of gentamicin to prevent proof-reading during the protein synthesis has 
been used as a treatment for patients suffering from Duchenne and Becker muscular 
dystrophies (Wagner et a/., 2001; Karpati, 2001). A subset of these patients possess a 
nonsense mutation, causing the premature termination of dystrophin translation. 
Gentamicin successfully suppressed the nonsense mutations, allowing translation of full- 
length proteins.
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Conclusions
The studies documented in this thesis were concerned with the modulation of Th1 type 
and Th2 type immune responses by ST2 and gentamicin.
ST2 has been shown to increase Th1 type responses and decrease Th2 type responses 
in ST2L expressing Th2 cells. This might be explained by a competition between ST2 
and ST2L for their common ligand. Results obtained in this study suggest that ST2 is 
able to decrease cytokine responses on activated naive T helper cells, which do not 
express ST2L. ST2 mediates this function by binding to an unidentified cell surface 
molecule. Restimulated Th cells become resistant to ST2, which can not bind to these 
cells.
ST2L is expressed on Th2 but not on Th1 cells due to the cytokine environment during 
polarisation. IL-4 augments the ST2L expression, while IFN-y decreases the ST2L 
expression. Further evidence found that ST2 and ST2L gene expression is differentially 
regulated.
Gentamicin, an aminoglycoside antibiotic, has been used as treatment for L. major 
infection. The success of this treatment might be due to its ability to selectively suppress 
Th2 type responses in vitro and in vivo. Excessive gentamicin treatment early during L. 
major infection causes a complete suppression of L. mayor-specific immune responses, 
while a shorter treatment selectively diminishes parasite-specific Th2 type responses. 
The sufficiency of this treatment to prevent the disease has to be further examined.
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Additionally, gentamicin decreases macrophage function and might alter parasite 
behavior.
Thus, our understanding of the mechanisms of action of ST2 and gentamicin would 
contribute to our ability in modulating Th1/Th2 cell-mediated diseases.
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Future studies
The following points provide a possible framework for future studies aiming at further
investigating the role of ST2 and gentamicin in immune responses and to assess their
potential as therapeutic agents.
• Identification of the ST2/ST2L binding molecule (soluble ligand or 
membrane-bound receptor).
• Demonstration of the influence of ST2 on effector functions of activated 
and non-activated B cells and DCs.
• Administration of ST2 to ST2L-deficient mice challenged with LPS or L. 
major Xo determine the effect of ST2 on ST2L(-) cells and investigate the 
immune response affected.
• Investigation of effect of short-term gentamicin treatment in Leishmaniasis
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Appendices
A.1 Suppliers
Abbott Laboratories #TDx system
American Type Culture Collection •RAW264, D10, Dorris,
Sf9, HighS cell line 
Amersham-Pharmacia #ECL detection kit
•Rainbow protein molecular weight 
markers
•Protein A Sepharose 
•nylon membrane 
•spectrophotometer 
ammonium persulphateBDH
Biogenesis Ltd. 
BioRad
Becton Dickinson
Cadisch Precision Meshes 
Costar
•RNAzol™B
•acrylamide 
•bis-acrylamide 
•nitrocellulose membrane 
•FACS Flow 
•FACS Lysing solution 
•nylon mesh
•all tissue culture flasks and plates 
•Eppendorf tubes (1.5ml; 0.5 ml)
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Diagnostic Scotland
DIFCO
Dynatech
Dynex
Genosys
Gibco-BRL
•all filter tips (1-1000 pi)
•plastic scraper
•all the HRP-conjugated secondary 
antibodies
•Streptavidine Peroxidase 
•thioglycollate broth 
•TMB
•MRX plate reader
•lmmunolon4 plates
•all the oligonucloetides and peptide
synthesis
•1 kb DNA markers 
•agarose
•dATP, dGTP, dCTP, dTTP 
•RPMI 1640 
•Schneider’s medium 
•DMEM w GlutamaxI medium 
•Fetal Bovine Serum (FBS)
•Fetal Calf Serum (FCS)
•FBS low IgG 
•MEM (lOx)
•Formaldehyde
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Harlan Olac 
Hoeffer Scientific Ltd. 
Kodak
Kroeplin
LKB Wallac, Turku, Finland 
Milenyi Biotec Inc.
Millipore Corp Ltd. 
Pharmacia
Pharmingen
•HEPES 
•L-Glutamine 
•Penicillin/Streptomycin 
•Phosphate Buffered Saline (PBS) 
•random primers
•Superscript II (reverse transcriptase) 
•geneticin sulphate (G418)
•DO.11.10 IC R  transgenic mice 
•whole electrophoresis system 
•X-ray film cassettes 
•X-omst AR autoradiography film 
•caliper
•Betaplate™96-well Harvester 
•Liquid scintillation counter 
•CS columns 
•anti-rat-dyn-beads 
•stirred ultrafiltration cell 8010 
•YM30 membrane 
•Protein-A/Sepharose 4B beads 
•nylon membrane 
•spectrophotometer 
•Propidium iodide
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•Annexin V-FITC
•most antibodies used for Flow cytometry 
Pierce •Coomassie® Protein Assay
Sigma •Human IgG (Reagent Grade)
•Lipopolysaccharide (LPS)
•TEMED 
•mitomycin 
•ethidium bromide 
•gentamicin sulphate 
•Tryptan Blue 
•MTT
Weber Scientific International Ltd. •counting chamber 
West of Scotland Radionucleotide •^H-Thymidine 
Dispensary, Western Infirmary,
Gifts • monoclonal anti-ST2L antibody (R.
Klemenz, Basel)
• IL-4 (Genzyme, Cambridge, MA)
• IL-12 (Hoffman-LaRoche, Nutley, NJ) 
• IL-2 (Genosys)
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#X4. X9. X12. group A streptococcal M protein 
(Dr JRobinson, University of Newcastle upon 
Tyne, UK
•CSF-1 (Professor David Hume,
Brisbane, Australia)
• stablv transfected CHO cell line (Dr. Daiwu 
Kang, Astra Zeneca, Sweden)
All the other chemicals used in this study are commercially available from SIGMA 
or BDH.
A.2. Table of antibodies used in flow cytometry
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Antibody Clone Isotype Host Concen­
tration
Company
m FITC anti-human 
lgG1
8cl6-39 lgG2a Mouse 2.6 pg/ml Sigma
m Biotin anti-mouse 
ST2
DJ8 lgG1,K Rat 2.5 pg/ml Dr. R. Klemenz, 
Switzerland
m PE anti-mouse 
CD4 (L3T4)
H129.19 lgG2a Rat 1 i^g/ml Pharmingen
m FITC anti-mouse 
CD4 (L3T4)
H129.19 lgG2a Rat 2.5 jLig/ml Pharmingen
m FITC anti- mouse 
CD19
1D3 lgG2a, k Rat 0.5 j^g/ml Pharmingen
PE Annexin V 5 pi Pharmingen
PI 0.5 pg SIGMA
m PE anti-mouse 
CD8
53-6.7 lgG2a Rat 0.1 jLig/ml Pharmingen
m FITC anti-mouse 
Pan-NK cells
DX5 IgM Rat 2.5 pg/ml Pharmingen
m Polyclonal anti­
mouse macrosialin 
(FA/11)
FA/11 lgG2a Rat 1:200 of 
culture sn
gift from Dr. Paul 
Crocker, Dundee 
(Lang et al., 2000)
m Biotin anti-mouse 
KJ1-26
KJ 1-26.1 lgG2a Mouse 5 pg/ml gift from Dr. Paul 
Garside, Glasgow
M FITC anti-mouse 
H-2D"
34-2-12 lgG2a Mouse 2.5 pg/ml Pharmingen
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m purified anti­
mouse 
CD16/32/Fcy 
receptor (Fc block)
2.4G2 lgG2b Rat 2.5 pg/ml Pharmingen
FITC Streptavidin 2.5 pg/ml Pharmingen
FITC-conjugated 
F(ab’ )2 fragment 
anti-rat IgG (H+L)
Donkey 6 pg/ml Jackson
ImmunoResearch
Laboratories
m = monoclonal 
p= polyclonal
A.3 Antibodies used for ELISA
A.3.1 Table of capture antibodies
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Cytokine Clone Isotype Host Concentration
(pg/ml)
Company
IFNy RA-642 lgG1 Rat 2 Pharmingen
IL-2 JES6-1A12 lgG2a Rat 2 Pharmingen
IL-4 11B11 lgG1 Rat 2 Pharmingen
IL-5 TRFK5 igGi Rat 4 Pharmingen
IL-6 MPS-20F3 igGi Rat 1 Pharmingen
IL-10 JES5-2A5 igGi Rat 8 Pharmingen
IL-12 C15.6 igGl Rat 8 Pharmingen
TGFp1 A75-2 lgG2a Rat 1 Pharmingen
TNFa
Duoset
polyclonal IgG Goat 0.3 R&D
A.3.2 Table of recombinant cytokines used in ELISA
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Cytokine Top Standard Bottom
Standard
Company
IFN-y 20 ng/ml 20-40 pg/ml Pharmingen
IL-2 10 ng/ml 10 pg/ml R&D
IL-4 10 ng/ml 10-20 pg/ml R&D
IL-5 10 ng/ml 40 pg/ml R&D
IL-6 10 ng/ml 10-20 pg/ml Pharmingen
IL-10 10 ng/ml 40 pg/ml Genzyme
IL-12 10 ng/ml 10 pg/ml Genzyme
TGFpl 10 ng/ml 40-60 pg/ml R&D
TNFa 10 ng/ml 20 pg/ml Biosource
international
A.3.3 Table of detection antibodies used in ELISA
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Cyto­
kine
Clone Isotype Conju­
gate
Host Concentra­
tion (jLig/ml)
Company
IFNy XMG1.2 IgGi Biotin Rat 0.5 Pharmingen
IL-2 JES6-5H4 lgG2b Biotin Rat 1 Pharmingen
IL-4 BVD6-24G2 IgGi Biotin Rat 1 Pharmingen
IL-5 RFK4 lgG2a Biotin Rat 4 Pharmingen
IL-6 MP5-32C11 lgG2a Biotin Rat 1 Pharmingen
IL-10 SXC-1 IgM Biotin Rat 4 Pharmingen
IL-12 C17.8 !gG2a Biotin Rat 1 Pharmingen
TGFpi A75-3 IGg2a Biotin Rat 0.5 Pharmingen
TNFa
Duo-
set
polyclonal IgG Biotin Goat 0.3 R&D
IgGi A85-1 IgGi Biotin Rat 1 Pharmingen
lgG2a R19-15 IgGi Biotin Rat 1 Pharmingen
